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INTRODUCTION 
Malaria is an infectious disease caused by parasitic protozoa of the genus 
Plasmodium and is responsible for millions of deaths annually. The discovery in 1897 
by Ronald Ross that mosquitoes transmit malaria not only contributed to the 
understanding of the life cycle of Plasmodium but perhaps prematurely motivated people 
to think that malaria could be easily eradicated. Since that time, eradication of the parasite 
and mosquito vector via chemical and mechanical means has been only partially 
successful mainly attributed to financial constraints (i.e., confinement of the disease 
primarily to developing countries) and the appearance of pesticide and drug resistant 
strains of mosquito and parasite, respectively. The idea of controlling the infection 
naturally via the development of a vaccine seems a viable alternative to the resistance 
problems; however, though encouraging reports have been made (Patarroyo et al., 
1987, see also Good, 1992), much more information about the nature of the immune 
system and its interaction with the parasite must be gathered. The purpose of this 
dissertation is to present studies aimed at defining aspects of host-parasite relationships 
which might be essential for the development of immunity and useful in revealing 
potential targets for intervention. A Plasmodium berghei mouse model was used. P. 
berghei infections in mice, if untreated, are normally always lethal, paralleling to some 
extent infections with P. falciparum infections in humans. The use of an animal model 
offers a method of obtaining information that might otherwise be unobtainable for ethical 
or technical reasons; however, caution should be exercised in interpreting the results 
obtained from the animal model, which may not necessarily apply to P. falciparum 
infections in humans. 
Two forms of the erythrocytic-stage rodent malarial parasite P. berghei were 
tested. Apart from the original 'wildtype' parasite (VP) (the virulent form which causes 
lethal infection if left untreated), another more immunogenic parasite (IP) (derived from 
the VP parasite) played an essential role in defining the importance of Τ cells, В cells and 
macrophages in the development and maintenance of immunity to malaria. The results 
suggest that analysis of the special properties of the immunogenic parasite (IP), rather 
than those of the virulent parasite (VP) (which until now were assumed to contain all 
necessary information), may reveal more important characteristics for the development 
of vaccines directed against the erythrocytic stages of the parasite. This may serve to 
restimulate studies on the use of attenuated parasites for vaccination or even better 
analysis of attenuated parasites to define what makes them suitable for the induction of 
immunity. 
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1.1 THE PARASITE 
1.1.1 Life cycle 
The life cycle of Plasmodium includes the host and the mosquito (genus 
Anopheles) vector. Figure 1 depicts the life cycle of the Plasmodium between host and 
mosquito, that is basically divided into four phases of which one is sexual and three are 
asexual (Wellcome Trust, Knell, ed. 1991). 
Phase 1. Fertilization (sexual stage in the mosquito) 
A female Anopheles sucks a blood meal from an infected individual. Macro-
(female) and micro- (male) gametocytes, when present in infected blood, are released 
from the erythrocytes to become free macro- and micro- gametes. The microgametocyte 
produces flagellated microgametes. If contact with a macrogamete occurs, then 
fertilization results in the production of a zygote. This zygote develops into an invasive 
ookinete, which plants itself in the stomach wall, migrates through the wall, then 
differentiates into an oocyst on the outside of the stomach wall. 
Phase 2. Sporogony (asexual development in the mosquito) 
This phase occurs entirely in the mosquito. The oocysts develop into thousands 
of (invasive) sporozoitcs which rupture through the mature cyst and migrate through the 
body of the mosquito to invade her salivary glands. 
Phase 3. Hepatic schizogony (asexual development in the liver) 
The subsequent feeding of the mosquito results in the release of sporozoites 
into the blood which eventually invade liver cells and become hepatic trophozoites. 
These grow and produce thousands of invasive merozoites which are then released into 
the blood. 
Phase 4. Erythrocytic schizogony (asexual development in the blood) 
The merozoites released from the schizonts invade the erythrocytes to become 
erythrocytic ring stages and trophozoites which grow and divide into 8-30 new 
merozoites. The merozoites are subsequendy released when the erythrocyte bursts. This 
cycle is repeated and as the disease progresses, some merozoites develop into male or 
female gametocytes which circulate, but only develop further if they are taken up by a 
mosquito to continue that part of the cycle (phase 1). 
1.1.2 Plasmodium species 
There are 4 major Plasmodium species that infect humans: P. falciparum, P. 
vivax, P. malanae, and P. ovale. To aid in the understanding of the events in human 
malaria, a search was done to find and develop parasites that would be infective to other 
animal species to facilitate the development of suitable animal models for easier study. In 
particular, the rodent or murine models have been important in studies on parasite-host 
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Figure 1: The Life Cycle οι Plasmodium 
relations, drug development, pathogenesis and development of vaccines. In many of the 
rodent models, infections are self-limiting, but some infections can be lethal. With the 
discovery of P. berghei, in particular, by Vincke (Van den Berghe, 1948, Landau and 
Boulard, 1978) in 1948 from a Katanga, Africa strain isolated from rodent No. 173 
(Grammomys surdaster or African tree rat), a long history of research using this parasite 
began. This rodent parasite, as well as other strains were adapted to laboratory rodents, 
particularly rats and mice, producing lethal results in the latter (Zuckerman and 
Golenser, 1970). A great variety of studies, including the use of live parasites, 
attenuated parasites, parasite extracts, isolated parasite molecules, released molecules 
and recombinant molecules have evolved, directed toward the development of 
immunization procedures and eventually the development of a vaccine. 
5 
Attenuated, less virulent forms of otherwise lethal parasites appeared useful in 
immunization against the virulent form of the parasite (Weiss et al., 1964, Weiss 1976, 
Waki et al., 1982, Waki el al., 1985, Waki et al., 1986, Waki et al., 1989, this 
dissertation), but interest waned when molecular techniques made it possible to develop 
subunit vaccines from recombinant parasitic products. These molecular biological 
techniques could be used to reduce the potential chance of contaminating pathogens and 
the problem of providing enough parasites. Recently, however, renewed interest in the 
development of attenuated parasites was noted (Good, 1992). 
1.1.3 Immunization 
An immune response to the injection of parasitized erythrocytes or sporozoites 
of rodent malaria can be effected by an array of different methods including the 
administration of anti-malarial drugs following long-lasting patent infections or repeated 
and cleared infections, modification of the host diet during infection (see Jerusalem, 
1969), use of attenuated parasites, killed parasites, formol-fixed parasites, and immune 
cell transfer (the latter, however, involves immunization of mice with one of the former 
methods). These types of treatments are able to depress parasitemia and fulminating 
infection to enable the host to acquire a certain degree of immunity. 
Anti-malarials 
Different immunization schemes have been reported which involve varying 
both the dose and length of exposure time of the host to the parasite, before eventually 
introducing anti-malarial drugs such as chloroquine phosphate or sulfonamides 
(sulfathiazole, sulfadiazine) to control (Cox, 1964, Eling, 1978b) or chloroquine, 
ataprine (Cox, 1964) or primaquine diphosphate (Box and Gingrich, 1958) to clear the 
infections. 
Diet 
Mice can be immunized by modification of the diet. For example, by reducing 
an essential growth factor for the parasite from the diet, namely para-aminobenzoic acid 
(PAB A), mice were found to develop a strong and long-lasting resistance to the parasite 
P. berghei (see Jerusalem, 1969). 
Attenuated Parasites 
Effective immunization of rodents can be achieved through the use of 
attenuated parasites which have arisen spontaneously or have been induced via tissue 
culture passage (Weiss and DeGiusti, 1964) or irradiation (Waki et al., 1982, Waki et 
al., 1986). 
P. berghei parasites cultured in vitro in rat bone marrow or liver demonstrated 
altered virulence when transferred to mice (Weiss and DeGiusti, 1964, Weiss, 1976). 
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Transfer of cultured material caused normal infections in rats; however, by frequent 
passages of parasitized material from rat to culture to rat, acceptor mice were capable of 
recovery and resistant to rechallenge with the attenuated strain, as well as the original 
virulent parasite (Weiss and DeGiusti, 1964, Weiss, 1976). 
Attenuated forms of P. berghei and P. yoelii parasites, for example, have been 
obtained by exposure of infected blood to irradiation (Waki et al., 1982, Waki et al., 
1986). When these parasites were injected to naive mice, mice were able to induce a 
protective immune response against a challenge inoculation with the original virulent 
strain. Experiments with the P. berghei parasites in particular, showed that the attenuated 
variant stimulated antibody production (reported to contribute protection against the 
parasites), while the virulent parasite caused more prominent harmful 
immunopathological responses (Waki et al., 1989). 
1.1.4 Parasites used in our model 
For the analysis of the role of the type of parasitized erythrocyte in the 
development and maintenance of immunity, two forms of the erythrocytic stages of P. 
berghei (strains K173 and ANKA) have been used in the work described in this 
dissertation: (1) the virulent form of the parasite referred to throughout this work as VP 
and (2) an immunogenic form (IP). The latter was obtained in this laboratory under 
conditions that led to the development of immunity. 
Virulent parasites (VP) and Immunogenic Parasites (IP) 
The P. berghei virulent parasite (VP, strains K173 and ANKA), used in the 
studies described in this dissertation cause lethal infections in mice independent of the 
number of parasites inoculated. In addition, depending on the mouse strain used, P. 
berghei induces cerebral malaria. Protection against development of the cerebral 
syndrome can be obtained by pretreatment with the parasite, in particular, the live 
parasite (Curfs, 1992, see Chapter 2). 
Though difficult to induce immunity against the VP by using disintegrated 
parasites (obtained via freeze-thawing or sonication) (Jerusalem and Eling, 1969), 
immunity can be induced by a chemotherapeutically controlled subpatent infection of 5 
weeks duration (Eling 1978a, 1978b, see Chapter 3). Interestingly, analyses of the 
parasite during this immunization procedure revealed the appearance of an attenuated 
parasite shortly before immunity to the virulent parasite was established. This attenuated 
parasite was assigned the name immunogenic parasite (IP) and appeared to provide an 
essential signal in the induction of immunity by transfer of cells (see Chapter 3). 
Moreover, fading of immunity (observed with the virulent form) was not observed with 
the immunogenic form and restimulation with IP provided immunity to VP within a 
week (see Chapter 7). 
In addition to the role of IP in development of immunity, in contrast to VP, the 
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following characteristics were observed: 
(1) low dose IP infections can be spontaneously controlled and end 
in immunity to both IP and VP 
(2) ΓΡ infections do not induce cerebral malaria 
(3) pretreatment with a two day IP infection does not protect against the 
development of cerebral malaria from a subsequent infection with VP 
and 
(4) IP remain stable in a mosquito transfer 
The concept wherein the use of attenuated pathogens in immunization to obtain 
protection against a virulent form of the asexual stages of the malaria parasite organism 
is old and well-established. When molecular biological techniques became available, 
interest in the development of attenuated parasites was lost. One of the arguments cited 
against their further development were the risks associated with their use (e.g., 
undesirable side-effects due to injection of unnecessary material, possible contamination 
with other microbial organisms). These risks would be avoided if subunit vaccines 
could be produced (see Liew, 1985, Zanetti et al., 1987). For the development of a 
subunit vaccine, however, it is important to identify the molccule(s)/epitope(s) of the 
parasite reacting with the (naturally occurring) immune effector. Important questions 
then to be addressed are: (1) whether the virulent parasite expresses that/those 
molecule(s)/epitope(s) or is/are only expressed in the attenuated form of the parasite, (2) 
is/are the desired molecule(s)/epitope(s) a constituent of the parasite or is/are it/they shed 
in the environment and (3) why are live, proliferating parasites much better immunogens 
than parasitic extracts. 
Vaccination studies using inactivated parasites, parasite extracts/molecules or 
recombinant molecules possess one or more of the following characteristics: (1) they act 
as poor immunogens, (2) are only active in combination with complete Freund's 
Adjuvant or (3) exhibit a temporary parasitemia after challenge before complete control 
of subsequent inoculations is obtained. In addition, existing immunity fades in the 
absence of the live parasite, both in humans and in experimental models (see 1.3.5, 
Chapters 2 and 7, Eling, 1978a ). In the latter, fading can be prevented by using live 
proliferating parasites, but not parasite extracts (Eling et al., 1991). Such observations 
suggest that virulent parasites (VP) are a poor source for the extraction and identification 
of parasitic factors involved in the development of immunity to the asexual stages of the 
parasite and analysis of the role of immunogenic/attcnuated rather than the virulent 
parasites in the development and maintenance of immunity should be undertaken. 
Experiments presented in this dissertation were carried out to compare the functional 
behavior of and differences between ΓΡ and VP in our model. 
The next two sections that follow (1.2 and 1.3) are intended to first give the 
reader an overview of general immune responses, cell types and general terminology 
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(section 1.2) as well as immune responses against malaria parasites (section 1.3). 
1.2 IMMUNE RESPONSE (GENERAL) 
-The word immune refers to the ability of individuals who do not succumb to 
a disease. 
-The status of natural resistance to a disease (pathogen, parasite) is referred to 
as immunity. 
-The immune system recognizes and selectively eliminates foreign invaders 
(e.g., bacteria, viruses and parasites) by a process known as the immune 
response which has 3 major characteristics: 
(1) it responds adaptively to foreign invaders 
(2) it exhibits specificity and 
(3) it can display a long-term memory of earlier contacts with specific 
foreign pathogens. 
The immune system itself consists of nonadaplive and adaptive systems: 
Nonadaptive systems protect against infection in a fixed way. Elements of this 
system include external skin (that provides a passive barrier to penetration by 
pathogens), internal defense cells (e.g., phagocytes and natural killer cells) and 
circulating proteins (e.g., humoral factors, lysozyme, C-rcactive proteins and properdin 
that bind to bacterial surfaces and initiate elimination reactions). 
Adaptive systems form a dual system in immune protection (in vertebrates) 
which maintain two basic defenses against foreign invaders. Both immune responses 
respond specifically to most foreign substances. Although one response is generally 
favored over the other, there can be overlapping protection. These two types of 
immunity are: 
(1) Cellular immunity which is provided by cells of the lymphoid system and 
(2) Humoral immunity which is provided by proteins called antibodies that 
circulate throughout the body fluids (i.e., serum and lymph) and protect vascularized 
tissues of the body as well as mucous membranes of the body. 
The duality of the adaptive part of the immune system results from two 
populations of morphologically indistinguishable lymphoid cells called lymphocytes (T 
cells, В cells) which must proliferate and differentiate before they or their products are 
capable of eliminating foreign invaders or antigen: 
(1) Τ lymphocytes (T cells) include cells that mediate the cellular immune 
response. When host cells are invaded by or interiorize foreign invaders or substances 
that can alter their normal surface characteristics, some of the Τ cells recognize the 
change and are activated. This initiates reactions that include binding to and eliminating 
the altered cells. In the process of proliferation, some progeny lymphocytes differentiate 
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into effector cells with different functions. The effector Τ cells are programmed by cell-
surface receptors to recognize other cells of the immune system in order to stimulate or 
inhibit them. When the T-ccll receptor binds to the infected host cell, the interaction does 
not involve an entire molecule but rather a small region or epitope on its surface. The 
epitope and epitope-binding site are complementary. T-cell receptors can cover a large 
repertoire of epitopes. When a lymphocyte first encounters the epitope for which it has a 
receptor, it will ignore it unless the epitope (which is nonself) is presented to it on an 
antigen-presenting cell (APC) in a linkage to the major histocompatability complex 
(MHC) molecules. This requirement for simultaneous recognition applies only to the Τ 
cells and the Τ cell receptors (TCR) (MacDonald, 1992). The TCR on Τ cells (which 
remain cell-bound) arc the first to encounter most of the antigens in a way that leads to 
the triggering of a specific Τ cell response. 
Τ lymphocytes can be divided into subsets based on the expression of one or 
other of two cell surface markers, their function and their MHC specificity. Mature 
human Τ lymphocytes fall into two main subsets depending on the CD4 and CD8 
molecules they possess. Mouse Τ lymphocytes are similarly divided by the cell surface 
antigens L3T4 and Ly-2. For uniformity, CD4 and CD8 will be used throughout this 
dissertation to refer to the murine Τ cells. Based on their function, Τ lymphocytes can be 
divided into at least two other subsets: Helper Τ (T
n
, CD4+), so designated because 
they secrete lymphokines upon activation which control and coordinate other cells 
participating in the immune response and cytotoxic Τ cells (CD8+), which acquire the 
capacity to lysc target cells carrying antigens recognized by their TCR's. Τ suppressor 
cells (sometimes called CD8+ Τ cells) secrete molecules that inhibit the response of other 
cells, but as of yet there is no definitive marker to distinguish this type of cell from other 
lymphocyte subsets. According to the specificities of the TCR's, Τ lymphocytes form 
two subsets: (1) lymphocytes that recognize class I MHC molecules (either alone or 
together with antigen) and (2) those that recognize class II MHC molecules (either alone 
or together with antigen). In particular, as a general rule (though with exceptions), 
CD4+T cells recognize and are activated by antigenic peptides presented on class Π 
MHC cell surface molecules (normally expressed on macrophages and В cells) and 
CD8+ Τ cells recognize and respond to antigenic peptides presented on class I MHC 
molecules (present on all nucleated cells) (Travers and Thorpe, 1992). It has been 
reported that naive and memory T-cell (i.e., cells previously exposed to antigen) (Akbar, 
1991) subsets differ in their ability to synthesize and respond to a variety of cytokines 
in vitro and each subset can produce cytokines that effect the response of the other 
subset. 
Murine CD4+ Τ cells can be further divided into two usually nonoverlapping 
subsets, Tjjl and T
n
2 cells, based on their patterns of lymphokine secretion (Mosmann 
and Coffmann, 1987, Street and Mosmann, 1991). All CD4+ Τ cells produce IL3 and 
granulocyte-macrophage colony stimulating factor (GM-CSF). The subset T
n
l cells 
10 
secrete, in addition, interleukin 2 (IL2), interferon gamma (IFN-γ) and lymphotoxin, are 
involved in the mediation of dclayed-type hypersensitivity and activate macrophages. 
The subset T
n
2 cells additionally produce IL4, IL5 and IL6 and act as helper cells for the 
production of specific antibody. A T-cell response can be "pushed" towards a 
predominantly T
n
l or Tj,2 phenotype by several factors including the properties of 
antigens, the dose of the antigen, the site of exposure and the ongoing immune response 
in the host (Romagnami, 1992). This so-called "switch" mechanism has been reported 
from several models where one response is favored over the other (e.g., Leishmania, 
Schistosomes, AIDS virus) (Bogdan et al., 1990, Locksley and Scott, 1991, Scott and 
Kaufmann, 1991, Bretscher, 1992, Clerici and Shearer, 1993). 
Such a mechanism has been proposed for CD4+ Τ cells and malaria because of 
their importance in immunity to various murine Plasmodium species (e.g., P. chabaudi 
(Langhorne, 1989, Langhorne et al., 1990, Taylor-Robinson and Phillips, 1992), P. 
berghei (this dissertation)) in mice. One mechanism (Langhorne , 1989) describing the 
involvement of the T
n
 subsets in P. chabaudi malaria immunity is given below under 
section 1.3.4. 
(2) В lymphocytes (B cells) are responsible for the humoral immune 
response and can act as APC to the T-cell system. Most В cells must wait for a signal 
from activated Τ cells to become activated themselves, even after they have bound the 
antigen. Individual В cells recognize cell-bound as well as soluble antigens without a 
simultaneous recognition of self MHC molecules.When activated by recognition of a 
foreign substance, В cells differentiate into plasma cells that secrete antibodies. The 
antibodies (which form a class of proteins called immunoglobulins (Ig)) bind specifically 
to the foreign substances (antigen) and initiate a variety of elimination responses. 
B-cell populations of normal mice can be divided into subpopulalions, just as 
the Τ cells, on the basis of phenotype, anatomical location, ontogeny, antibody repertoire 
and physiology (Herzenberg and Kantor, 1993). There is much interesting debate, 
however, about where and how these populations are generated (Haughton et al., 1993, 
Herzenberg and Kantor, 1993, Osmond, 1993) and these will not be discussed in detail 
here. 
Homeostasis 
The sizes of T- and B-cell populations are maintained independently, that is, a 
similar number of mature В cells are found in normal, thymectomized and athymic mice, 
while in mice that lack В cells, the number of Τ cells is similar to normal mice (Freitas 
and Rocha, 1993). The homeostatic control of cell numbers implies a kinetic steady state 
where cell production equals cell loss. If one looks specifically to Τ cells, it has been 
reported that in the absence of either the CD4+ or CD8+ T-cell subset, cell loss can be 
compensated for by the remaining cellular subset and the total number of Τ cells remains 
similar to that of normal mice. This has been demonstrated in various models by 
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reconstitution of athymic mice with purified T- cell populations followed by anti-CD4 or 
anti-CD8 antibody treatment as well as through analysis of "knockout" mice (Freitas and 
Rocha, 1993). The balance between cell types and the effect of depletion of specific cell 
populations using our model in intact and thymectomized mice are discussed in Chapter 
5 of this dissertation. 
B-ccll and T-cell survival is influenced by selection. For example, in 
experiments involving the transfer of mature В cells, it was reported that if the cells were 
given the appropriate antigenic challenge soon after transfer, expansion and survival of 
the donor cells resulted (Freitas and Rocha, 1993). It is rather difficult to precisely say 
when cells renew themselves because of the dependence on the number of 
measurements and the measurement method itself. Nonetheless, it has been reported, by 
using multiple approaches, that 30-40% of peripheral immunocompetent В and Τ cells 
are renewed every 3 days and that most В cells are renewed every 10 days (Freitas and 
Rocha, 1993). In rodents, unless the lymphocytes of the peripheral B-cell pool are 
activated by antigen, they have an estimated lifespan from three to a few weeks 
(MacLcnnan and Chan, 1993). Though the mechanism for this renewal differs for В and 
Τ cells, В cells are renewed via continuous production and export from the bone 
marrow, while Τ cells are primarily renewed by cell generation at the periphery (Freitas 
and Rocha, 1993). 
It appears, however, that the lifespan of lymphocytes is not an intrinsic 
property of a cell but that lymphocytes, at different stages of differentiation, have a 
different probability rate of survival which is modulated by their interactions with the 
environment (Bradley et al., 1993, Gray and Matzingcr, 1991, Freitas and Rocha, 
1993). Their selection is mediated by clonally distributed receptors and depends on 
several parameters, including the affinity and concentration of existing ligands and the 
presence of growth and differentiating factors. Ultimately, this demonstrates the 
competitive selection behavior within the immune system. (Freitas and Rocha, 1993). 
Accessory cells 
In addition to lymphocytes, several other kinds of accessory cells are essential 
to the immune system. Their functions include accumulation of foreign substances in the 
body for processing and presentation to lymphocytes (e.g., macrophages, dendritic 
cells, В cells), scavenging of foreign invaders attacked by the immune system (e.g., 
macrophages) and mediation of physiological changes that accompany the immune 
response (e.g., monocytes, granulocytes, tissue macrophages, mast cells, natural killer 
cells). 
Τ cells, В cells and accessory cells have been found to play important roles in 
immunity to malaria. The presence of the parasite is important in their stimulation. Some 
of these cells and their role in the development and control of malaria are discussed in 
the following sections. 
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1.3 IMMUNE RESPONSE (MALARIA) 
Malaria is a blood-bom infection. The spleen being the lymphoid organ that 
controls the presence of pathogens in the bloodstream, has an important role in the 
defense against malaria. The thymus is important for the delivery of matured, 
differentiated T-cells that are integrated in specific immune responses (e.g., in the spleen 
to control malaria infection and develop specific immunity). 
1.3.1 The thymus 
The thymus is a primary lymphoid organ essential to the maturation of the 
thymic lymphoid cells or T-cells. Mature and differentiated T-cells leave the thymus and 
home in secondary lymphoid organs (e.g., spleen and lymph nodes) where they can 
recognize specific antigens and become involved in integrated immune responses. Adult 
thymectomy usually has no serious effects on immunity, but in combination with 
depletion of T-cells or subclasses of T-cclls, it prevents the recmergence of mature T-
cells, thereby depleting the immune system of their function. In this way, the role of the 
thymus, that is, more particularly, the role of the thymus-derived T-cells in induction and 
maintenance of immunity can be studied. 
Thymus-dependent resistance to malaria has been confirmed in both rat and 
mouse models (Brown et al., 1968, Stechschulte, 1969, Jayawadena et al., 1977, Spira 
et al., 1970, Eling, 1979). Infections in neonatal thymectomized rats and congenitally 
athymic nude mice have been reported to be more severe than infections in euthymic 
mice (i.e., possessing a thymus). Furthermore, nude mice even succumb to infections 
which in intact mice are normally avirulent (Clark and Allison, 1974). These data show 
that the thymus or rather the matured T-cells derived from the thymus, play an essential 
role in the development of malaria immunity; however, a mechanism of their 
involvement has not been currently elucidated. One proposed mechanism suggests that 
neonatal thymectomy depletes helper Τ cells (CD4+ Τ cells), which are required for the 
production of protective antibodies by В cells to sequentially appearing variants of the 
parasite (Brown, 1971). Another mechanism suggests that T-cell dependent cell-
mediated immune mechanisms essential for malaria immunity are suppressed by neonatal 
thymectomy (Allison and Clark, 1977). These proposals are based on findings from 
mice that have been given a primary infection with the parasite. These experiments 
highlight the importance of the thymus and particularly the thymus-derived T-cells in the 
balance between development of (immuno)pathology and immunity to malaria. The role 
of different subclasses of T-cells involved in malaria immunity is discussed in more 
detail below. 
1.3.2 The spleen 
The spleen is a secondary lymphoid organ and the site of the largest collection 
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of cells belonging to the mononuclear phagocytic system in the body. It is composed of 
sponge-like tissue (splenic pulp) consisting of white pulp for immune responses and red 
pulp for the filtering of red blood cells. The bulk of the lymphoid tissue is arranged 
around a central arteriole called the periarteriolar lymphatic sheath (PALS). The PALS is 
composed of Τ and В cell areas. The Τ cells are found around the central arteriole and 
the В cells are found in the follicles beyond this zone. Follicular dendritic cells and 
tingible body macrophages are found in the germinal centers. Specialized macrophages 
are found in the marginal zone (area surrounding the PALS). Marginal zone 
macrophages together with follicular dendritic cells of the primary follicles arc the cells 
which present antigen to В cells (Roitt, 1989). Marginal zone macrophages form a 
concentric ring around marginal metallophilic macrophages (which are located at the 
periphery of the white pulp at its border with the marginal zone). Lymphocytes leave and 
enter the PALS via capillary branches of the central arterioles that merge into the 
sinusoids of the marginal zone. Both Τ and В cells are found in this area. 
In both virulent and avirulent malaria, the spleen is considered essential for the 
resolution of a primary infection and in part for the induction phase of immunity 
(Dockrell et al. 1980, Osler et al., 1980, Eling, 1982a, 1982b). Resistance to and 
immunity from murine malaria are usually dependent on an intact spleen (Good and 
Currier, 1992). Splenectomy of P. vinckei-immune mice abrogates immunity (even 
when immune spleen cells arc transferred back into these mice) (Kumar et al., 1989). In 
addition, splenic enlargement involving an increase in numbers of cells of the immune 
system (in mice, there is increased erythropoietic activity), as well as a change in the 
architecture of the spleen, accompany infection and development of immunity. One of 
the architectural changes involves the proliferation of so-called 'barrier cells' to form 
channels that constitute a preferred pathway for the (infected) erythrocytes facilitating the 
interaction (Weiss et al., 1986, Weiss, 1990) between parasitized red blood cells and 
cells of the immune system (Good and Currier, 1992). It was suggested that 
splenomegaly and splenic changes probably occur as a critical event in the development 
of immunity to malaria (Good and Currier, 1992). The role of macrophages in malaria is 
also an important one and has been examined in the adoptive transfer and maintenance of 
immunity to P. berghei. More details of their function are given below under "activation 
of effector cells by Τ lymphocytes" and the results of the experiments are presented in 
Chapter 6 of this dissertation. 
1.3.3 The role of nonspecific immunity 
Immunomodulating agents such as Corynebacterium parvum and BCG have 
been used to activate mechanisms protective against malaria (Clark et al., 1976, 1977, 
Winkel and Good, 1991); however, generally, these nonspecific mechanisms are 
dependent on persistence of the stale of activation, are short-lived (lasting for periods of 
days to months) and lack a memory component (Melancon-Kaplan and Weidanz, 1990). 
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1.3.4 Cell-mediated and humoral immunity 
Through the use of different murine malaria models, various ideas about the 
type of immunity to malaria were developed. There were early reports that resistance to 
Plasmodium could be achieved by the passive transfer of immune sera (Phillips, 1970, 
Jayawardena et al., 1978, McDonald and Phillips, 1980 ), which not only supported the 
idea of acquired immunity but also that this immunity was mediated by antibodies. 
However, through further studies targeted on the eventual development of a vaccine, it 
was seen that immunity to malaria is dependent on antibody as well as cell-mediated 
mechanisms with antigen-specific Τ cells playing a pivotal role in both (Playfair, 1982, 
Miller et al., 1986, Good, 1992, Taylor-Robinson and Phillips,1992). By the 
characterization of these cells and their functions, as well as the identification of the 
antigenic epitopes that stimulate or activate them, useful information can be obtained in 
designing malaria vaccines. The rest of this introduction will deal with the evidence for 
the role of cell-mediated immunity and the role of antibodies reported in other studies 
using murine malaria models. 
Immunity in B-cell deficient hosts 
Studies designed to determine a role for В cells, using В cell deficient hosts, 
have produced variable results. Mice made В cell deficient by continuous treatment with 
anti-mouse μ chain sera (Weinbaum et al., 1976, Roberts and Weidanz, 1979) died after 
infection with a normally avirulent P. yoelii, while an increase in the duration of infection 
was observed in mice that lacked specific subsets of В cells (e.g., CB A/N ) (Hunter et 
al., 1979, Jayawardena et al, 1979). Other studies involving B-cell deficient mice, 
showed that mechanisms, independent of antibodies, played an important role in 
resistance to the infection (Gran and Weidanz, 1981, Kumar et al., 1989, Cavacini et 
al., 1990). In one study, which demonstrated T-cell dependence, B-cell deficient mice 
resisted challenge with homologous parasites (Roberts and Weidanz, 1979) when a 
primary parasitemia (being chronic itself) was cleared by chemotherapy before the 
challenge was given. By contrast, other studies using no chemical intervention, showed 
that B-cell deficient hosts infected with P. chabaudi adami (Gran and Weidanz, 1981), 
P. vinckei peneri, P. chabaudi chabaudi and Babesia microti appeared to resolve their 
infections spontaneously. 
A study by Mcding and Langhorne (1991) showed that both Τ cells 
(specifically CD4+ Τ cells) and В cells were necessary for protective immunity to P. 
chabaudi chabaudi. In their transfer studies using severe combined immunodeficient 
(SCID) mice (mice defective in both Τ and В cells), they found that though transfer with 
immune or normal CD4+ Τ cells enabled a majority of mice to be protected from a 
normally lethal challenge, the mice were unable to clear their parasitemias. However, 
when SCID mice were given both normal and immune CD4+ Τ cells along with immune 
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В cells, the infection could be eliminated. When the same cells were given to athymic 
nu/nu mice, the acceptor mice were able to control and clear their infections. In addition, 
the clearance of parasitemia correlated with the presence of malaria specific antibodies in 
the serum. 
In some studies, it was observed that Τ cell-dependent cell mediated immunity 
showed limited specificity in the ability to resist infection. More specifically, in В cell 
deficient mice immune to P. chabaudi adami, while able to resist infection when 
challenged with the closely related P. vinckei vinckei , died when infected with the more 
distantly related P. yoelii (Gran and Weidanz, 1983). Conversely, В cell deficient mice 
immunized against P. yoelii could resist challenge with P. chabaudi adami but not with 
P. vinckei (see Melancon-Weidanz, 1990). 
All of these findings serve to illustrate the complexity of malaria immunity to 
erythrocytic-stage murine malaria and suggest that immunity may be mediated by an 
integrated set of different immune responses or that different species of parasites vary in 
their ability to modulate host immune responses (see Melancon-Kaplan and Weidanz, 
1990, Say les and Wassom, 1992). In some murine malaria models, both antibodies and 
cell-mediated immunity are required to suppress Plasmodium infections (Meding and 
Langhorne, 1991) while in others, Τ cell-dependent cell-mediated immunity, in the 
absence of antibodies, is sufficient (Grun and Weidanz, 1981). It appears, too, that the 
presence of the parasite is essential. The continued presence of parasites or prcmunition 
(Sergent, 1963, Eling 1978a, 1978b, Gran and Weidanz, 1981, this dissertation), as it 
is called, is necessary for the maintenance of immunity (this dissertation). The concept 
of premunition and sterile immunity is discussed in our own model in further detail in 
Chapters 4, 5 and 7 of this dissertation. 
Mechanisms of Τ cell immunity 
Direct intervention by Τ lymphocytes 
While there is evidence for the participation of Τ lymphocytes in protective 
immunity to malaria, the actual mechanisms of control of growth of the parasites and 
resolution of infection by the lymphocytes remains still to be defined. It is possible that 
Τ cells may act directly by cytolysis of infected erythrocytes or by the production of 
inhibitory or toxic factors including IFN-γ. In vitro studies using IFN-γ indicate that 
there is no direct inhibition on the proliferation of erythrocytic-stage parasites (Carlin et 
al., 1985), while in vivo studies have yielded conflicting results (Clark et al., 1987, 
Playfair and DeSouza, 1987, Curfs et al. 1993). The direct lysis of parasitized 
erythrocytes and direct killing of released, erythrocytic stage parasites by Τ cells (CD8+ 
Τ cells) is considered unlikely because the cytolytic process requires the recognition of 
parasite antigens in association with MHC class I antigens which are not present on 
human erythrocytes, however, are present on rodent erythrocytes (see Melancon-Kaplan 
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and Weidanz, 1990). Transfer experiments and CD8+ Τ cell depiction experiments in 
rodents have shown that CD8 + Τ cells do not confer protection when transferred or do 
not effect immunity when depleted in several murine malaria models (Jayawardena et al., 
1982, Brinkmann et al., 1985, this dissertation) supporting the idea that CD8+ Τ cells 
are probably not involved in the development of immunity against erythrocytic-stage 
parasites. Conversely, in malarial infections initiated by sporozoite infection, the CD8+ 
T cells do play a major role in protection against this stage or the liver stage of the 
parasite (Schofield et al., 1987b, Weiss et al., 1988). Sporozoite-immunized mice were 
seen to lose their immunity when depleted for CD8+ Τ cells, but did not when depleted 
for CD4+ Τ cells. The authors speculated that CD8+ Τ cells exert their action at the level 
of the infected hepatocyte and that the recognition by CD8+ Τ cells of parasite antigens 
in the context of class IMHC molecules expressed on the surface of hepatocytes might 
lead to the direct lysis of the infected hepatocytes or to the inhibition of growth of the 
parasite via IFN-γ released by the activated CD8+ Τ cells (Schofield et al., 1987a, 1987b 
and Weiss et al., 1988). In further support of a role for IFN-γ, it has been shown to 
inhibit, both in vivo and in vitro, the development of exoerythrocytic forms in liver cells 
(Ferreira et al., 1986, Schofield et al., 1987a), however, not in erythrocytic forms of the 
parasite (Ferreira et al., 1986). It is postulated that in a natural infection, sensitized 
CD8+ Τ cells could represent a natural immunological barrier to the liver stage infection 
by the sporozoitcs injected through mosquito bites (Melancon-Kaplan and Weidanz, 
1990). 
Activation of effector cells by Τ lymphocytes 
Parasite destruction or the suppression of the growth of the erythrocytic stage 
parasite may be reached by T-ccll dependent-activation of other cell types (primarily by 
macrophages and natural killer (NK) cells, factors released from activated Τ cells 
(lymphotoxin or IFN) (Meding et al., 1990, Scott and Kaufmann, 1991) or toxic factors 
released through activation of other cells of the immune system (Allison and Eugui, 
1983 ). 
NK cells have been proposed as a first line of defense against the parasite prior 
to the development of an immune response in which they may participate via the lysis of 
parasitized red blood cells (Eugui and Allison, 1980 ). Thereafter, it has been proposed 
that products (e.g., IL2, IFN-γ) of activated Τ cells lead to the enhancement of their 
cytolytic activity (Braakman et al., 1986). Even though many studies reported the 
appearance of increased NK activity during the course of malarial infections (Eugui and 
Allison, 1980, Ojo-Amaize et al., 1981, Ojo-Amaize et al., 1984, Hunter et al., 1981), 
other evidence negates the theory of NK-mediated killing of malaria parasites (see 
Melancon-Kaplan Weidanz, 1990). 
Phagocytosis is known to be a prominent feature of malaria infections and 
macrophages play an important role therein. Increases in blood monocytes, Τ cells, and 
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the accumulation of macrophages (Jayawardena et al., 1975, Freeman, 1978, 
Jayawardena et al., 1978, Lee et al., 1986) result from infections with malarial parasites 
and effect changes in their surface phenotypes and secretory activity (Playfair et al., 
1979, Shear et al., 1979, Lee et al., 1986). The recruitment and activation of monocytes 
and macrophages are mediated by lymphokines (e.g., IFN-γ, macrophage chemotactic 
factor, IL2) which are secreted by Τ cells, themselves activated by plasmodial mitogens 
and specific malarial antigens (Wyler and Gallin, 1977, Ockenhouse and Shear, 1983 ). 
Activated macrophages release factors that are considered toxic lo the parasite. Reactive 
oxygen species (ROS) and lipid peroxidation products generated from these molecules, 
factors in tumor necrosis serum and enzymes (e.g., polyamine oxidase) have also been 
implicated in causing intraerythrocytic death of the parasite (Allison and Eugui, 1982). 
However, it has been reported from animal models that though there is enhanced 
phagocytosis and macrophages form an important part in malaria immunity, they do not 
play a decisive role in recovery from infection (Playfair, 1979, see also Melancon-
Kaplan and Weidanz, 1990 ). The role of macrophages is further discussed in our 
murine model presented in Chapter 6 of this dissertation. 
A proposed mechanism of immunity in а Я chabaudi murine model 
In murine malaria, CD4+ Τ cells have been found to be necessary for the 
development of a protective response at two stages of the infection in the vertebrate host. 
The first stage is the exoerythrocytic phase in the liver (Figure 1, phase 3) where CD4+ 
T cells act as helper cells for antibody production and as helper cells for the generation 
of CD8+ effector cells, which kill the parasite via a γ-interferon-mcdiated pathway 
within the hepatocyte (Schofield et al., 1987a, Weiss et al., 1988, Good et al., 1987a). 
The second stage is the erythrocytic cycle (Figure 1 phase 4), where CD4+ Τ cells play 
an important role both as helper cells for antibody production and as effector cells (Süss 
et al., 1988). A possible pathway, adapted from a mechanism proposed by Langhorne 
(1989), leading to the elimination of erythrocytic stages of P. chabaudi is given in Figure 
2. It is presented to show the complexity of interactions of the Tjjl and T^2 cells in the 
elimination of the parasite. Tj,l cells recognize peptides derived from phagocytosed and 
processed parasites being subsequently presented in association with MHC class II 
molecules on macrophages (or also В cells) and are in tum activated to produce IL2 and 
IFN-γ, as well as other lymphokines. IL2 acts both as an autocrine factor (indicated by 
curved arrow emanating 
and returning to the T^l cells) and together with IL4, as a growth factor for Tj,2 cells 
(indicated by arrow leading to T^2 cells). The T^2 cells, after encountering the same or 
different antigens, help В cells to produce specific antibodies. IFN- γ (produced by the 
Tjjl cells) activates macrophages so that they express more MHC class II molecules. 
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This leads to an increase in phagocytosis, processing and antigen presentation, and the 
release of several mediators such as TNF and reactive oxygen intermediates (which may 
be directly toxic for intraerythrocytic parasites). 
Agglutination 
Intracellular death 
ofPlasmodium 
Figure 2: The possible interactions between CD4+ Tj,l and Th2 type Τ cells as proposed 
by Langhorne (1989) 
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The production of malaria-specific antibody serves several functions. B-cell surface 
immunoglobulins specific for epitopes of surface molecules of merozoites or infected 
erythrocytes can function in the facilitation of antigen uptake or processing and 
presentation of that antigen to Τ lymphocytes and thereby inducing further effector Τ 
cells. Circulating antibodies can function as neutralizing antibodies which prevent the 
reinvasion of merozoites or result in the agglutination of infected erythrocytes. 
Circulating antibodies serve as opsonins for Fc-receptor-mediated phagocytosis which 
provide a signal for further macrophage activation followed by the release of soluble 
factors toxic to the intraerythrocytic parasites. The above mechanism suggests that 
protective immunity is dependent on the generation of antigen specific CD4+ Τ cells. 
The precise mechanism may involve macrophage activation or antibody production or 
both (Groux et al., 1990). 
1.3.5 Fading of malarial immunity 
Immunity to malaria in humans is established under natural conditions; 
however, repeated infections for many years are necessary to develop immunity. 
Moreover, immunity is not absolute because parasites usually persist in the absence of 
clinical disease. Furthermore, most studies report that in the absence of persistence of 
parasites and/or repeated infections, malaria immunity is short-lived (Melancon-Kaplan 
and Weidanz, 1990, compare also Deloron and Chougnet, 1992). This is evidenced by 
outbreaks of malaria reported in previously immune individuals who became susceptible 
to infection upon their return to malarious areas after an absence of less than a year 
(Maegraith, 1973, Neva, 1977, Melancon-Kaplan and Weidanz, 1990) and in people 
from areas that have ceased control programs and have been reexposed to parasites. 
Similar observations in animal models have been reported (Maier and Coggeshall 1944, 
Eling and Jerusalem 1977a, 1977b, Eling, 1978a, Eling et al., 1991, this dissertation). 
These studies indicate that persistence of the parasite is functional in the maintenance of 
immunity. Our studies on the role of both the virulent and immunogenic form of the 
parasite in maintenance and stimulation of preexisting immunity are described in Chapter 
7 on fading. The role of CD4+ Τ cells and macrophages on maintenance/persistence and 
fading are also discussed in Chapters 5 and 6. 
1.4 ADOPTIVE TRANSFER MODEL 
A well-established method used to study the specific types of cells involved in 
immunity to malaria is that of the transfer of (un)fractionated populations of immune 
spleen cells to nonimmune (naive) acceptor mice. This has been most commonly applied 
to studies of erylhrocytic-stage malaria using P. yoelii and P. chabaudi in mice and P. 
berghei in rats but has been done to show that sporozoite immunity (e.g., P. berghei) too 
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could be passively transferred to naive mice with immune spleen cells (Verhave et al., 
1978). 
Numerous studies with blood-stage parasites, over the years, have shown the 
ability of unfractionated spleen cells (but not lymph node cells) to confer protection 
when transferred to naive acceptor mice (Jaywardena et al., 1978, McDonald and 
Phillips, 1978, 1980, Brinkmann et al., 1985, Cavacini et al., 1986, Fahey and 
Spitalny, 1986, Mogil et al., 1987, Süss et al., 1988, Podoba and Stevenson, 1991) or 
rats (Roberts and Tracey-Pattee, 1969, Phillips, 1970, Brown et al., 1976, Gravely and 
Kreier, 1976). When transfer studies were done using fractionated immune spleen cell 
populations, both Τ and В cells were found to give some level of protection against the 
immunizing parasites (Gravely and Kreier, 1976, Brinkmann et al., 1985, Cavacini et 
al., 1986, Mogil et al., 1987, Süss et al., 1988, Kumar et al., 1989, Vinetz et al., 1990, 
Winkel and Good, 1991). Subsequent experiments showed that immune Τ cells of the 
CD4+ subset (vs that of the CD8+ subset) were able to transfer immunity to P. yoelii in 
naive mice (Jayawardcna et al., 1982, Brinkmann et al., 1985). It was also found that 
interaction(s) of transferred cells with normal host Τ cells was/were required to mediate 
protection to P. yoelii (Fahey and Spitalny, 1976, Brinkmann et al., 1985) and P. 
chabaudi adami (Cavacini et al., 1986) suggesting that the function of the acceptor Τ 
cells was to expand the immune response following the interaction with the transferred 
spleen cell population (Fahey and Spitalny, 1976)). 
Though most of the studies reported that CD4+ Τ cells were required for 
protection with erythrocytic-stage parasites; one study, in particular, by Mogil et al. 
(1987) reported that both CD4+ and CD8+ Τ cells were required to transfer P. yoelii 
protection. This protection was dependent on the co-transfer of IJ+, non-T non-B null 
cells. Comparable experiments were performed by others (Jayawardena et al., 1978, 
Vinetz et al., 1990), but failed to produce the same results. To explain the variable 
results, different activities in the cell populations recovered for transfer was attributed to 
differences in time at which immune spleen cells were harvested and used from the 
donors (Mogil et al., 1987). Another problem in adoptive transfer regarding time could 
be explained using the concept of barrier cells (Weiss, 1990). If spleen architecture is 
essential then immunity cannot be transferred directly. Stimulation and time may be 
essential factors. Infection in mice that develop immunity develop a low-grade, 
temporary parasitemia before a complete control which may depend on the host-parasite 
combination. 
The time variable may indeed be important in explaining the variable results in 
transfer experiments as it has been seen to be important in primary infections (Langhorne 
et al., 1990, Podoba and Stevenson, 1991). One study of primary-infected mice 
(Langhorne et al., 1990) reported that depletion of CD4+ Τ cells early during a P. 
chabaudi infection led to death of animals; however, when the depletion was delayed, 
mice survived an infection. The accumulation of antibody before CD4+ Τ cell depletion 
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was believed to be responsible for controlling the parasitemia. However, the reason for 
the survival of the mice through more technical reasons can not be excluded based on the 
results of our own experiments reported in Chapter 5. We observed that monoclonal 
antibodies, used to eliminate Τ cell subsets, were less effective when parasites were 
present (a condition we call premumtion). Premune mice did not die after given the anti-
CD4 monoclonal antibody while mice cleared of parasites (sterile immune mice) did. 
The reported mice above, (Langhorne el al., 1990), while perhaps experiencing the 
elimination of CD4+ Τ cells early in the infection by the monoclonal antibodies, 
similarly to our results, may not necessarily have experienced the full elimination of the 
CD4+ Τ cells (via monoclonal antibody effectiveness) later in the infection, when more 
antigen-specific CD4+ Τ cells are present. The mice survived, but not necessarily 
through the sole accumulation of antibody. 
Most studies report the use of parasites that give transient or nonlethal 
infections. These models may be easy in which to work, but they do not necessarily 
give the full array of immune responses. Our model includes the use of the lethal P. 
berghei infections which may evoke other responses (e.g., activation of one Τ subset 
over the other) that may serve to complement the vast array of literature. Both transfer 
experiments using (un)fractionated immune spleen cell populations and in vivo studies 
of established immune mice depleted of Τ cell subsets, reported in this dissertation, were 
performed to determine the part of these cells in the development and maintenance of 
immunity to P. berghei. The results are reported in Chapter 5 of this dissertation. 
1.4.1 Τ cell lines 
The development of human and/or rodent continuous Τ cell lines and clones 
that react to plasmodial antigens (i.e., from erythrocytic stages, gametocytes or 
sporozoites) have been reported (Chemtai et al., 1984, Gross et al., 1984, Brake et. al., 
1986, Chizzolini and Perrin, 1986, Good et al., 1987b, Pink et al., 1987, Simitsek et 
al., 1987, Sinigaglia et al., 1987, Brake et al., 1988, Tsuji et al., 1990, Taylor-
Robinson and Phillips, 1992). Τ cell lines developed from humans were, however, 
reactive to antigen appearing in the erythrocytic stages or gametocytes, independent of 
the individual being exposed to malaria (Chizzolini and Perrin, 1986, Good et al., 
1987b, Pink et al., 1987, Simitsek et al.,1987. Sinigaglia et al., 1987). This 
phenomenon was attributed to several reasons including nonspecific stimulation of Τ 
lymphocytes by mitogenic components of the parasite, sensitization of naive Τ cells 
during the process of in vitro cultivation with the malarial antigen or presence of Τ cells 
sensitized to common environmental antigens cross-reactive with malarial antigens (see 
Melancon-Kaplan and Weidanz, 1990). 
The actual culture of the antigen-reactive cells is accomplished by their 
exposure to IL2, malarial antigen and APC (Taylor et al., 1987) using various schemes. 
Cloning is usually accomplished by limiting dilution procedures that produce specific Τ 
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cell clones (Waldmann et al., 1987). Though in vitro studies were useful in 
demonstraling that clones (both CD4+ and CD8+) (Sinigaglia et al., 1987) could be 
made, transfer studies in mice could attest to their functionality. Brake (Brake et al., 
1986, 1988) described a clone that was derived from CD4+ Τ cells from erythrocytic-
stage P. chabaudi chabaudi-immunized mice which was able to confer immunity when 
transferred to naive mice. More recently Tj,l and Tj,2 clones developed against P. 
chabaudi were functionally characterized (Taylor-Robinson and Phillips, 1992) and 
found to confer protection to T-cell-depleted mice infected with P. chabaudi. The 
production of clones, however, was not expressly limited to erythrocytic-stage parasites. 
A CD4+ line derived from spleen cells from mice immunized with P. berghei sporozoites 
was also found to confer protection when transferred to naive mice and challenged with 
P. berghei sporozoites (Tsuji et al., 1990). 
1.4.2 Our transfer model with IP and VP 
The model used to carry out the experiments is specified in Chapter 4 and 
reported throughout the chapters. It is slightly different from other models because it 
involves the use of two parasites: the immunogenic parasite (IP) of P. berghei; found 
absolutely essential for the development of immunity when given along with immune 
spleen cells and the lethal or virulent parasite (VP) of P. berghei; used to test the 
immunity of mice. More information about the characteristics of these parasites is given 
throughout this dissertation. 
Briefly in the model, immune spleen cells are transferred on Day 0 to naive, 
intact, thymectomized, or thymectomized and T-cell subset depleted acceptor mice 
(where indicated throughout the chapters). Mice are then stimulated with IP. IP 
stimulation can be given on Day 0 or delayed to a period of months (Chapter 7). Mice 
are challenged 7 days after stimulation with IP, presumably the amount of time required 
for the development of an effector immune response. Immune mice are those mice able 
to control a challenge with the VP independent of the number of parasites in the 
inoculum. This model has been manipulated in several ways to examine the cells 
important in protection. 
A remarkable observation in all transfer studies reported (sec section 1.4, 
1.4.1) thus far is that acceptor mice develop temporary parasitemia after a challenge 
infection. Once this temporary parasitemia is controlled, all further challenges are 
efficiently controlled. This suggests that the temporary infection contributes to 
development of a more complete immunity and that the transferred cells in themselves 
are not able to control infection, but in reaction to the parasite during the challenge 
infection have to collaborate with host cells for the development of the effector 
controlling parasitemia which may include changes in architecture. The significance of 
this temporary infection after transfer of cells and challenge to development of immunity 
in the acceptor is usually not discussed in studies on adoptive transfer of immunity. Such 
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observations are important when trying to define factors relevant for the development of 
immunity. Therefore, important questions are: (1) can immunity be transferred at all or 
must transferred cells always be stimulated before parasite proliferation can be 
controlled, (2) can transferred cells be stimulated by parasitic products or must they be 
stimulated by live, proliferating parasites to produce the effector function and (3) can 
virulent parasites present the proper signal for stimulation of transferred cells? Answers 
to these questions determine which models should be used and which materials should 
be analyzed to determine relevant factors in the development of a malaria vaccine. The 
observations in the P. berghei mouse model presented in this dissertation that transferred 
cells must be stimulated with live, proliferating, immunogenic parasites (IP) to develop 
immunity to the virulent parasite (VP) (see Chapters 3 and 4) suggest that the virulent 
parasite (VP) is at best a poor tool for the identification of parasite molecules involved in 
the development of immunity. One should, however, always exercise caution in 
interpreting the results and extrapolating findings of different studies in the development 
of a universal mechanism for protective immunity. 
1.5 CHAPTER SUMMARY 
The experiments reported in this dissertation were carried out to gain better 
insight into malaria immunity with the hope that it may contribute some information 
relevant to the events of human malaria and eventual development of a vaccine. The 
consequences of the importance of live parasites for induction and maintenance of 
immunity to the erythrocytic stages is not usually recognized in studies that evaluate or 
aim at determining targets for the development of vaccines against the erythrocytic 
stages. Chapter 2 describes the need for live parasites in long-term immunity. 
Furthermore, different parasites are able to evoke protective immune responses. The 
development of an immunogenic parasite (IP) and its comparison functionally to the 
virulent parasite (VP) in an immune response were examined. Chapter 3 describes the 
actual procedure of development, isolation, and characteristics of the IP while Chapter 4 
describes its use in a mouse transfer model. 
There have been many proposals about the mechanisms of immunity. By using 
monoclonal antibodies against subsets of Τ cells (Cobbold et al., 1984 , Grau et al., 
1986) and liposome-encapsulated dichloromethylcne diphosphonatc (LIP-CI2MDP) 
(Van Rooijen, 1989, Van Rooijen et al., 1989) that is able to temporarily remove 
macrophages, we have looked at the effect of depletion of cells in our model to try to 
determine the involvement of Τ cells, В cells (Chapter 5) and macrophages (Chapter 6), 
respectively, on the development and maintenance of immunity to P. berghei. Chapter 7 
examines the loss of immunity when exposure to the parasite has been interrupted for 
24 
extended periods of time in a condition referred to as fading. There is a loss of immunity 
to VP but not to IP; however, recovery of VP immunity occurs if IP stimulation is given 
1 week earlier. 
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The consequences of the importance of live parasites for induction and 
maintenance of immunity to the erythrocytic stages is not usually recognized in studies 
that evaluate or aim at determining targets for the development of vaccines against this 
stage. The following examines the role of proliferating erythrocytic Plasmodium 
berghei parasites in immunization. 
Live parasites are much more efficient than "dead" parasites in 
immunization 
P. berghei (strain К173) infections obtained with a calculated inoculum size 
ranging from 1 parasite per mouse to 10° were found to be uniformly lethal in several 
mouse strains tested (6). 
Because of the high mortality associated with these infections, could mice 
therefore be immunized using P. berghei and if so what might be the effective antigen? Is 
it a parasite molecule, the living nonproliferating parasite, the living proliferating parasite 
or perhaps even the attenuated parasite? To examine these questions, a series of 
experiments involving different immunization procedures was carried out. Since the 
parasite infects erythrocytes and might directly effect the evolution of an immune or 
protective response, the first experiments included immunization of mice using disrupted 
parasitized erythrocytes (PE) obtained via sonification or freezing and thawing. The 
results of experiments with this type of material indicated that multiple injection regimens 
using large amounts of parasitic material (e.g., material equivalent to 10° parasites/shot), 
which in itself is very toxic, protected only a proportion of mice to a challenge infection 
with the parasite (7). With respect to induction of protection to this challenge, these 
preparations were poorly immunogenic. 
Subsequent experiments, this time using whole, live PE showed that infection 
of mice controlled by sulfonamide treatment to prevent development of patent infection, 
while allowing low level proliferation of the parasite (i.e., 1 parasite per lfP to 10 ' 
erythrocytes), efficiently induced immunity in the majority of the animals. Immunity is 
defined as the absence of parasitemia accompanied by clinical disease after a challenge 
infection with the parasite. Using this procedure, an optimal immunization period of 5 
weeks was found (5). Interestingly in mice, whose average life expectancy is 1.5 to 2 
years the immunization period takes 5 weeks, while in humans where the life expectancy 
is 70 years, this period corresponds to 5 years. 
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Live parasites are much more efficient than "dead" parasites in 
maintenance of immunity 
In the majority of animals immunized by a drug-controlled infection the 
challenge infection did not lead to a patent infection. When mice were immunized by less 
optimal procedures (i.e., drug concentration too high or immunization period too short) 
either a slowly developing fatal infection was found or immunity developed after a 
parasitemia in an increased proportion of the mice. 
At this point, we shall consider two types of immunity: 
1. Immunity occurring with the persistence of parasites (termed premunition) 
and 
2. Immunity occurring without the persistence of parasites (termed sterile 
immunity). 
1. Premunity, where individuals are carriers of the parasite and are protected 
from overt disease at the same time, is found in both human as well as in P. berghei 
malaria in mice. Immunization by a sulfonamide-controlled parasitemia induces a carrier 
type immunity in all mice. In such animals, 1 parasite site is found for every 10* to 10' 
erythrocytes. Challenges with as much as 10" parasites are rapidly suppressed to these 
levels. When premune animals remain unchallenged, a gradually increasing proportion 
of the animals cleared their parasites (tested by subinoculation of blood to naive mice). 
The kinetics of this process are specific for the mouse strain used (Figure 1). 
2. Sterile immune mice became sensitive to infection approximately 3 months 
after the disappearance of the parasite. The longer the sterile period, the more severe the 
course of the challenge infection. When the challenge was given after a sterile period of 
one year, an infection indistinguishable from that found in naive animals, was observed 
(3,4). In addition, it was found that this fading of immune reactivity after clearance of 
the parasite followed the same kinetics when parasites were eliminated by radical 
chemotherapeutic (chloroquine) treatment of premune mice. 
What is the role of parasites in the maintenance of immunity? Experiments, 
schematically described in Figure 2, were carried out to specifically test if immunity 
could be maintained. The results showed fading of immunity in the absence of persisting 
parasites (either by spontaneous disappearance or after chloroquine treatment). Neither 
the injection of sonicated or freeze-thawed material of 10' PE given at monthly intervals 
nor the injection of 10 ' live parasites given under a chloroquine (CQ) cover, to prevent 
proliferation of the parasite, prevented fading of immunity. However, when animals 
were regularly challenged with low numbers of live parasites at weekly or monthly 
intervals, no fading of immunity occurred, even when challenges were given under 
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suppressive, sulfonamide treatment (which limits but does not prevent proliferation of 
the parasite). 
PROPORTION (%) OF MICE WITH PARASITES 
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Figure 1. Immune mice were challenged. Persistence of parasites was determined at 
several time points by subinoculation tcsLs. The range of proportions of parasite-positive 
mice is summarized (except В10LP). 
From the experiments described above it appeared that only live parasites 
provided the adequate signals for maintenance of immunity. 
Though the presence of the parasite is essential in maintaining immunity, 
immunity apparently cannot be improved by repealed challenges given before the 
beginning of the fading period. Repeated challenges (e.g., in one test where 8 challenges 
о 
with 10° parasites were given within a period of 14 days) neither turned premune mice 
into sterile immune mice nor delayed fading of immunity in sterile (CQ-treated) immune 
mice. 
This set of experiments testing the maintenance of immunity showed that mice 
were immune as long as they were carriers of parasites and when they were no longer 
carriers (i.e., when they cleared their parasites or parasites were cleared by chloroquinc 
treatment, their immunity lasted for a period of approximately 3 months thereafter. This 
situation resembles that which has been described for human malaria by Maegraith (8) 
and what is observed in areas with seasonal malaria. 
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Figure 2. Experiments testing the effect of challenge with live proliferating parasites 
(before or during infection), disrupted, or live non-proliferating parasites (during the 
fading period) on fading of immunity. 
Live parasites are much better immunogens than "dead" parasites 
The experimental results seem to highlight three points : 
1. live parasites are important for the induction as well as the maintenance of 
immunity 
2. nonproliferating parasites or parasite extracts are poor immunogens with 
respect to induction of immunity and are nonimmunogens with respect to 
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maintenance of immunity and 
3. the effector mechanism can be maintained but not improved by boosting 
with parasites. 
Furthermore these results imply that: 
1. the important signal may only be produced in sufficient amounts by 
the living parasite, like milk is only produced by a living cow, or 
2. only living parasites can make contact with or deliver appropriate signals 
to an essential part of the immune system. 
An intriguing aspect of this latter concept is the possibility that a special 
architecture (e.g., the barrier-cell complex in the spleen, as described by Weiss (15)) 
must be induced in order for the control of infected erythrocytes to take place. The 
induction of such a system, its characteristics and efficiency may be species specific and 
is not improved by boosting. This may have serious implications for vaccine 
development. 
Pregnancy dependent suppression indicates a cell-mediated rather than a 
humoral effector mechanism in malaria immunity 
The role of live parasites in malaria immunity was further investigated in other 
experimental situations including pregnancy and cerebral malaria (CM). Both in human 
(14) as well as in P. berghei-mousc (10) malaria, suppression of malaria immunity is 
observed during pregnancy. In both cases, the problem is proportionally more severe in 
Primigravidae than in multigravidae, though the physiological processes (e.g. hormone 
levels) are the same in both conditions. Immune mice radically cured before entering 
their first pregnancy and challenged to be made premune before entering a subsequent 
pregnancy, lost their immunity during the second pregnancy as in the primigravid 
condition. However, when mice experienced a sulfonamidc-controlled infection during 
their first pregnancy, recrudescence occurred much less frequently during subsequent 
pregnancies (11). Only live, proliferating parasites present during the second part of the 
pregnancy period could accomplish this. 
Experiments done in pregnant mice where repeated parasitic challenges were 
given shortly before the first pregnancy showed that these challenges did not prevent 
loss of immunity during pregnancy (12). The average gestation period in the mouse is 3 
weeks. Recrudescence of parasitemias appeared in the second week. Despite boosting of 
antibody levels by challenges with live parasites shortly before pregnancy, the mice still 
lost their malaria immunity within two weeks of their pregnancy. In other words, mice 
lose their malaria immunity during pregnancy despite high antibody levels. Furthermore, 
it appears that a pregnancy-associated increase in the corticoid level is responsible for 
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suppression of malaria immunity both in mice and in women (12, 14). In addition, it 
was found in mice, that the humoral response was normal, but the T-cell mediated 
immune response in general, as well as the one specifically directed against P. berghei 
antigens was suppressed (13). 
These phenomena raise a question about the role of specific antibody in the 
effector system of immunity. 
In addition to the above phenomena, antibody from immune mice, even after 
repeated challenges, neither prevents (but delays onset of patency), nor cures (but 
temporarily suppresses) an infection in naive mice. Thus, antibody alone is not sufficient 
and the effector mechanism of malaria immunity may be a multifactorial system. 
Live parasites or their products are better immunogens than "dead" 
parasites in the immunization against CM 
Live parasites also appear to be important in induction of immunity against CM, 
another important aspect in P. berghei-infectcd mice. The proportion of mice that develop 
cerebral hemorrhages between Day 9 and 14 after infection with P. berghei is dependent 
on the mouse strain tested. Approximately 85% of infected female C57BL/6J mice, the 
type used in this laboratory, develop the syndrome. Analysis of the pathogenesis of the 
cerebral syndrome revealed that a timely treatment with antibody from immune mice 
(before Day 5 of infection) prevented CM normally occurring between Day 9 and 14 (1). 
This suggested that mice could be immunized against the syndrome and that having the 
proper antibody in sufficient quantity and in time (before Day 5 of infection) would 
prevent development of CM. 
In a series of early experiments it was found that increasing numbers of 
parasites used to infect the mice reduced the proportion of mice developing CM. Thus, 
when 10 ' or more parasites were used for inoculation, none of the mice developed CM. 
The proportion of mice with CM gradually increased when less parasites were used for 
infection; therefore, despite an earlier increase in parasite number with the high 
infections, no CM developed. One explanation for this occurrence might be that high 
numbers of parasites appearing early during infection are able to trigger antibody 
synthesis sufficiently to prevent development of CM later. When antigens produced by 
live parasites (such as the exoantigens described by Taverne et al. (2) play a role, the 
production of IgM is important. Ongoing malaria infections suppress antibody 
production, particularly of the IgG type. Induction of IgM production may take place by 
this time and possibly continues for some time after this. 
Attempts were made to immunize mice against CM. Mice were preimmunized 
with: 
1. sonicated or freeze-thawed parasites, either used as such or 
in combination with Complete Freund's Adjuvants 
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2. live parasites, either under a chloroquine cover, or chloroquine treatment 
started one or two days alter infection or 
3. exoantigens obtained from the supernatant of a 24 hour cultivation of the 
parasite as described by Taverne et al. (9). 
Optimal protection against CM was obtained when mice were immunized with 
live parasites, treated with CQ 2 days after infection, and reinfected 7 to 12 days later to 
establish whether immunization against CM was successful. When disrupted (freeze-
thawed, sonificatcd) parasites or exoantigens were used for immunization, results varied 
from no effect, (i.e. no protection at all against CM) to protection in a proportion of the 
animals. None of these immunization procedures had an effect on the course of the 
parasitemia. Mice immunized successfully against CM exhibited the same parasitemia in 
the first one and a half weeks of the infection, but did not die in the second week. They 
eventually died between 3 and 5 weeks after infection with severe anemia, secondary 
infections and other pathological changes, but without brain pathology; the hallmark of 
CM. Repeated injections of the same material (killed parasites or exoantigens) did not 
improve immunization against CM. It was also clear in the case of exoantigens that in 
order to have an immunizing effect, the material had to be collected from parasites that 
had been cultured in vitro. 
These experiments on immunization against CM indicate that proliferating 
parasites are better immunogens than nonproliferating, killed or disintegrated parasites. 
In addition, the results support the hypothesis that products secreted by proliferating 
parasites protect against CM. 
Another aspect of experiments on induction of immunity against CM is that IL-
1 treatment early during infection (Day 0 to Day 5) could prevent development of CM 
during a P. berghei infection (2). IL-1 treatment has been reported to stimulate 
proliferation of banier cells in the spleen. The development of barrier-cell-complexes 
was implicated in protection in murine malaria (16). (This aspect too may have important 
implications for the development of a vaccine). 
Summary 
All of the results of the various experiments support a role for living, 
proliferating parasites in the efficient induction of anti-parasitic as well as anti-disease 
(CM) immunity. Non-proliferating parasites or material from disrupted parasites are poor 
or nonantigens in this respect. 
Three possibilities as to why living parasites are important in immunity could 
be considered: 
1. circulating parasites contain insufficient antigen to induce protective 
immunity, but sufficient antigen can be produced during proliferation, 
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2. only circulating parasites arrive at critical places ( e.g., parts of the white 
pulp of the spleen) for the presentation of the important antigen or 
induction of appropriate signals and 
3. architectural changes are needed (i.e., formation of barrier -cell 
complexes) for the immune response to be effective. 
The first possibility explains why exoantigens, as well as live, proliferating 
parasites are efficient inducers of anti-CM immunity. Since these immunizations have no 
effect on parasitemia, additional/other immune reaction(s) arc needed for anti-parasitic 
immunity. The important role of the spleen in malaria and malaria immunity is well-
known. 
The second possibility includes the idea that live, proliferating parasites 
circulate through the spleen continuously where unsatisfactory or infected erythrocytes 
are removed rather than in the liver. Injected killed parasites or material from them when 
present in the circulation is to a larger extent taken up by the Kupffer cells from the liver 
rather than the spleen. Presence and uptake of parasites in the spleen may provide the 
critical confrontation and/or delivery of signals necessary for the development of 
immunity. 
The third possibility, apart from possible specific immune responses induced or 
stimulated locally, uptake of parasites in the spleen macrophages may provide sufficient 
local IL-1 release for the stimulation of a barrier cell network, that in turn plays a role in 
anti-malaria immunity. The anti- parasitic effect of IL-1 and its protective effect against 
CM support this possibility. 
The results apparently also indicate that anti-parasitic immunity is not a 
monofactorial process. If architectural changes are essential in the spleen or other 
effector organs for the control of infected erythrocytes, development of an epitope or 
molecular vaccine may become exceedingly complicated. With respect to erythrocytic 
stages, only with regard to anti-CM immunity does the development of an antibody 
based vaccine look promising. 
Research on the use of attenuated parasites for immunization and analysis of the 
mechanisms of induction and effector function should be further emphasized. 
Footnote: PE corresponds to erythrocytes parasitized with the virulent form of P. 
berghei (strain K173, wildtype) referred further throughout the dissertation text as VP or 
virulent parasite. 
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SUMMARY 
During the course of a 5 week sulfonamide-controlled immunizing infection in 
mice using the virulent form of Plasmodium berghei, an attenuated type of parasite 
developed. The attenuated parasites were less virulent in that they did not induce cerebral 
malaria (CM) in naive mice as seen in wildtype infections. Pretreatment with virulent, 
but not with attenuated parasites, protected against development of CM in a subsequent 
challenge infection with the virulent parasite (VP). In addition, mice could be protected 
against virulent type challenge infections when infected with the attenuated parasites 
which were controlled by sulfonamides for 3 weeks. By contrast, a drug-controlled 
infection with the virulent parasites themselves required a minimal immunization period 
of 5 weeks. Furthermore, the attenuated parasite appeared to be an essential stimulant 
for the successful transfer of immunity by spleen cells from an immune donor. VP were 
not appropriate for the stimulation of such responses. Transferred spleen cells protected 
against the attenuated, but not the VP; however, protection against the virulent form 
could develop (within a week) but only after stimulation with the attenuated parasites in 
the acceptor. Because of its immunogenic properties, these parasite(s) were called 
immunogenic parasites (IP). 
INTRODUCTION 
Untreated Plasmodium berghei infections in mice are lethal. This is 
independent of the number of parasites that arc inoculated either by mosquito bite or by 
injection of erythrocytic stages. Immunity against the malarial parasite can be induced by 
the use of live, proliferating parasites with self-resolving infections (11) or by the 
administration of virulent parasites under chemotherapeutic control (1, 2). These 
methods were designed to evoke persistent (subpatent) infections which eventually 
produce strong immunity without harming the host. Attenuated rodent strains produced 
by radiation or intermittent in vitro cultivation have been studied as live vaccines (19, 
20). Waki et al. (19, 20), for example, developed attenuated strains by irradiation of 
different species of rodent malaria parasites, including P. berghei and P. yoelii, which 
were able to immunize against the virulent parent strains. Chemotherapeutics, such as 
sulfonamides and chloroquine (CQ) (1, 2), used to control the load and length of 
exposure time of the host to the parasite have also been effective in immunizing mice. In 
previous experiments in this laboratory, it was found that mice could be effectively 
immunized against P. berghei by a chemolherapeutically-controlled, subpatent infection 
(6). The optimal immunization period was 5 weeks. Immunosuppressive treatment 
(dexamethasone or anti-T cell serum) used to interfere with the development of 
immunity was only effective when applied in the last week of the immunization period 
(7, 8). This suggests that the actual priming of the lymphocytes occurred late in the 
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immunization period and that this priming occurs after other biological processes have 
taken place. It was hypothesized that selection or adaptation of parasites during the early 
phase of the immunization procedure might be required for the induction of the late 
phase. To determine whether the parasite population changed during the immunization 
process, first spleen cells and later samples of peripheral blood were prepared from mice 
at various time points during the 5 week immunization period and transferred to naive 
mice. The capacity to induce immunity in naive acceptors was assessed. This might give 
an indication as to the time point of lymphocyte sensitization in vivo and thus reflect the 
presence of attenuated parasites. 
The results described-in this paper show that in the course of the immunization, 
an attenuated parasite developed which lacked characteristic pathological properties 
(e.g., development of CM). In comparison to the virulent parent parasite, this IP: (a) 
exhibited transient parasitemias and subsequent immunity to the virulent parasite when 
injected in low numbers, (b) immunized mice in 3 weeks compared to 5 weeks when the 
wildtype parasite was used, (c) was essential for the stimulation of immune spleen cells 
(ISC) transferred to naive mice to generate protection against the original wildtype. 
Finally, this IP remained immunogenic after mosquito passage. 
MATERIALS AND METHODS 
Mice. Male and female, C57BL/10, -/6J, -/Rij, B10LP, СЗН/StZ and Swiss mice were 
used in the experiments. Mice were obtained from the Central Animal Facility at the 
University of Nijmegen (The Netherlands), housed under specific pathogen-free 
conditions in plastic cages and received food (RMH, Hope Farms, The Netherlands) and 
water ad libitum. All mice in any particular experiment were age-matched. Compiled 
results from several experiments are reported. 
Parasites. The virulent form of Plasmodium berghei-КПЪ or P. berghei-ANKA were 
designated VP. The K173 strain has been maintained in our laboratory by syringe 
passage only for many years and can no longer be transmitted to mosquitoes. The 
ANKA strain, originally obtained from Dr. B. Mons (Department of Parasitology, 
University of Leiden, The Netherlands), was maintained by a combination of syringe 
passage and a monthly mosquito passage from which new syringe passages were done. 
VP were kept viable by weekly passage in intact mice of the strain specified in 
the experiments, using 1(P parasitized red blood cells (RBC) obtained via the tail blood 
of mice. Tail blood was collected in sterile, phosphate-buffered saline (PBS, 10 mM, pH 
7.2) containing 5U heparin/ml to prevent clotting, adjusted to the appropriate 
concentration by determination of parasitemia and injected intraperitoneally (i.p.) into 
mice. 
Mosquito passage oí P. berghei-ANKA. For the mosquito passage of P. berghei-
ANKA, normal intact mice were infected with 10' parasites. Three days later female 
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Anopheles gambiae mosquitoes were allowed to feed on the mice, fed and unfed 
mosquitoes were separated, and 18-21 days later these mosquitoes were allowed to feed 
again on naive mice. For the passage of the VP normal intact mice were used. 
Parasitemia. The parasitemia is expressed as the relative number of peripheral RBC 
infected with malaria parasites. It was determined from bloodsmcars stained with May-
Griinwald/Giemsa (Merck, Germany)-stain solutions. 
Challenge infection. For challenge infection, mice were injected i.p. with 1(P 
parasites/mouse obtained from blood passage. This was done in the following manner. 
Thin smears were made from passage mice and their parasitemia determined as 
mentioned above. The sample was diluted with PBS to obtain 5 χ IO5 pRBC per ml and 
200 μΐ per mouse injected. 
Drug treatment. Drugs needed to control (sulfonamides) or eliminate (CQ) the 
parasite were included in the drinking water. Sulfathiazole-Na (300 mg/1) or 
sulfadiazinc-Na (20 or 30 mg/1) were used to keep infections at subpatent levels. CQ-
phosphate (100 mg/1) was used for a period of 5 days to radically cure the mice. Drugs 
in the drinking water were freshly prepared 2 times a week. 
Body temperature. Rectal temperatures were taken daily using a digital thermometer 
(Technolherm 1200). 
Histology. To determine the presence of cerebral lesions in experimental mice, post­
mortem tissue was investigated using routine histological procedures as described before 
(4). 
"5 week immunization" procedure with the VP (see Figure 1 A). Mice were 
immunized, as described earlier (5, 13), by the i.p. injection of 1-3 χ 10' P. berghei 
K173 or ANKA VP followed 2 days later by sulfonamide therapy included in the 
drinking water. Mice were kept on sulfonamide until Day 33. After this time, on Day 35, 
a challenge with VP was given to test their ability to resist infection. Mice were judged 
immune when after a challenge infection, parasitemia remained subpatent or did not 
exceed 1% and then returned to subpatent levels. It should be noted that immune mice 
are carriers of low numbers of parasites which is functional in the maintenance of 
immunity (9, 13). 
Isolation and maintenance of the IP. In the final adopted procedure, blood 
containing IP was collected at Day 28 during the 35 day immunization procedure and 
injected i.p. into splenectomized acceptor mice. These parasites were maintained by a 
biweekly transfer of 105 parasites to naive, splenectomized animals. IP were 
characterized by their ability to induce immunity in (drug-treated) mice within a period of 
3 weeks (see below) or within a period of 1 week in mice that had received spleen cells 
from immune donors. Isolates of IP were stored as stabilates in liquid nitrogen. 
"21 day immunization" procedure (see Figure IB): Transfer of cells from mice 
developing immunity. Parasite-containing blood samples or spleen cell preparations 
52 
were prepared from donor mice at different time points during the 35 day immunization 
period with VP (see Figure 1A) and transferred to naive acceptor mice. The acceptors 
were treated with sulfonamide from Day 0 or 2 to 19 after transfer and challenged with 
virulent parasites 2 days later. In the case of blood transfer, each acceptor mouse 
received 0.2 ml of 5x diluted blood in PBS or tissue culture medium (M199, pH 7.2, 
Gibco). For spleen cell transfer, cell suspensions were made in a final volume of 1 ml 
per spleen. Of this suspension, 0.2 ml was injected i.v. into acceptor mice. Where 
indicated, pooled spleen cell suspensions were used. 
Immunization using IP lines. Mice were injected (i.p. or i.v.) with IP obtained 
from passage in splcnectomized mice. From Day 0 or 2 to Day 19, mice received 
drinking water supplemented with sulfonamide (see above). Two days later, animals 
were challenged with virulent parasites. 
Adoptive transfer of immunity using spleen cells. In the final adopted method, 
spleen cells were collected from immune donor mice which had been treated with CQ to 
clear parasites starting 7 days before the transfer. The spleen from the immune donor 
mouse was removed, mixed with M199 and added to a 10 ml syringe fitted with a nylon 
sieve and a plug of cotton wool. The spleen cells were dissociated by gentle pressure 
with a glass rod. Spleen cells were washed with M199 and counted. 1-4 xlO' spleen 
cells were injected i.v. into groups of naive acceptor mice. In addition, 1(F IP were 
injected i.p. into the acceptors of the spleen cells on the day of transfer and 7 days later 
the mice were challenged with VP to determine whether immunity had developed. 
In part of the experiments, acceptor mice given spleen cells from either normal 
or immune mice and IP or VP were kept on sulfonamide-containing drinking water for a 
period of 5 days from the day of transfer. 
Subinoculation test. The presence of parasites in immune mice was determined by 
the subinoculation of 30-50 μΐ of tail blood into naive acceptor mice. Intact, naive mice 
were used to detect the presence of the wildtype parasite (VP) and splenectomized mice 
were used to detect the presence of the IP. 
Preimmunization with IP. To determine if IP, like VP (3) could immunize mice 
against CM, mice were given 105 to 10** IP or VP for 2 days. CQ was given thereafter 
for 5 days (Day 3 to 7) to radically cure the infection. A challenge with IO3 VP, which 
causes CM on its own (3, 4), was given on Day 8 or 14 to determine if there was a 
protective effect against the development of CM. Control mice were treated in the same 
manner, however, received PBS in place of the preimmunizing parasites. It should be 
noted that mice that are successfully immunized against development of the cerebral 
syndrome during a subsequent VP infection exhibit a normally developing parasitemia as 
observed in control-treated mice (3). 
Mixed infections with IP and VP. Various amounts (given in the tables) of IP and 
VP were tested in combination in mice to determine if either parasite dominated the 
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infection. Mice were scored positive for a VP infection if they died early in the second 
week and exhibited a severe reduction in body temperature, as seen in mice with CM 
(4). Mice were scored positive for an IP infection if they did not match the 
characteristics seen in mice that developed CM (i.e., survived for more than 2 weeks 
(usually 3-5 weeks) and exhibited a transient, limited decrease in body temperature early 
in the second week). 
RESULTS 
Immunization by transfer of spleen cells or peripheral blood 
Mice were immunized in a 35-day immunization procedure (Figure 1A). At 
several time points both during the immunization period and after the VP challenge, 
spleens were collected from the donor mice and single cell suspensions were injected 
into naive acceptor mice. Acceptors receiving spleen cells and left untreated (i.e., no 
sulfonamide treatment) developed ongoing infections and died (results not shown). This 
is apparently due to the fact that these donors were carriers of parasites, a well-
established phenomenon of immunized mice (13). However, when acceptors receiving 
spleen cells from donors during specific days of a 35-day immunization were placed on 
sulfonamides for 19 days to control the transferred parasites (Figure IB), mice were 
able to control a subsequent challenge with VP given 2 days after the completion of the 
sulfonamide treatment. That is, mice on sulfonamides became immune within 21 days 
after receiving spleen cells removed during the 35-day immunization. Figure 2 shows 
the summarized data of several independent experiments. The figure shows the 
proportion of donor mice that could successfully be used for a 21-day immunization 
with sulfonamides. The proportion of donor mice that could be used for the 21-day 
immunization increased to a maximum around Day 28. A significantly lower percentage 
of the donors could be successfully used at Day 36, that is, one day after the donors had 
been challenged with VP. A high proportion of successful donors was also found at Day 
41. Almost no suitable donors were found 3 weeks after challenge (i.e., Day 54). The 
results carried out with donor material obtained at Day 36 or 54 were unexpected 
because parallel mice not used in the transfer, but challenged with VP, were immune and 
resisted a VP challenge infection. The possible explanation for these results will come 
from experiments described below in the sections on the course of mixed IP and VP 
infections and the clearance of IP in immune mice. 
The role of parasites in the transferred spleen cells was determined in additional 
experiments (Table 1 ). Spleen cells of immunized mice (removed at Day 28 during the 
immunization procedure) were transferred to acceptors and the acceptor mice received 
sulfonamide treatment (either on the day of transfer or 2 days later). After increasing 
periods, these mice were either (a) transferred to normal drinking water and challenged 2 
days later or (b) given CQ-containing drinking water to remove proliferating parasites 
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and challenged 21 days after transfer (Table 1). The results showed that by using both 
procedures an optimum immunity was obtained in acceptor mice with a 16 to 21 day 
immunization period. The data suggested that the parasites in the transferred spleen cell 
suspension played an important role in the immunization of the acceptors. To test this 
further, both spleen cells and peripheral blood were taken from donor mice and later 
injected into separate groups of acceptor mice. The mice were kept on sulfonamides for 
19 days and challenged 2 days later. Both transferred spleen cells and peripheral blood 
collected from the same donor at various time points during the 35 day immunization 
period (Figure 1) and given to separate acceptor groups, were able to immunize these 
mice by the 21 day procedure. The results of these experiments arc included in the data 
of Figure 2 and are not shown separately (see also Table 2). 
10 VP 10 VP 
Sulfonamide 
0 2 21 28 33 35 54 
• • * H + t i i 
Spleen cells/ blood 
from Immunized 
mice (A) 
Sulfonamide 
5 
10 VP 
19 21 В 
Day 
Figure 1: (A) 35-day immunization. Mice were injected with 1-3 xlO7 VP on Day 0 and 
placed on sulfonamide drinking water on Day 2 until Day 33. A VP challenge was given 
on Day 35 to test their ability to control a reinfection. Spleen cells or blood were 
removed at different times (small arrows indicate days) during the immunization or after 
the challenge and (B) injected into groups of naive mice. Mice were then placed on 
sulfonamide for 17-19 days. This is the 21 day immunization. Immunity was tested by 
giving a challenge with VP 2 days after removal of sulfonamides. 
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Figure 2: The percentage of donor mice inducing immunity in acceptors. Spleen cells or 
blood from mice were removed during the 35-day immunization or after challenge 
(Figure 1 A) and injected into naive acceptor mice (Figure IB). The percentage of donor 
mice able to transfer immunity to acceptors is shown on the graph on the y-axis. 
(Numbers between parentheses indicate the number of donors). The day during the 35-
day immunization with VP at which spleens or blood were removed from donors and 
given to acceptors is shown on the x-axis. 
Spleen cells or peripheral blood of mice at Day 28 of a 5 week immunization 
procedure were also transferred to acceptors varying in age from 1 day to 6 weeks 
(Table 2). To control parasitemia in the young mice, mothers of fostered mice received 
sulfonamide treatment for 19 days. Although acceptors of Day 28 spleen cells developed 
immunity more easily than acceptors of Day 28 peripheral blood when acceptors were 1 
or 4 days old, no difference was found when 16 day old or 6 week old acceptors were 
used (Table 2). 
The immunizing capacity of peripheral blood of donor immunized mice 
suggested that the immunizing principle in the spleen cell suspensions of the same donor 
mice could be the presence of a particular type of parasite that was able to immunize 
acceptor mice in 21 days instead of the original 5 weeks (35 days) needed for the 
wildtype parasite. It was decided to isolate this apparently more immunogenic parasite 
from the donor mice and determine its characteristics. 
Isolation of the attenuated parasite 
Since the proportion of donor mice that could successfully be used for the 
immunization of acceptor mice by transfer of blood or spleen cells was high on Day 28 
of the 35 day immunization period (Figure 2), peripheral blood of these mice was used 
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for the isolation of the parasite. Acceptor mice were splenectomized because they 
appeared more sensitive to infection with this type of parasite than intact mice (data not 
shown). 
Table 1 
Determination of the immunization period and relevance of 
proliferating parasites in acceptors of Day 28 spleen cells 
Period (days) of treatment with: Day of challenge Immune 
sulfa CQ (IO5 VP) 
0/2-12 no 14 8/19 
0/2-19 no 21 16/19 
0/4 
0/4 
2/4 
4/4 
0/5 
3/5 
0-7 
0-12 
0-16 
0-14 
0-18 
2-6 
7-11 
12-16 
16-20 
14-18 
18-22 
21 
21 
21 
21 
28 
28 
Spleens were removed from mice taken on Day 28 during the 35-day immunization with 
virulent parasites (VP). To prevent development of patent parasitemia, acceptors of 
spleen cells received sulfonamide (sulfa) treatment, either starting on the day of transfer 
or 2 days later. Clearance of persisting parasites was done by chloroquine (CQ) therapy. 
When parasitemia developed in the splenectomized mice, parasites were 
passaged as described above. Characteristic differences between these parasites (IP) and 
the original wildtype (VP) are described in the following sections. 
Dilution experiments aimed at the infection of mice with 1 IP to obtain clones of 
parasites were performed in splenectomized mice. Two cloning rounds were performed. 
The IP clones obtained in this way exhibited the same immunogenic characteristics as 
described for the parent lines in this paper. All further results presented were performed 
using an uncloned line of P. berghei-КПЗ. 
Isolation of IP at Day 28 of a 5 week immunization period was successfully 
performed using either P. berghei-КПЗ or P. berghei-ANKA or either one of these 
parasites in combination with different mouse strains (i.e, Swiss, В10LP, СЗН/StZ or 
C57BL). Both parasites exhibited the same characteristics and could either be used as IP 
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in the mouse strain from which they were originally obtained or in a different mouse 
strain, yielding the same results. P. berghei-ANKA IP remained immunogenic after 
repeated passages through mosquitoes. IP from K173 obtained from immunized Swiss 
mice, the first IP to be isolated, were used in most of the experiments reported here. 
Table 2 
Effect of age on development of immunity after transfer 
of spleen cells or peripheral blood cells 
Mice receiving: 
Age of acceptors Spleen cells Blood 
1 day 3/4 0/4 
4 day 6/6 0/4 
16 days 3/5 7/7 
6 wks. 5/5 5/5 
The number of immune acceptors of various ages resulting after receiving either Day 28 
spleen cells or Day 28 blood from the same donors immunized by the 5 week 
immunization procedure with virulent parasites (VP). 
Characteristics of IP infection 
Whereas a single VP is enough to give a rapidly fatal infection (within 2 
weeks), the course of an IP infection in normal intact mice depended on the size of the 
inoculum used. Inoculation of less than 1000 parasites in intact, normal mice resulted in 
(1) no patent parasitemia at all, (2) transient parasitemia or (3) development of slowly 
increasing parasitemia (Table 3). 
In particular: (1) If no parasites could be detected in the peripheral blood after 
IP injection, a challenge with VP 3 weeks later always exhibited a rapidly fatal infection 
as observed in untreated mice. This suggested that in these cases, the infection was not 
established. (2) Transient, usually low grade parasitemia (<1% infected cells, but 
occasionally reaching peak levels of 10% infected cells) resolved within 3 weeks (not 
shown). When such mice were challenged with VP, they all appeared to be immune, 
independent of the number of VP in the challenge inoculum. (3) Development of slowly 
increasing parasitemias, particularly when more (>10^) IP were injected resulted in 
eventual death of mice (not shown). In splenectomized mice, however, untreated IP 
infections were always lethal, independent of the number of IP in the inoculum. 
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Table 3 
Effect of size of inoculum on the course of infection 
Swiss B10LP 
Number of parasites** immune *** parasites** immune*** 
IP* found to VP found to VP 
16 
80 
400 
IO3 
IO4 
0/3 
0/3 
1/3 
3/3 
3/3 
0/3 
0/3 
0/3 
1/3 
1/3 
0/3 
0/3 
0/3 
2/3 
3/3 
0/3 
0/3 
0/3 
2/3 
2/3 
The course of the infection by immunogenic parasites (IP) depends on the size of the 
inoculum: <100 IP results in no patent infection. Only those mice that controlled IP were 
challenged (21 days after inoculation of IP) with virulent parasites (VP) to determine 
immunity to VP. *Number of IP in infection inoculum, ** Number of mice with 
peripheral parasites/inoculated mice, *** Number of mice immune to VP 
challenge/inoculated mice. 
IP and VP infections and development of CM 
IP infections developed more slowly than VP infections. The most remarkable 
observations in fatal IP infections were that (1) IP-infected mice always survived for 
periods of 4 to 5 weeks before they died with high parasitemia and severe anemia and 
(2) in contrast to VP infections, the development of CM (highlighted by death early in 
the second week and severe reduction in body temperature) was never observed in IP 
infections (Figure 3). IP-infected mice only exhibited a temporary decrease in body 
temperature and died later. Light microscopical observation of brain tissue of IP-infected 
mice never showed the lesions observed in VP-infected mice (4,9). 
The course of mixed IP and VP infections 
Although during the 35-day immunization period, mice were carriers of the 
parasite, they were not always successful donors of peripheral blood or spleen cells for 
immunization of acceptor mice (as shown in Figure 2). The possibility was considered 
that mixed infections of IP and VP occurred and that the course of infection in acceptors 
depended on the proportion of both types of parasites in the inoculum. 
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Since VP infections resulted in CM and early death (< 2 weeks after infection), 
while IP-infected mice never developed CM and survived for periods of 4-5 weeks, 
these characteristics were used to describe the course of mixed IP and VP infections 
utilizing varying numbers of each type. These experiments were carried out in 
C57BL/6J mice since almost all of these mice develop CM when infected with VP (4). 
The results described in Table 4 show that the VP characteristics of the infection (i.e., 
CM) were dominant, except when 100 times more IP were present, at which point, the 
IP type of infection dominated. A regression analysis of the log ratio IP/VP versus the 
proportion of VP type infections as a result of the mixed infections exhibited an r-value 
of0.86(p<0.01). 
Immunization against development of CM 
Previous investigations showed that VP infection for a period of 2 days 
(preimmunization) followed by radical cure with CQ treatment was able to immunize 
1 , 1 
60 
against development of CM in a subsequent infection with l ( r VP (3). IP 
preimmunizations for a period of 2 days were performed in 3 independent experiments, 
Table 4 
Mixed infections with IP and VP 
Type of infectiona: 
Amount IP 
1С)2 
103 
104 
104 
104 
104 
104 
105 
10* 
106 
108 
Amount V P 
ιοί 
103 
ιοί 
102 
103 
104 
105 
103 
1()4 
104 
103 
VP 
2 
3 
1 
1 
9 
3 
3 
2 
2 
0 
0 
IE 
1 
0 
5* 
2* 
0 
0 
0 
4 * 
1 
3* 
3* 
a
 The characteristic type of infection resulting from mice receiving a mixture of 
immunogenic (IP) and virulent (VP) parasites. * = IP/VP ratio where the amount of IP 
is 100 times or greater than the amount of VP 
along with VP preimmunizations. Summarized data from these experiments showed that 
non-preimmunized control mice were not protected against CM (0/9). Mice were 
protected when preimmunized with VP (44/58); however, only 4/20 mice were protected 
when preimmunized with IP controls. Thus, IP immunizations could not prevent the 
cerebral syndrome in a subsequent VP infection. 
IP immunization against IP or VP challenge infection 
Earlier reported experiments with VP showed that disintegrated parasites were a 
poor immunogen (8,9,13). Likewise, attempts to immunize with disintegrated IP were 
unsuccessful (results not shown). 
Chemotherapeutically-controlled VP infections could be used to immunize mice 
(6). Since untreated low dose IP infections only immunized a proportion of the mice 
(Table 3), immunization by a chemotherapeutically-controlled IP infection was 
investigated. 
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Table 5 
Period of immunization to VP by sulfonamide-controllcd IP infection 
Amount IP Sulfa treatment Day of challenge Immune mice 
0-12 
0-19 
0-19 
2-19 
0-7 
0-11 
0-19 
2-19 
0-12 
14 
21 
21 
21 
9 
15 
21 
21 
14 
5/9 
9/9 
88/136 
302/366 
0/12 
0/6 
46/72 
38/45 
0/3 
Immunization schemes against virulent parasites (VP) employing different amounts of 
immunogenic parasites (IP) and sulfonamide schedules. 
To determine an optimum immunization scheme, infection with different 
numbers of IP were tested in combination with sulfonamide treatment for several 
periods of time (Table 5). Experiments showed that infections with НУ, 10" or 10' IP 
per mouse controlled by sulfadiazine (20 mg/1) for a period of 17-19 days were most 
effective in inducing VP immunity in 21 days. Results were the same as those found for 
Day 28 spleen cells or Day 28 peripheral blood. 
Clearance of IP in immune mice 
Immunized mice challenged with VP usually carry the parasites for considerable 
periods of time (premunity) (5, 6). These persisting parasites exhibit VP characteristics 
upon subinoculation into naive mice (results not shown). By giving more parasites or 
repeated boosting, this situation is not changed (5, 6,9). That is, there is no change to a 
parasite-free or sterile immunity. Experiments were performed to analyze whether IP 
also persisted in immune mice. IP-immunized and VP-challenged mice were cleared of 
residual VP parasites and then challenged with varying numbers of IP parasites. On 
several days after IP challenge, 10-25 μΐ blood samples were collected from the tail 
vein, taken up in 0.2 ml of saline and then injected into splenectomized mice to observe 
the development of infection when parasites were present in the inoculum. The results 
(Table 6) show that part of the mice cleared IP parasites used for the challenge, and 
contrary to what might be expected, the proportion that cleared IP tended to be higher 
when more IP were injected. Immune mice that were treated with CQ to eliminate all 
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persisting parasites and then challenged with VP were usually all positive in 
subinoculation tests during the 2 week test period and even longer (5,10). 
Table 6 
Clearance of IP from immune mice 
Challenge with: Number of mice Subinoculation negative on day: 
2 5 14 
105IP 3/8 2/3 4/8 4/8 
106IP 3 1/3 1/3 1/3 
107IP 5 2/5 3/5 3/5 
108IP 7 0/7 2/7 5/7 
Immune mice were infected with various amounts of immunogenic parasites (IP) 
followed by subinoculation of blood into splenectomized mice to determine if the IP 
parasites remained in the immune mouse or were cleared. 
The role of IP in transfer of immunity 
Experiments were carried out to immunize mice by transfer of spleen cells from 
immune mice to naive mice. The results of a typical experiment, that as a whole or in 
parts was repeated many times with the same results, are depicted in Table 7. Transfer of 
ISC collected from premune donors resulted in a lethal infection in the acceptor mice, 
apparently because of the presence of VP parasites in the transfer inoculum (results not 
shown). Immune mice were, therefore, treated with CQ (100 mg/1 for a period of 5 
days) and left untreated for 2 days before transfer of the spleen cells. Acceptor mice 
receiving ISC were not able to resist a challenge infection with VP parasites and 
developed a rapidly increasing parasitemia and died as if no protection at all was 
transferred. Even when all of the ISC of one donor mouse were transferred to a single 
naive acceptor mouse, no protection to VP challenge was obtained, not even when low 
numbers of VP were used for challenge. In contrast, acceptor mice were immune to IP 
challenge. Immunity was not found when IP were given without ISC or when only ISC 
were given. Furthermore, mice receiving both ISC and IP could also control a challenge 
with VP 7 days later. 
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Table 7 
Conditions under which immunity develops in acceptor mice 
Cells transferred 
Normal donor 
NSC 
NSC 
NSC 
Sterile immune donor 
ISC 
ISC 
ISC 
Parasite donor 
IP alone 
IP alone 
VP alone 
Stimulus 
— 
IP 
IP 
— 
IP 
IP 
— 
— 
— 
Challenge ÍDav 7) 
VP 
— 
VP 
VP 
— 
VP 
— 
VP 
— 
Immune 
0/6 
0/6 
0/6 
0/6 
6/6 
6/6 
0/6 
0/6 
0/6 
Acceptor mice were given normal spleen cells (NSC) or immune spleen cells (ISC) to 
determine if immunity would develop. Immunogenic (IP) and virulent (VP) parasites 
used at 105 parasites/mouse were also tested. 
DISCUSSION 
The immunizing principle of a chemotherapeutically-controlled (sulfonamide 
treatment) infection with VP for a period of 35 days is the development of an attenuated 
IP. Thus, the comparatively long immunization period of 35 days is not needed for the 
development of complicated immune reactions, but for a large part for the attenuation of 
the parasite. This explains why immunosuppressive measures only have an effect in the 
last week of the immunization period (7), that is when these attenuated parasites (IP) 
actually stimulate protective immune responses. How attenuation is achieved is not 
known. Attenuation was observed for both P. berghei strains (K173 and ANK.A) and 
did not depend on the mouse strain used. It is not likely that IP is selected from the 
original VP population of К173 and ANKA parasites. The results of mixed infections 
suggest that a 100-fold higher number of a given type or parasite apparently eliminates 
the other type (Table 4). In combination with the lower proliferation rate of IP compared 
to VP and a syringe passage of VP in the laboratory for many years, it is not expected 
that IP survive in the VP population. The course of mixed IP and VP infections may 
explain why donors selected on Day 36 ((i.e., 1 day after VP challenge). Figure 2)) 
were less effective in induction of immunity by the 21 day sulfonamide procedure. 
These donors harbored not only IP, but also VP obtained from the challenge infection. 
The VP from the challenge probably inhibit IP proliferation and stimulation of immunity. 
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Since immunity tends to eliminate IP, but not VP (Table 6 and subinoculation tests), this 
explains why donors 2 weeks or more after challenge, that are carriers of the parasite, 
are ineffective in induction of immunity by the 21 day procedure. In such donors VP, 
but not IP, persist. 
Attenuation was apparent from (a) the course of untreated infections, (b) the 
ability to induce immunity faster, and (c) the capacity to stimulate ISC for the generation 
of VP immunity. Whereas a single VP is enough to establish infection and cause CM, IP 
at low numbers either did not establish infection, produced transient infections followed 
by immunity, or resulted in long lasting, lethal infections that never led to CM. This 
suggests that in comparison to VP, IP either have developed qualities that enhance 
induction of immunity or have lost dominating qualities that induce pathology. The 
gradual change in the course of primary untreated infection when increasing numbers of 
IP are inoculated, from no infection to transient, to lethal infection, may even suggest 
quantitative rather than qualitative changes in IP compared to VP. The lower parasitemia 
after IP as compared to VP infection (Figure 3) may relate to the lower sensitivity of 
intact mice to IP and/or a stronger antigenicity of these parasites/parasitized erythrocytes. 
The observation that preimmunization against the cerebral syndrome was 
possible with VP, but not IP, suggests that IP have lost the capacity to induce this 
immunopathological reaction (4,12) which points to a phenotypic difference between IP 
and VP. The IP phcnotype was stable during mosquito transfer as shown for P. berghei-
ANKA IP and remained stable after passage by subinoculation of infected blood in 
splenectomized mice for several years now. 
Immunity to IP induced by a primary transient or chemotherapeutically-
controlled infection developed in 21 days. Such mice were also protected against VP 
challenge. This was not only found when IP obtained from passage mice were used, but 
also when peripheral blood or spleen cells from mice submitted to the 35 day 
immunization procedure (e.g., at Day 28) were used. Not only for peripheral blood, but 
also for spleen cell preparations (e.g., from Day 28 mice), a 21 day period was needed 
to develop immunity in the acceptor mice (Table 1). Thus, suggesting that the 
immunizing principle was the presence of IP in these preparations and that the spleen 
cells did not provide additional information. On the other hand, transfer of Day 28 
spleen cell suspensions containing IP were more efficient in induction of immunity in 1 
or 4 day, but not 16-day or 6-week, -old mice than peripheral blood (Table 2). This may 
be explained by the suppletion of immunocompetent cells not yet present in the very 
young mice. 
When specific information is available after transfer of ISC to naive mice, IP 
challenge can, but VP challenge cannot, be controlled. However, after IP stimulation of 
ISC, VP immunity is generated within a week. Thus, IP immunity can be transferred, 
but VP immunity cannot. IP stimulation is necessary to generate VP immunity, both for 
primary immunization and after transfer of ISC. This suggests that IP stimulation drives 
65 
the immune system to protective reactions that can suppress development of pathological 
reactions stimulated by VP. Like in other parasite-host combinations (sec 11), IP or VP 
stimulation may preferentially activate Τ cell subsets (e.g., T
n
l versus T
n
2 or vice 
versa). Once IP have preferentially stimulated a given subset of T-cells, the 
accompanying cytokine output helps to suppress other subsets when VP is given. This 
cytokine driven regulation of activation and suppression of T-cell subsets has been 
described before (15,16). 
The most remarkable observation is that IP, but not VP can stimulate 
transferred ISC to induce immunity. Not even when transferred ISC were stimulated by 
chemosuppressively-controlled VP could immunity be established. This favors the 
hypothesis that VP lack the immunizing principle that IP have. In addition, this implies 
that in this parasite-host combination, VP are a poor source for the detection of a vaccine 
target. Moreover, the observation that live, proliferating IP must be present during the 
entire 21-day immunization period (Table 1), may suggest that the immunizing principle 
concerns a parasite-released product rather than a parasite surface molecule, which again 
may have serious consequences when looking for vaccine targets. 
The principle of immunity against virulent pathogens after immunization with 
an attenuated, less virulent form of that pathogen is well-known (e.g., cow pox 
infection to protect against small pox), even in malaria (11,14,17, 19,20). The special 
point in the work presented here is that the attenuated form is generated during 
immunization and not by irradiation (14, 19, 20) or tissue culture passages (21) and is 
stable upon passage by subinoculation, as well as by passage through the mosquito. 
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Chapter 4 
Attenuated immunogenic parasites are essential in the transfer of 
immunity to virulent Plasmodium berghei 
С M. Cclluzzi, Ρ .L, Liem, Th. van de Wiel and W .M. C. Eling 
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SUMMARY 
During immunization against the virulent wildtype of Plasmodium berghei by a 
chemotherapeutically-conlrolled infection, an attenuated immunogenic form of the 
parasite (IP) was isolated. The IP was found to play an essential role in the transfer of 
immunity with immune spleen cells (ISC) to the virulent parasite (VP). ISC, but not 
lymph node cells (LNC), could transfer immunity to IP in acceptors, but not to VP 
(even low numbers of VP). However, stimulation of transferred ISC with IP was able 
to generate VP immunity within one week. Both the number of ISC and IP were 
important for successful development of VP protection in acceptors. Live, proliferating 
IP for a period of 1 week was necessary to develop VP protection. ISC transferred to 
acceptors could not be stimulated by freeze-thawed IP to protect against VP challenge. 
Stimulation of the acceptor with the parasite before the transfer of ISC was also unable 
to give VP protection. It was observed that ISC persisted in acceptor mice, since ISC 
transferred from female to male, then from this male to a subsequent male and finally 
from the second generation male back to a female induced immunity after IP challenge (a 
procedure lasting 5 months). A relationship between successful VP immunity in 
acceptors after transfer of ISC and IP stimulation and development of antiparasitic 
antibody was also observed. 
INTRODUCTION 
It is known that immunity against the malaria parasite Plasmodium can be 
induced in some animal models. In the mouse, in particular, several immunization 
procedures have been employed using parasites with self-resolving infections (15, 28, 
29) or parasites that have been administered under chemotherapeutic control (1, 3, 6, 
16, 30). The latter type of immunization allows the parasite to be maintained at 
appropriate levels capable of stimulating the immune system without totally 
overwhelming it. 
One such immunization procedure employed in this laboratory involved the 
injection of 1-3 χ 10' virulent/? berghei (K173) parasites and the application of 
sulfonamides for 5 weeks (16). After this time, mice were able to control a new 
challenge with the parasite. It appeared that the persistence of the live parasite during the 
5 week immunization period was important for development of immunity (6, 7, 8, 9, 
16). In addition, immunosuppressive measures preventing induction of immunity were 
particularly effective in the last week of the 5 week immunization period (10, 11). This 
suggested that during the last part of the immunization period specific changes occurred 
in the host-parasite interaction. By transfer of spleen cells or blood of mice that were 
immunized by the 5 week immunization procedure to naive acceptor mice, it appeared 
that the persisting parasites in immunized mice were attenuated (Chapter 3). Normal, but 
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not splenectomized mice were less sensitive to infection with this parasite. These 
parasites were isolated, passaged in splenectomized mice and their character studied. In 
normal mice these parasites did not induce cerebral malaria (while VP did) (4). Transient 
infections were observed when inoculated in low numbers (<103 parasitized RBC 
(pRBC)/mouse); however, higher doses were lethal, unless there was chemotherapeutic 
control. Under chemotherapeutic control, mice could be immunized within a 3 week 
period compared to a 5 week period necessary when VP were used. Because of these 
characteristics, this type of parasite was called immunogenic (IP) in comparison to the 
original more virulent wildtype (VP). IP was developed from P. berghei-КПЪ and -
ANKA parasites. The latter maintained its characteristics after mosquito passage. IP 
appeared to be essential for the induction of immunity in mice that received spleen cells 
from immune donor animals. 
Transfer models (i.e., the transfer of cells from one animal to another) have 
been most useful in gathering information about the type of immunity (humoral or cell-
mediated) and the specific cell populations that offer protective immunity against malaria. 
A variety of transfer models (e.g., rat, mouse) using parasites with self-limiting 
infections, attenuated parasites or parasites that are virulent in some, but not all, hosts 
have been reported (12,15,22). 
Immunity generated in response to non-virulent, self-limiting infections in mice 
and donors from such infections have been studied in transfer models. A role for 
attenuated parasites was not established in any of these studies. However, the finding by 
Fahey and Spitalny (12) that 7 and 14 days, but not 21 and 28 days after an immunizing 
infection with P. yoelii that immunity could be transferred by transfer of spleen cells, is 
compatible with a role of the parasite in an immunizing inoculum. 
This paper reports the immunization of mice by the inoculation of spleen cells 
from P. berghei-immunc donors, being stimulated with IP. The experiments show that 
transfer of ISC protect against IP but not VP challenge and stimulation of these ISC by 
live, proliferating IP is essential for induction of immunity to the VP of the parasite in 
acceptor mice. In addition, it is shown that transferred ISC persist in the acceptor mice. 
Different parameters of the model were developed including, the number of cells 
necessary to transfer immunity, the time limitations involved in the administration of the 
cells, the need for IP and the number of IP necessary to effect immunity. In addition, 
development of antiparasitic antibody appeared to be related to development of immunity 
in ISC acceptor mice stimulated with IP. 
MATERIALS AND METHODS 
Mice. Naive, male and female C57BL/10 or C57BL/6J mice used as acceptors at 6 to 8 
weeks old were obtained from the central animal facility at the University of Nijmegen, 
The Netherlands. Mice were housed under specific pathogen-free conditions in plastic 
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cages (39 χ 22 χ 14 cm) and received food (RMH, Hope Farms, The Netherlands) and 
water ad libitum. All mice in any particular experiment were age-matched. Experiments 
were repeated and results of experiments comparing the amount of ISC and stimulation 
with the IP involved 6-69 mice. All other reported experiments involved at least 3 mice. 
Parasite. Both the original wildtype, VP, and an immunogenic form , IP, derived from 
the wildtype of Plasmodium berghei К173 were used in these studies. The development 
of the immunogenic form has been described in detail elsewhere (Chapter 3). Briefly, IP 
were isolated on Day 28 of a 5 week immunization procedure by the subinoculation of 
blood of mice being immunized by a chemotherapeutically-controlled infection (see 
below) into splenectomized mice. 
VP were kept viable by weekly passage in intact mice and IP by weekly or 
biweekly passage in splenectomized C57BL/10 mice using ICH pRBC obtained via the 
tail blood of infected mice. Tail blood was collected in sterile, physiological saline 
containing 5U heparin per ml, adjusted to the appropriate concentration by determination 
of percent parasitemia and injected intraperitoneally (i.p.) into passage or experimental 
mice. The percent parasitemia was determined by counting pRBC to uninfected RBC 
appearing in May-Griinwald/Giemsa (Merck, Germany)-stained thin bloodsmears. 
Aliquots of parasitized blood were stored in liquid nitrogen. 
Immunization of mice. Immunization of mice to VP by a chemotherapeutically-
controlled 5 week infection has been described elsewhere (16). Briefly, mice were given 
1-3 χ 10 ' parasitized RBC of the VP. To prevent clinical malaria, suppressive treatment 
was started 2 days thereafter by the addition of sulfalhiazole-Na (150-300 mg/1) or 
sulfadiazine (20-30 mg/1, S20, S30) to the drinking water for 33 days. Two days after 
withdrawal of the sulfonamide treatment, the mice were challenged with 10* VP to 
ascertain immunity. Mice were judged immune if parasitemia did not go above 1% or 
stayed at or returned to subpatent levels. 
Adoptive transfer studies. Various steps (described below) were taken in the final 
adoption of the transfer model. Part "A" describes the general format of the final model 
and parts "B-D" give the various preparative steps leading to the development of the 
model, as well as manipulations of the chosen format. 
A). Immunization of acceptor mice by transfer of ISC and stimulation with IP. 
A basic format of the finally adopted transfer model is given in Figure 1. Briefly, 1-4 χ 
10' spleen cells from immune donors cleared of parasites with chloroquine (CQ), 
termed sterile immune (ISCs, see below), were transferred intravenously (i.v.) to 
acceptor mice along with IP on the same day. Seven days after transfer/stimulation with 
IP, a challenge infection was given using 10^ VP/mouse. Bloodsmears were made on 
the day of challenge with VP and at least once a week thereafter, for a minimal period of 
4 weeks after the VP challenge when mice exhibited subpatcnt infections, low transient 
infections or death. Spleens of immune donors were pooled to obtain enough of a 
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homogeneous preparation for injection to all experimental mice. 
Basic format of transfer model 
Bloodsmears 
ISC + IP VP 
ι ι 
14 21 28 
Day 
Figure 1. Basic format of immunization of mice against the virulent parasite (VP) by 
transfer. Mice receive immune spleen cells (ISC) and stimulation with immunogenic 
parasites (IP) on Day 0. A challenge with VP is given on Day 7. Bloodsmears are taken 
on Day 7 and at weekly intervals thereafter to monitor the infection and establishment of 
immunity. 
B). Preparation of spleen cells. Spleens and/or lymph nodes (where indicated) 
were removed from premune mice (i.e., mice possessing parasites, not cleared with CQ, 
referred to as ISCp in the text) or from immune mice cleared of parasites by giving CQ 
(Nivaquine®), 100 mg/1 drinking water ad libitum for 5 days, starting 7 days before 
their use (referred to as ISCs in the text). Mice given CQ drinking water were placed on 
normal drinking water for 2 days before collecting their cells for transfer to clear any 
residual CQ. The organs were dissociated by gentle pressure with a glass rod and passed 
through a sieve fitted in a 10 ml syringe containing a plug of cotton wool. Cells were 
counted in a 0.2% trypan blue /physiological saline solution (diluted 1:4) on a 
hemocytometer (Neuberg, Germany). RBC were removed from the spleen cell 
suspensions by treatment with ammonium chloride Tris (ACT) (14). ISC, normal spleen 
cells (NSC) or LNC (where indicated) were injected i.v. via the tail. 
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С). Determination of the development of immunity. Because of the unique 
qualities of IP, its use was investigated in transfer experiments. Mice were given ISC 
and stimulation with IP on Day 0. To test if and when mice had developed immunity, a 
challenge with the VP was given on days 5, 7, 9 and 14 after the injection of ISC and 
IP. From these experiments, the day of challenge with the VP in the final model was 
determined. 
D). Across sex transfers. Male donor ISC are rejected by female acceptors 
because of the presence of the Η-Y antigen on male cells (5). Using this information, 
same-sex transfers and across-sex transfers were performed to further analyze the role 
and persistence of transferred ISC. ISC from either male or female donors were 
transferred to both male and female acceptors, stimulated with ГР and challenged with 
VP according to the model shown in Figure 1. In appropriate cases, ISC of acceptors 
with an established VP immunity were collected approximately 1 month after the first 
transfer and given to naive male and female acceptors again using the basic model 
(Figure 1). In this way, up to 4 subsequent transfers were performed. 
E). Preslimulation of acceptors with IP. To determine if IP could stimulate 
protective cells in the acceptors of ISC, several groups were given IP stimulation before 
receiving ISC. The basic format was slightly altered in that : a group of mice were 
infected with IP and 7 days later received ISCs and a challenge with VP. Another group 
was treated likewise; however, mice were placed on sulfadiazine (20 mg/1) drinking 
water for 5 days after the IP stimulation to control proliferation of the parasite before 
then receiving ISC and VP 7 days later. Control groups included mice that received only 
IP or VP stimulation before challenge 7 days later with VP, and mice that received ISC 
and IP stimulation on the same day followed by challenge with VP 7 days later (i.e., 
basic format). 
Malaria-specific ELISA. Immunoglobulin (Ig) titers to VP antigens were measured 
from plasma samples 5,7,10 and 14 days after infection with IP or VP or in acceptors 
of ISCs stimulated with IP and challenged with VP 7 days later. Briefly, 96-well, flat-
bottom plates were coated with a parasite extract (100 μΐ/well) prepared by the lysis of 
IO7 VP/mi (K173) with 1% Triton χ 100 in PBS. Sodium azide (0.05%) was added to 
prevent bacterial contamination and the plates were stored at 4°C until use. Directly 
before use, plates were emptied, coated with 1% BSA/PBS/0.1% Tween 20 buffer 
(buffer A) at 100 μΐ/well and left to stand for 1 h at room temperature. All operations 
were performed at room temperature. Thereafter, plates were emptied and two-fold 
dilutions (100 μΐ/well) of the test plasma or control sera (prepared from pooled immune 
mouse sera, IMS) were made in buffer A. Plates were allowed to incubate for 1 h then 
washed with PBS. An incubation with 100 μΐ/well of RAMPO (rabbit anti-mouse 
immunoglobulin peroxidase, dil. 1:1000 in buffer A, Dakopatts, Denmark) for 1 h 
followed. Plates were then washed with PBS and incubated with TMB 
(tctramethylbenzidine, degassed before use) for 20 min. The reaction was stopped with 
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4N H2SO4. Antibody concentrations were read at 450 nm on a Titertek Multiskan 
MCC/340, MKII reader. A pool of serum collected from mice with an established 
immunity (IMS) was used as a positive reference sample. Antibody titers in test samples 
are reported as a percentage of the IMS values. 
RESULTS 
The results of typical experiments carried out to develop the model of induction 
of immunity in naive acceptor mice by transfer of spleen cells from immune donors are 
summarized in Table 1. In these experiments spleen cells were obtained from either 
premune donors (ISCp; immune but carrier of parasites in subclinical numbers) or sterile 
immune donors (ISCs; premune donors treated with CQ to eliminate all parasites). For 
transfer experiments, initially the equivalent number of cells obtained from one spleen 
were given to 3-5 acceptor mice. Later, 1-4 χ 10 ' ISC from a pool of spleens were 
transferred to acceptor mice. Results of repeated experiments were summarized. This 
was also done when small differences in the experimental set up had no effect on the 
outcome of the experiment A basic format of the transfer model is depicted in Figure 1. 
Transfer of immunity by ISC 
Spleen cells from premune mice (i.e., ISCp), immunized by a 
chemotherapeutically controlled VP infection over a period of 5 weeks, were transferred 
to naive acceptors (Table 1). The acceptor mice developed rapidly increasing infections 
and died. Either control of the parasites in the ISCp preparation or control of additionally 
injected VP in acceptors by sulfonamide treatment of acceptors did not result in immune 
mice after VP challenge. When the parasites in the premune mice were given to normal 
mice by subinoculation of blood, parasitemia developed similarly to that observed in 
mice infected only with the VP (results not shown). Moreover, when spleen cells from 
immune donors cured of their subpatent infections with CQ (i.e., ISCs) were transferred 
to acceptor mice and challenged with VP directly or later, no protection was observed, 
even when low amounts of VP were given. Not even all ISCs (the equivalent of one 
immune spleen) from one immune mouse given to one acceptor mouse was able to 
protect the acceptor (results not shown). In addition, when immune donors received 
additional challenges with either VP (results not shown) or IP in an attempt to boost the 
donors before transfer of their ISCs, no protection to VP challenge was obtained in the 
acceptors (results not shown). These results suggested that a direct transfer of immunity 
to VP by ISC from mice with an established immunity was not possible. 
Immunity after transfer of ISC and stimulation with IP 
When ISC from immune donor mice, cured of their subpatent infection by CQ 
treatment before transfer (i.e., ISCs) were given to naive acceptors, mice controlled a 
challenge with IP (Table 1). In addition, such mice resisted infection with VP when the 
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challenge was given 7 days or later after stimulation with IP. This was also independent 
of the presence of VP (seen in tests where both VP and IP were given as stimuli; Table 
1) as long as the VP proliferation was controlled by sulfonamide treatment. Comparable 
results were obtained when ISCp were used in combination with IP stimulation and 
sulfonamide treatment, even when additional VP were given. 
These results showed that IP immunity could be transferred by ISCs and that 
stimulation of acceptors of ISCs by IP generated protection to VP within a week. 
Immunization by transfer of LNC from immune donor animals and stimulation in the 
acceptor with IP were never successful (Table 1); however, transfer of spleen cells from 
the same mice could successfully induce immunity in acceptors. Transfer of NSC and IP 
stimulation in the acceptors, as well as stimulation with IP alone (Table 2), in the 
absence of any transferred cells, were unable to protect acceptor mice when challenged 
with VP 7 days later. 
Persistence of IP essential for induction of immunity by transfer of ISC 
Observing that IP stimulation of ISCs in acceptors generated protection to VP, 
the role of IP was further analyzed. Stimulation of mice with freeze-thawed VP or IP, 
even when given the equivalent of up to 10° VP or IP/mouse every other day after 
transfer of ISCs, was not able to generate VP immunity (Table 1). This suggested a role 
for live IP for the stimulation of ISCs after transfer. In a series of experiments, the need 
for persistence of IP in acceptors of ISCs for the development of VP immunity was 
analyzed. In one scries, ISC from sterile immune donors were transferred to acceptors 
receiving IP stimulation. At several time points after stimulation, a VP challenge was 
given. When IP stimulation periods of 1 week or longer were used, immunity to VP had 
developed (Table 1). In additional experiments, ISC from immune donors transferred to 
acceptors were stimulated by IP, but the period of parasite proliferation was limited by 
CQ treatment. An IP stimulation period of 6 days was not sufficient to obtain VP 
immunity in the acceptor. Knowing that IP stimulation of acceptors of ISC was 
essential, the question was raised as to whether that stimulation must be given to the ISC 
given to the acceptor or that IP stimulation independent and before the transfer of ISC 
prepares for the development of VP immunity. The results of experiments described in 
Table 2 show that stimulation of acceptors before transfer of ISC was not effective while 
stimulation of acceptors in the presence of ISC was.not effective while stimulation of 
acceptors in the presence of ISC was. 
Results indicate an essential role of ISC and stimulation of ISC by proliferating 
IP during a period of 7 days in the generation of immunity to VP. There is no immunity 
to VP after transfer and VP stimulation of acceptors of ISC is ineffective. Consequently, 
subpatent infections in donors of ISC were routinely cleared by CQ therapy starting 7 
days before transfer of ISC. In addition, stimulation of ISCs with IP in the acceptors 
was routinely carried out for a period of 7 days, followed by VP challenge to measure 
immunity in acceptor mice. 
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Table 1 
IP and VP immunity by transfer of spleen cells 
Transfer Stimulus Treatment acceptor: Day of challenge Immune 
Period of treatment f day) with VP 
ISC protect against IP but not VP 
ISCp 0/3 
ISCp lf^VP S30; 0-5/8 7/10 0/7 
ISCs 102VP 7 0/6 
ISCs 105VP 7 0/3 
ISCs 7 0/3 
ISCs 104-106 IP 6/6 
ISCs 104-106IP 7 14/14 
ISCs 105 IP S30; 1-5 7 8/8 
ISCs 105IP+105VP 7 0/8 
ISCs 105IP+105VP S30; 0-5/8 7/10 16/16 
IP boosting of donors before transfer of ISC on day 0 
ISCs 5xl06IP 
(in donor on: day -3) 7 0/3 
7 0/3 
7 0/3 
5 0/3 
7 
9 5/5 
14 5/5 
11 0/6 
7 0/6 
7 0/3 
7 0/6 
7 6/6 
7 0/6 
7 0/6 
The conditions for the development of immunity. ISCpflSCs=immune spleen cells from 
premune/sterile immune donors, NSC=normal spleen cells, 
IP/VP=immunogenic/virulent parasites, LNC=lymph node cells, 
S/CQ=sulfonamide/chloroquine treatment 
-7 
-14 
Effect of IP proliferation period 
ISCs 
ISCs 
23/26 
ISCs 
ISCs 
ISCp 
105IP 
105IP 
105IP 
105IP 
105 IP S30; 
Effect of live or freeze-thawed (f/t) IP 
ISCs 
ISCs 
ISCs 
ISCs 
NSC 
LNC 
108 IP f/t 
(day 0,2,4,6) 
108VPf/t 
108IP 
105IP 
105IP 
105IP 
0-6/CQ; 6-9 
CQ;0-5 
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Table 2 
Effect of IP Stimulation before or after ISC on VP immunity 
Preinfection Transfer of ISC and/or Challenge with Immune 
(Day) parasite infection VP 
(Day 0) (Day 7) 
Control mice (basic format) 
-
— 
--
-
Prcinfected mice 
IP (-7) 
IP (-7) + 
IP (-13) 
S20 (-7 to 
IP(-13) + S20(-13' 
-2) 
toO) 
ISCs + IP 
ISCs + IP 
(S20 0-5) 
IP 
VP 
ISCs + VP 
ISCs + VP 
ISCs 
ISCs 
+ 
+ 
+ 
+ 
-
-
-
~ 
5/5 
5/5 
0/6 
0/6 
0/6 
1/6 
0/3 
0/3 
Preinfection of acceptor mice with immunogenic (IP) or virulent (VP) parasites to 
determine if there was stimulation of protective cells in the acceptor before the transfer of 
immune spleen cells from sterile immune donors (ISCs). Mice were prcinfected with IP 
or VP (on the days indicated) before receiving ISCs. The basic format for transfer of 
ISC to acceptor mice was used as a control. Acceptors received ISC and stimulation 
with 10-* IP or IP or VP alone. A challenge with 10^ VP, 7 days later, was then given to 
ascertain immunity. In some cases, acceptors were further placed on sulfonamides (S20 
mg/1) to control the infections. 
The effect of the number of ISC and IP in the transfer model 
Transfers using varying amounts of both ISC from immune donor spleens and 
IP for stimulation of ISCs in the acceptors were carried out. Figure 2 shows the results 
from a group of transfer experiments that were designed to test amounts of ISCs ranging 
from 5 χ 106 to 1 χ 108 ISC/mouse and amounts of IP ranging from 103 to 106 
IP/mouse. The results reflect the percentage of VP immune mice after transfer of various 
numbers of ISC and VP derived from the summarized data of several experiments. Data 
points represent the results from 6 to 69 mice. It was observed that the number of 
positive transfers increased as the number of transferred ISC increased. Higher 
percentages of immune mice were observed when greater than 1 χ 10' ISC were used. 
In addition, the number of IP used effected the success of the transfer. Success rates 
increased to 100% in some conditions, when more IP were used (i.e., 
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10"*, 10-\ 10^), depending on the number of ISC. Transfers involving more than 1 χ 
10' ISC were generally more successful, especially when higher amounts of IP (10 , 
10^ or 10") were used, but there were optimum conditions reached. Transfers using 1 χ 
10^ ISC were most successful when using 10^' 10* and 10" IP, reaching high (92 -
100%) success rates. It should be noted, that in Figure 2 the summarized data of a series 
of experiments are depicted, combining successful and less successful transfer 
experiments with the same number of ISC and IP. Thus, most immune mice were seen 
from pooled data where 1 χ 10° ISC were used, but in individual experiments less ISC 
could also repeatedly result in 100% immune mice. For practical reasons, the use of 2-4 
χ 10' ISC and 10* IP was adopted for subsequent transfer experiments. 
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Figure 2. The percentage mice immune to a virulent parasite (VP) challenge after transfer 
of varying amounts of immune spleen cells (ISC) and stimulation with varying amounts 
of immunogenic parasites (IP) for a period of 7 days. 
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Figure 3. (A) The percentage parasitemia in acceptor mice receiving immune spleen cells 
(ISC) and/or virulent (VP) or immunogenic parasites (IP) and (B) antibody titers in 
those same mice measured on Days 5,7, 10 and 14. (t=conditions where mice died) 
The course of infection in acceptor mice in relation to transfer of ISC 
and IP stimulation 
Figure ЗА shows the average parasitemia in one experiment of acceptor mice that 
received VP alone, IP alone, IP and challenge with VP on Day 7 or ISC, IP and a 
challenge on Day 7. Differences in the height of parasitemia were seen. Usually IP 
infections either a given alone or after ISC transfer remain low (<1%) during the week 
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before VP challenge. In the absence of ISC, IP infections, without additional VP 
challenges, continue to rise and animals die 4-6 weeks later. Mice subsequently given 
VP 7 days after IP, develop a rapidly increasing parasitemia and die. Acceptor mice 
receiving ISC, stimulated with IP and challenged with VP 7 days later frequently exhibit 
low grade infections (<1%) throughout; however, patency can be observed and 
occasionally infections can reach as high as 10% infected cells. In the majority of cases 
with elevated parasitemias, however, infections return to subpatent levels between 7 and 
14 days after challenge with VP (results not shown). More information on kinetics of 
infection in relation to transfer conditions is described elsewhere (Chapter 5). 
Measured anti-parasitic antibody titers are depicted in Figure 3B. It is seen that 
between days 10 and 14, mice in the group that developed immunity (i.e., ISC+IP/d7 
VP) possessed a significantly higher antibody titer than the groups that did not become 
immune (i.e., those groups that received only parasites). 
Table 3 
The ability of immune spleen cells to transfer immunity from donors to 
same-sex or across-sex acceptor mice 
Type of transfer Immune 
C57BL/6J 
male-male 7/9 
male-female 0/9 
female-male 9/10 
female-female 16/16 
С57В1Л0 
male-male 9/9 
male-female 0/9 
female-male 10/10 
female-female 7/7 
fcmale-male-male 5/5 
female-male-male-female 4/4 
ISC transferred from donors to same-sex or across-sex acceptor mice. 
The significance of transferred ISC was further analyzed by transfer of ISC to 
acceptors of the same or different sex (Table 3). The results show that immunity after 
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transfer was obtained when male ISC were transferred to same-sex acceptors and 
stimulated with IP. Transfers of female ISC to male acceptors stimulated by IP also gave 
immunity, but transfers of male ISC to female acceptors stimulated with IP did not, as 
expected. To further analyze the role of transferred ISC, female ISC were transferred to 
males, stimulated with IP and challenged with VP. Using the same protocol, ISC of 
these males were transferred to males again and finally ISC from the second generation 
males was transferred back to females. In all of the subsequent steps, immune mice 
were obtained and, as described in Table 3, the final transfer of male ISC back to 
females was successful. Since we have never observed successful immunization by 
transfer of ISC from male to female, these results indicate that the female ISC survived 
in the males during subsequent passage to the second generation males and finally back 
to the females. The ISC generations apparently not only survived through 3 subsequent 
passages, which took a total period of 5 months, but were still sufficient to induce 
immunity in the female acceptors after transfer in the third passage. 
DISCUSSION 
Mice with an established immunity to virulent P. berghei (VP) cannot transfer 
immunity by ISC to these parasites directly. Not even all spleen cells of one donor 
transferred to a single naive receptor can protect against a low dose challenge with VP. 
Transferred ISC, however, confer protection to IP challenge and stimulation of ISC 
with IP generates protection to VP within a week. In addition, sufficient numbers of 
both ISC (>107 ISC/mouse) and IP (>104 IP) must be given for optimal transfer 
results. Additional challenges in the donor with IP, shortly before transfer of ISC, is not 
protective, suggesting that boosting of the donor does not provide more efficient ISC 
and that interaction between IP and ISC must take place in the acceptor. 
Both transferred ISC and stimulation of acceptors of ISC by IP are essential for 
immunization of acceptors to VP challenge infection by the transfer procedure. LNC 
cells from immune donors or NSC are not protective. IP stimulation alone or VP 
stimulation (even under chemotherapeutic control) are not protective in the one week 
procedure. In addition, not only in this transfer model, but also for primary 
immunization (i.e., a chemotherapeutically-controlled VP infection induces immunity in 
a 5 week period), IP immunity precedes VP protection. 
The results suggest either that IP have, but VP, lack essential information for 
the stimulation of immune effector cells or that IP stimulation drives the immune system 
to protective reactions that subsequently control pathological reactions triggered by VP. 
Indeed, VP infections tend to trigger immunopathological reactions like cerebral malaria 
(4) and IP do not (Chapter 3). One hypothesis,therefore, is that IP preferentially trigger 
a particular Τ cell subset, the activity of which controls the stimulation of another subset 
specifically triggered by VP (e.g. T^2 versus T^l). Cytokine regulated activity of Τ cell 
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subsets (18, 19, 24, 32) and a role of activation of Τ cell subsets producing either 
pathology or protection has been described in several parasite-host combinations (13, 
20,26), including Plasmodium infections in mice (17,27). 
The observation that not even a chcmotherapeutically controlled VP stimulation 
of ISC in acceptor mice can induce immunity, but either IP alone or in combination with 
VP can (Table 1) suggests that VP lack essential stimulatory information, which may 
make them a poor source for vaccination targets except those that aim at anti-disease 
protection (24). 
Successful immunization by transfer not only depends on the presence of ISC 
and IP, but IP must proliferate for a period of approximately 1 week to induce VP 
protection. Neither freeze-thawed IP nor IP proliferation limited by CQ treatment to 
periods shorter than 1 week could induce VP immunity. The reason why IP must 
proliferate for a period of 1 week is not clear. One possibility is that the immunizing 
principle is released by IP rather than being a surface molecule. Another possibility is 
that only live proliferating ΓΡ arrive at places where cells of the immune system can be 
stimulated (e.g. in the white pulp of the spleen). Still another possibility is that only 
proliferating IP (not VP) can induce an essential architectural change in the spleen like 
the barrier cell system described by Weiss (31). In an attempt to further analyze this 
point, acceptor mice were infected with IP one week before transfer of ISC (Table 2). 
This IP infection could either stimulate development of the right architecture in the spleen 
or drive the immune system towards a dominant activity of a specific subset of T-cells. 
This IP pretreatment, however, was not successful suggesting that interaction of IP with 
immunocompetent cells in the transferred ISC is essential. The observation that extra IP 
challenges of donors immediately before transfer of ISC did not protect acceptor mice to 
VP challenge support this notion. 
Induction of immunity by IP stimulation of transferred ISC was successful 
when ISC were transferred to same-sex acceptors or to male acceptors, but not when 
male ISC were transferred to female acceptors. These data are explained by a well 
established Η-Y dependent rejection of male cells in female acceptors (5). The 
observation that female ISC could be transferred to 2 subsequent male acceptors and that 
ISC of the last male induced immunity in subsequent female acceptors suggests that the 
original female cells survived in 2 subsequent male passages which were still sufficient 
for subsequent transfer to females. This supports a role of specifically triggered cells in 
these ISC for the development of protection. Moreover, these specifically triggered cells 
survive in acceptors for a minimum period of 5 months. 
Previous work showed that IP infection (<1000 IP/mouse for transient 
infections or higher numbers combined with sulfonamide treatment to control the 
infection) induced immunity in a period of 3 weeks (Chapter 3). In the work reported in 
this paper, immunity to IP was transferred directly by ISC and immunity to VP was 
generated within one week after transfer, which may suggest that memory function is 
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developed during immunization. 
In murine malaria, Τ cells have not only been found to contribute to protective 
immunity, but also to pathogenesis of the disease (29). Involvement of CD4+ Τ cells, in 
particular, the T
n
l and T
n
2 subsets, have been implicated in different parasitic infections 
(17, 24, 27 see also 2 and 30). T
n
l reactions are often associated with protection while 
T
n
2 are associated with pathology; however, several models have suggested interactions 
between both subsets of CD4+ Τ cells (17, 27) or the predominant activation of one 
subset dependent on the strain of parasite used giving cell-mediated or humoral 
protection. Antigens may mediate specific types of responses. With respect to rodent 
malaria, it has been shown that both T
n
l and T
n
2 clones confer protection in а Л 
chabaudi chabaudi model (27). In a P. yoelii model there is a strong T
n
l activation and 
no T
n
2 response while in a P. chabaudi adami, there is strong T
n
2 activation and no T
n
l 
activation (compare 18, 25 and 27). If protective T
n
l (or T
n
2) cell responses or 
pathology-inducing T
n
l (or T
n
2) responses can later be demonstrated, then it will be 
important to identify antigens that mediate these protective or pathological outcomes for 
the identification of targets for development of protective immunity. 
In our model, there is a clear association between development of immunity in 
the acceptor mice after transfer of ISC being stimulated by IP and production of anti­
parasitic antibody. This may indicate that T
n
2 activity is important for the development 
of immunity in this model; however, the role of T
n
l cells is not ruled out nor other 
subsets of cells associated with protective cytokine activity. In other parasitic infections 
(e.g., Leishmaniasis, Schistosomiasis) T
n
2 responses were associated with pathology 
rather than protection (13, 20) whereas in a Theiler's infection a T
n
l response was 
associated with pathology (21). It cannot be excluded, however, that in our model, 
antibody level parallels rather than precedes development of immunity and that other 
protective mechanisms are involved. 
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Chapter 5 
В Cells and CD4+ Τ Cells are Important in the Adoptive Transfer 
and Maintenance of Immunity to Plasmodium berghei in Mice 
Christina M. Celluzzi, Theo J. J. M. van de Wiel, 
Joep Η. Ε. Th. Meuwissen and Wijnand M. С. Eling 
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SUMMARY 
Transfer experiments using В cell, CD4+- and CD8+ Τ cell-depleted immune 
spleen cells (ISC) and intact as well as thymectomized (TX), CD4+- and CD8+ Τ cell-
depleted acceptor mice were done to demonstrate the necessity of CD4+T cells and 
especially В cells in the development of immunity to two forms of Plasmodium berghei 
(strain КПЗ): (1) the virulent parasite (VP) and (2) an attenuated form or immunogenic 
parasite (IP), developed in this laboratory. Evidence is presented to show that 
thymectomy negatively influences the development of protective immunity by 
involvement of CD8+ Τ cells and that normal, host CD4+ Τ cells contribute to the 
development of immunity. In addition, the importance of CD4+ Τ cells as well as the 
type of parasite in the maintenance of immunity was observed when immune mice 
depleted in vivo for CD4+ Τ cells failed to maintain protection against the VP challenge 
but remained immune to the IP. 
Furthermore, the role of antibodies in the development of immunity was 
examined by measuring Day 7 and 14 antibody titers from intact and TX/CD4+ or 
TX/CD8+ Τ cell-depleted acceptor mice receiving non-treated or depleted ISC. It was 
seen that those mice that developed immunity after receiving either non-depleted or 
CD4+ or CD8+ Τ cell-depleted ISC had higher antibody titers on Day 7 when given to 
intact acceptor mice than when given to TX mice depleted for CD4+ or CD8+ Τ cells. 
On Day 14, in all mice developing immunity, the antibody titers were significantly higher 
than those in non-immune mice. The role of CD4+ Τ cells, CD8+ Τ cells, В cells and 
antibody is discussed. 
INTRODUCTION 
Studies have been conducted to determine the specific subsets of immune cells 
involved in protection against erythrocytic stage malaria infections. In studies on 
transient infections, there is now a wide body of evidence suggesting a protective role 
for Τ cells, in particular CD4+ Τ cells, while only a minor role has been suggested for 
CD8+ Τ cells. The role of Τ cells has, for instance, been suggested by studies which 
failed to find immunity after infection with P. berghei and P. yoelii of neonatal, TX rats 
and athymic mice (5, 12,17, 25, 26) and by adoptive transfer studies with Τ cells (1, 2, 
4, 9, 13, 25). Moreover, the fact that mice deficient in В cells were able to clear a 
number of Plasmodium spp. and related protozoan infections, was taken as support for 
the major importance of Τ cells (4,10,12). 
The results of several studies indicated that a specific role for CD4+ Τ cells exists 
in protective immunity against erythrocytic stage malaria infections. In several of these 
studies adoptive transfer paradigms with P. chabaudi adami and P. yoelii were used (3, 
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4, 17), while other studies worked with in vivo depletion of immune mice and 
subsequent challenge with P. chabaudi adami AS (19, 21). Still further studies used the 
approach of both adoptive transfer and in vivo depletion of mice against P. yoelii, (24), 
P. chabaudi (16) and P. vinckei (14, 28). Other Τ cell subsets, such as CD8+ Τ cells, 
though shown to be protective against sporozoite stages of infection (20, 27), have not 
been clearly indicated in protective immunity against erythrocytic stage malaria, as 
indicated in the variable results reported by Mogil et al. (18), Vinetz et al. (24), Podoba 
et al. (19), Süss et al. (21), and Meding and Langhorne (16), to name a few. 
In contrast to the importance of Τ cells, specifically the CD4+T cells, the role of 
В cells in protective immunity against erythrocytic stage malaria in animals is much less 
clear. Some studies indicate that both Τ and В cells synergize to generate protective 
activity (12, 13), while other studies, particularly by Jayawardena et al. (12, 13) showed 
that although promoting recovery from P. yoelii infection, В cells were not essential for 
the maintenance of resistance to reinfection. This was mainly attributed to cell-mediated 
mechanisms, supporting the hypothesis that immune CD4+ Τ cells function as Τ helper 
cells in the production of antibodies by В cells. Furthermore, immune CD4+ Τ cells 
appear to require interaction with normal host Τ cells in order to mediate protection 
against P. yoelii (1,7), suggesting that the function of the Τ cells of the recipient may be 
to expand the immune response following the interaction with the transferred cell 
populations in adoptive transfer experiments (7). Furthermore, it has been reported that 
CD4+ Τ cells were activated early during P. с adami infection and were required for the 
subsequent expansion of other Τ cell populations such as the γδ (CD4-CD8-) Τ cell 
subset (23) which occurred maximally during the period of descending parasitemia, thus 
indicating the role of still other subsets in the resolution of erythrocytic-stage malaria in 
models of self-limiting infections. 
In view of the various results, coupled with earlier reports that passive transfer 
of serum removed from immune animals on Day 14 after a P. chabaudi infection (15) 
could give protection against subsequent parasite infections, the present studies were 
designed in an attempt to obtain further evidence for the protective role of В cells and 
antibody production, while confirming an important role of CD4+ Τ cells and a 
regulatory role of CD8+ Τ cells. The protective role of these cell types was investigated 
by utilizing both transfer from and in vivo depletion of mice that were immunized against 
a lethal infection with virulent P. berghei (VP). For transfer experiments, intact or Τ cell-
depleted, naive mice received non-depleted or depleted ISC from an immune donor 
along with absolutely necessary stimulation from an attenuated variant of the lethal 
parasite, collectively called IP. IP were obtained from the virulent wildtype parasite. A 
description of its derivation is given more extensively elsewhere (Chapter 3). Because 
this model requires IP to produce immune mice, in vivo depletions of Τ cells in 
previously immune mice followed by transfers were also carried out to determine if 
differences exist between IP and VP immunity. 
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MATERIALS AND METHODS 
Mice. Naive, female, C57BL/10 mice, used as acceptors at 6 to 8 weeks old were 
obtained from the central animal facility at the University of Nijmegen (The 
Netherlands). Mice were housed under specific pathogen-free conditions in plastic cages 
(39 χ 22 χ 14 cm) and received food (RMH, Hope Farms, The Netherlands) and water 
ad libitum. All mice (6 or more/group) in any particular experiment were age-matched. 
Results are summarized from repeated experiments. 
Parasite. Plasmodium berghei, strain К173 ,VP, was used in these studies. Aliquots of 
parasitized red blood cells (pRBC) were stored in liquid nitrogen. Parasites were kept 
viable by weekly passage in C57BL/10 mice using 10* pRBC. For passage or infection, 
blood was collected from mice by bleeding via the tail.and RBC counted. The percent 
parasitemia was determined by counting the percentage of pRBC to uninfected RBC 
(200 or more) appearing in May-Griinwald/Giemsa (Merck, Germany)-stained thin 
bloodsmears. RBC were diluted in sterile, physiological saline, adjusted to the 
appropriate concentration of pRBC, and injected intrapcritoneally (i.p.) into passage or 
experimental mice. IO5 VP were used in both passage and challenge infections in 
experimental mice. 
In addition to the passage of the VP, an attenuated form of the K173 parasite, IP, 
was also used. The detailed characterization of the IP is given elsewhere (Chapters 3 and 
4). Briefly, IP was isolated on Day 28 from mice being immunized on Day 0 with 3 χ 
10' VP and given either sulfathiazole-Na (300 mg/1) or sulfadiazine (30 mg/!) on Day 2 
(6). IP were passaged similarly to the VP, however, in splenectomized C57BL/10 mice. 
Immunization of mice against P. berghei. Mice used as immune donors in the 
transfers were immunized with IP (Chapter 3). Briefly, mice were infected with 10" -
107 IP and placed on sulfonamide-containing drinking water for 19 days. On Day 21, 
mice were challenged with 10-* VP to determine immunity. Immunized mice were given 
another 10-* parasite challenge with VP before use in experiments to determine their 
immune status. Usually parasitemia remained subpatcnt after this challenge. Patent 
parasitemia, however, did not go above 0.5% in immune mice. All immune mice were 
then treated with chloroquine (Nivaquine®, CQ) 100 mg/1 drinking water ad libitum for 
5 days to clear any parasites. After CQ treatment, mice were termed sterile immune. 
Adoptive Transfer Studies. 
a). Preparation of spleen cells. Spleens were removed from normal or immune donors, 
crushed gently with a glass rod and passed through a sieve fitted in a 10 ml syringe, 
containing cotton wool. Spleen cells were treated with ammonium chloride-Tris (pH 
7.2) (11) to lyse RBC. An equally adjusted number of non-depleted or further depleted 
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cells (3-5 χ 10' cells per mouse) were collected and injected i.v. to naive, intact or 
thymectomized (TX) and additionally CD4+ - or CD8+T cell-depleted acceptor mice. 
b). Depiction of cells by in vitro treatment with mAb. The mAb used in in vitro 
depletions for transfer experiments were obtained from cell lines, Η129.19 (MT4) (anti-
CD4; rat IgG2a) and 53.6.72 (anti-CD8; rat IgG2a) kindly provided by Dr. W. van 
Ewijk, Erasmus University, Rotterdam, The Netherlands. Aliquots of mAb were diluted 
to the desired concentration in RPMI1640 (Gibco, Paisley, Scotland) containing 10% 
fetal calf serum (FCS). Spleen cells were incubated with the mAb at 4°C for lh with 
rotation, centrifuged at 1000 RPM to remove excess antibody, then incubated for an 
additional lh (at 4°C) with magnetic Dynabeads (Dynal AS, Norway) coated with sheep 
anti-rat Ig. The depletion was effected by separating the cells bound to the Dynabeads 
from the unbound cells with the use of a M-450 magnet (Dynal). The unbound cells 
were used in the transfers. 
с). В cell depletions. В cells were removed by a similar procedure as described 
above using Dynabeads coated with sheep anti-mouse Ig to bind the В cells. 
d). Τ cell depletion in acceptor mice by in vivo treatment with mAb. The mAb 
YTS 191.1.2 (anti-CD4; rat IgG2b) and YTS 169.4.2 (anti-CD8; rat IgG2b) were 
purchased from Sera Lab (England). Aliquots of mAb were diluted in sterile, pyrogen-
free phosphate-buffered saline (PBS) to the desired concentration. Naive or immune 
mice, previously thymectomized to prevent new Τ cell recruitment after cell depletion, 
were treated twice with anti-CD4 or anti-CD8 mAb administered intravenously (i.v.) at 
5-6 days apart. Thymectomy was performed on mice anesthetized with a 4.5% 
chloralhydrate solution at 10 μΐ per gram mouse weight. TX mice were given a 1-2 week 
recovery time before use in experiments. 
e). Transfer model and stimulation with IP. Acceptor mice received ISC or 
normal spleen cells (NSC) plus stimulation with 1CP IP (i.p.) on Day 0. Immunity was 
assessed by giving the mice a 10* VP challenge infection (i.p.) on Day 7 and following 
the parasitemia. Mice were considered immune when no patent parasitemia was seen 
after the challenge infection. Occasionally temporary patent infections were seen that 
returned to subpatent levels within 2-3 weeks after challenge. 
Τ cell depletion in immune mice by in vivo treatment with mAb (see 
Figure 1). Immune status was confirmed by the control of a VP or IP challenge. 
(Subpatent) infections were cleared by CQ treatment. The beginning of the CQ period 
was designated as Day 0 in these experiments. Mice were thymectomized on Day 7 then 
randomly assigned to 2 groups: 
1). Sterile immune mice (Figure 1A)- This group was treated with anti-CD4 
(YTS 191.1.2), anti-CD8 (YTS 169.4.2) mAb, or PBS on Days 13 and 19 and 
rechallenged with 10^ VP or 10^ IP on Day 26. In these mice, Τ -cell depletion was 
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performed in the absence of parasites. 
2). Premune mice (Figure IB)- This group was given a IO5 VP challenge on 
Day 7, to restore the premune status, treated with the above m Ab on Days 13 and 19 and 
rechallenged with 1(P VP on Day 26. Mice were later given another challenge with 105 
VP on Day 40. In these mice, parasites were present under mAb treatment. The 
parasitemias were followed to determine the ability of immune mice to control subpatent 
infections present during the mAb treatment, as well as after the 1CP VP challenges once 
a particular Τ cell type had been depleted (see IF assay below). 
Transfer with ISC from in vivo CD4+ Τ cell-depleted, IP immune mice 
(see Figure 1 AI and All). CD4+ Τ cell-depleted IP immune mice that resisted IP 
challenge (see procedure in Figure 1 A) received additional treatments before their ISC 
were transferred to naive mice. All mice were given CQ treatment to eliminate persisting 
parasites from the IP challenge. Mice in group AI (Figure 1A and 1 AI) were CD4+ T-
cell depleted and resisted a subsequent IP challenge. They were made parasite free by 
CQ treatment and received PBS treatment on Days 59 and 65. Their ISC were 
transferred to naive intact mice on Day 75. Group All (Figure 1ΑΠ) consisted of TX and 
PBS-treated (i.e., non-depicted) mice that resisted challenge with IP (Day 26). They 
received CQ treatment to clear parasites (Days 47 to 52) and were depleted for CD4+ Τ 
cells (Days 59 and 65) in vivo before having their ISC transferred to naive intact 
acceptors. The primary difference between the two groups was the time when the CD4+ 
T cell depletions were done. Both CD4+ Τ cell depletions were done on sterile immune 
mice (i.e., parasite-free); however, in group AI (Figure 1AI), VP immune mice were 
depleted for CD4+ Τ cells then challenged with IP before using their ISC in a transfer, 
while in group All (Figure 1AII), IP immune mice were depleted for CD4+ Τ cells 
directly before transfer. 
IF Assay. The extent of all depletions was determined by immunofluorescence (IF). 
ISC used in transfers described above in b and с were measured directly after in vitro 
depletion with Dynabeads (Table 1). Buffy coats from peripheral blood (PBL, 
approximately 50 μΐ) from the treatment of control mice or mice depleted in vivo were 
tested 5 days after the last treatment with the mAb. In the case of premune mice where 
mice were treated in vivo with mAb and later rechallenged with VP, an IF assay of the 
PBL was not only done 5 days after the last mAb treatment (i.e., VP on Day 26) but 
again 14 days after the rechallenge of the same mice (i.e., VP on Day 40, Table 1). In 
the transfers involving ISC removed from in vivo CD4+ Τ cell-depleted (group AI, 
Figure 1 AI) and further IP-stimulated (group All, Figure 1AII) immune donors, IF was 
done on the day of the transfer (Table 2). 
Briefly, spleen cells (10" per ml) or PBL were suspended in mAb (see above), 
appropriately diluted in IF medium (PBS with 10% RPMI 1640/0.5% sodium azide) and 
incubated at 4°C for 30 min. The cells were then washed twice at 1000 RPM and a 
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second 30 min incubation at 4°C with rabbit anti-mouse Ig FITC or rabbit anti-rat Ig 
FITC (Dakopatts, Denmark) followed. Thereafter, cells were washed and resuspended 
in 50% glycerol/IF medium for examination under a fluorochrome, lOOx water 
immersion objective lens (Leitz, Germany). 200-500 cells were counted. 
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Figure 1 : Diagram of the Τ cell depletion procedure used on immune mice. In vivo 
treatment with anti-CD4 mAb, anti-CD8 mAb or PBS in sterile immune (A) or premune 
mice (B) followed by challenge with virulent (VP) or immunogenic (IP) parasites. To 
test if mice could transfer IP immunity, mice from group AI (i.e., sterile immune mice 
that survived treatment with anti-CD4 mAb and challenge with IP) were given 
chloroquine (CQ) to remove the IP then their ISC used in a transfer (TR) according to 
the scheme given in AI. Mice from group All (i.e., sterile immune mice that survived 
treatment with PBS and challenge with IP) were given CQ to remove parasites, but then 
were given anti-CD4 mAb to remove the CD4+ Τ cells and used in transfer according to 
scheme AIL TX=day thymectomy performed, anti-CD4/anti-CD8/PBS=treatment with 
monoclonal antibodies (mAb) or phosphate-buffered saline 
Malaria-specific ELISA. Antibody titers (IgG and IgM) to the parasite were 
measured from plasma samples removed on Days 7 and 14 after the transfers of ISC and 
stimulation with ΓΡ. Briefly, 96-well, flat-bottom plates (Costar, Massachusetts, U.S.A) 
were first coated with parasite proteins obtained via lysis of VP in 1% triton in PBS. 
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Sodium azidc (0.05%) was added to prevent bacterial contamination and the plates 
stored overnight at 4°C. Directly before use, plates were emptied, subsequently coaled 
with a 1% BSA/PBS/0.1% Tween 20 solution and allowed to stand for lh at room 
temperature. Thereafter, dilutions of the test or control sera (prepared from a pool of 
immune mouse serum (IMS) that was taken from immune mice rechallengcd with VP 2 
weeks before use and treated with CQ 7 days before use ) were added to 100 μΐ of the 
diluent in the wells and incubated for Ih. After a series of washes with PBS, two other 
incubations (also accompanied by PBS washes in between) followed: 1) a 1 h incubation 
with the same volume of a RAMPO conjugate (Dakopatts, Denmark) and 2) a 20 min 
incubation with TMB in DMSO. The reactions were stopped with 4N H2SO4 and the 
antibody concentrations measured at 450 nm on a Titertek Multiskan MCC/340, MKII 
reader attached to an IBM computer (Model 502). Antibody titers are reported as a 
percentage of the IMS values. 
Statistics. Statistical analysis was done using the test of proportions and Student's t-
test. 
RESULTS 
Adoptive Transfer Studies 
Previous experiments, performed in our laboratory, showed that, in our model, 
transfer of immunity was only possible with ISC combined with stimulation by living, 
undisrupted IP. The use of NSC alone, IP alone or both NSC and IP were incapable of 
transferring immunity against VP (Chapters 3 and 4). Consequently, the transfer of non-
depicted ISC given to intact acceptors formed the basis for further in vitro depleted cell 
manipulations presented in this report. As seen in Figure 2A, non-depleted ISC given to 
intact acceptors yielded approximately 93% immune mice (referred to from here on as 
'positive' transfers) while transfers using ISC depleted for CD4+ or CD8+ Τ cells 
yielded less successful transfers (33 and 50%, respectively). ISC depleted for В cells 
(Figure 2A) or В cells in combination with CD4+ or CD8+ Τ cells (results not shown) 
failed to give any positive transfers at all. Because the number of cells given to mice was 
corrected for the depletions, the less effective transfers were probably not due to cell 
loss. The extent of all depletions was monitored using IF (Table 1). 
Due to a reduction, but not total loss in the ability of CD4+ or CD8+ Τ cell 
depleted ISC to give positive transfers when transferred to intact acceptor mice, the role 
of these particular cell types in the acceptor was also investigated. Moreover, because the 
mice were first thymcctomized before being depleted, TX mice were included as 
controls. Figure 2B shows that when non-depleted ISC were given to TX acceptors, the 
percentage of positive transfers was significantly reduced (p< 0.001) from 93% 
recorded in their intact acceptor counterparts (Figure 2A) to 54%, while В cell-depleted 
ISC remained incapable of transferring immunity. This sharp difference was not seen in 
the transfer of CD8+T cell-depleted ISC where 50% immunity was recorded in transfers 
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Table 1 
in vitro depleted ISC transferred to acceptors : 
non-treated 
CD4-depleted 
CD8-depleted 
Percentage Positive Cells 
CD4+Tcells CD8+ Τ cells В cells 
14 (±1.9) 22 (±11.0) 40 (±10) 
<1 (±0.8) 18 (±4.6) 48 (±20) 
30 (±2.8) <1 (±0.7) 42 (±13) 
in vivo depiction of naive mice used as acceptors 
of ISC in transfer: 
non-treated 18 (±0.5) 
CD4-depleted <1 (±0.1) 
CD8-depleted 6 (±1.0) 
10 (±1.0) 27 (±6.5) 
10 (±1.0) 21 (±1.0) 
<1 (±0.7) 21 (±1.5) 
in vivo depletion of sterile immune mice: 
non-treated 22 (±7.7) 
CD4-depleted <1 (±0.7) 
CD8-deplcted 22 (±16.1) 
20 (±4.2) 13 (±7.3) 
24 (±10) 47 (±7.6) 
<1 (±0.8) 46 (±7.0) 
in vivo depletion of premune mice: 
(soon after treatment with mAb) 
non-treated 
CD4-deplete 
CD8-depleted 
25 (±3.5) 
<1 (±1.0) 
15 (±1.0) 
21 (±1.0) ND 
22 (±9.0) ND 
2.5(±3.9) ND 
(same mice 2 weeks after a rechallenge with VP) 
non-treated 18 (±2.0) 24 (±2.0) ND 
CD4-depleted 12 (±8.5) 31 (±18.3) ND 
CD8-depleted 24 (±14.0) 7 (±7.6) ND 
Immunofluorescence analysis showing the extent of depletions (i.e., the percentage of 
positively fluorescing cells) with monoclonal antibodies (mAb) from in vitro depleted 
immune spleen cells (ISC) used for transfer to acceptor mice and in vivo depleted naive 
acceptors, sterile immune mice and premune mice. Spleen cells were measured from in 
vitro depletions and PBL from in vivo depletions. Percentages refer to 3 or more 
measurements. (ND=not determined) 
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Figure 2: Percentage immune mice resulting from transfers of non-depleted immune 
spleen cells (non-depleted ISC), CD4+ Τ cell-depleted ISC (-CD4 ISC), CD8+ Τ cell-
depleted ISC (-CD8 ISC), В cell-depleted ISC (-B cell ISC) or immunogenic parasites 
(IP) to Intact (A), thymectomized (TX) (В), thymectomized and CD4+ T-cell depleted 
(TX -CD4) (С) or thymectomized and CD8+ T-cell depleted (TX -CD8) (D) acceptor 
mice. (Standard deviation of the means arc indicated by thin bars) 
to intact and 66% immunity was recorded in transfers to TX acceptors. CD4+T cell 
depleted ISC, however, completely lost their ability to transfer immunity when given to 
TX acceptors. Figure 2C gives the results of transfers to TX/CD4+ Τ cell-depleted 
acceptors, and except for a slight reduction in the percentage of immune mice receiving 
CD8+ Τ t u l depleted ISC (from 66% in TX to 52% here), similar results to those seen 
in TX acceptors were observed. With again, ISC depleted for CD4+ Τ cells or В cells 
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failing to yield immune mice. Of all the transfers, however, the most remarkable results 
were those seen in TX/CD8+ Τ cell-depleted acceptors. Figure 2D shows that while В 
cell-depleted ISC remained incapable of transferring immunity, when non-depleted ISC 
were transferred to TX/CD8+ Τ cell-depleted acceptors, the percentage of immune mice 
approached the levels seen in intact acceptors. The CD8+ Τ cell-depleted ISC transfer 
immunity was greatly improved compared to their transfers to intact, TX, or TX/CD4+ 
T cell-depleted acceptors. Most striking of all, CD4+ Τ cell-depleted ISC were now 
capable of positive transfer at levels not even seen in the intact acceptors (i.e., the only 
condition where CD4+ Τ cell-depleted ISC produced immune mice). 
Parasitemia and antibody levels 
Though a high percentage of intact mice receiving non-depleted ISC became 
immune (93% ± 15), there was a small percentage that did not survive challenge 
infections. В cell-depleted ISC and IP given alone always failed to transfer immunity. 
Figure ЗА shows the average representative pattern of parasitemia on Days 7 and 14 for 
those conditions in intact acceptors where transfer most often produced immune (e.g 
intact ISC and CD8+ Τ cell-depleted ISC) or did not become immune (e.g. В cell-
depleted ISC, CD4+ Τ cell-depleted ISC and IP alone) mice. In the conditions where the 
majority of animals died (indicated by t). parasitemia increased to 30% or higher, often 
presenting anemia around Day 14. This pattern was also seen in the mice that were 
expected to become immune (i.e, mice receiving non-treated ISC), but did not due to 
technical or unknown reasons. Though parasitemias on Day 7 are usually low, they 
ranged in these experiments from < 1% to 10% across the conditions. Moreover, 
because mice becoming either immune or not did have the same parasitemia on this day 
of infection, the early Day 7 time did not serve as a sufficient indicator of immunity. By 
Day 14, however, mice were immune. By this time, immune mice maintained a low (< 
1 %) to negative parasitemia for weeks thereafter and were able to control a subsequent 
VP challenge. Similarly, transfers involving depleted acceptors showed infection 
patterns comparable to those of the intact mice described above (data not shown). 
To determine if antibody production played a role early in the development of 
immunity, parasite-specific ELISA's were done. IgG and IgM titers were determined for 
Days 7 and 14 corresponding to the parasitemia measurements in both transfers of 
depleted ISC to intact acceptors (Figure 3) and depleted acceptors (Figure 4). Because 
there was little difference in the pattern of IgG and IgM titers, only the IgG titers are 
given in figures 3BC and 4. It was found in both cases, that is, in transfers to both intact 
and depleted acceptors, that higher antibody titers (25-70% of IMS values) on Day 14 
correlated with mice that became immune and lower titers (1-10% of IMS values) were 
seen in mice that did not become immune, including the controls that received IP alone. 
Overall higher Day 7 antibody titers were seen in intact acceptor mice that went on to 
become immune (Figure 3B) compared to titers on the same day in depleted acceptor 
mice (Figure 4A). Furthermore, there was no apparent correlation between antibody titer 
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and parasitemia on Day 7. In other words, there could be either a low or high 
parasitemia associated with approximately the same antibody titer. In mice that eventually 
became immune, the antibody titers were higher than in their counterparts that did not 
become immune. 
Non-treated ISC 
-B cell ISC 
-CD4+ Τ cell ISC 
-CD8+ Τ cell ISC 
Ρ 
Non-treated ISC 
-B cell ISC 
-B/-CD4+TcelllSC 
-B/-CD8+ Τ cell ISC 
-CD4+ Τ cell ISC 
-CD8+TcelllSC 
Ρ 
mmune Mice 
Intact Intact 
Figure 3: Transfer of non-treated immune spleen cells (Non-treated ISC), CD4+ Τ cell-
depleted ISC (-CD4+ Τ cell ISC), CD8+ Τ cell-depleted ISC (-CD8+ Τ cell ISC), В cell-
depleted ISC (-B cell ISC) or immunogenic parasites (IP) to intact acceptor mice: (A) 
Average parasitemia in mice in the conditions where mice most often die (f) or become 
immune (no symbol) and average IgG titers on Day 7 (B) and Day 14 (C). (Standard 
deviation of the mean are indicated by thin bars) 
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Figure 4: VP ELISA: IgG titers with respect to immune mouse sera (IMS) values after 
transfer of non-treated immune spleen cells (ISC), CD4+ Τ cell-depleted (-CD4+ Τ cell) 
or CD8+ Τ cell-depleted (-CD8+ Τ cell) ISC to either CD4+ Τ cell-depleted (-CD4) or 
CD8+ Τ cell-depleted (-CD8) acceptors on (A) Day 7 and (B) Day 14. Bars represent 
treatment of donor ISC and x-axis represents treatment of acceptor. (Standard deviation 
of the means are negligible) 
In vivo depletion of immune mice 
CD4+ Τ cells were seen to be important in the transfer of immunity. To determine 
if these cells were important in the maintenance of immunity, immune mice were 
depleted in vivo under two conditions: premune and sterile immune. In the premune 
condition, parasites were present when the mAb were administered. In the sterile 
immune condition, parasites were removed before the mAb were given. Figure 5 shows 
the results of these depletions. It is seen in the premune condition (Figure 5A) that there 
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was no loss of immunity when the mice were depleted either for CD4+ or CD8 + Τ 
cells. When sterile immune mice were depleted, there was no visible effect on immunity 
when depleted for CD8+ Τ cells; however, when CD4+ Τ cells were removed, mice 
developed high parasitemias approximately 7 days after the VP challenge infection and 
died soon thereafter (Figure 5B). 
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Figure 5: In vivo Τ cell depletion of immune mice: Percentage parasitemia in (A) 
thymectomized (TX), thymectomized and CD4+ Τ cell-depleted (TX CD4-) or 
thymectomized and CD8+ Τ cell- depleted (TX CD8-) premune mice challenged with 
virulent parasites (VP) (i.e., TX (VP), TX CD4- (VP), TX CD8- (VP) and (B) 
thymectomized and/or depleted sterile immune mice challenged with either VP or 
immunogenic parasites (IP) (i.e., TX (VP), TX CD4- (VP), TX CD8- (VP), TX (IP), 
TX CD4- (IP)), (t = death of mice) 
Alternatively, mice depleted for CD4+ Τ cells and challenged with IP developed only a 
slight parasitemia that was soon controlled. When these mice were later challenged with 
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VP, the parasite was controlled. There were no parasitemias seen after infections with 
either VP or IP in non-depleted control mice. In both the sterile immune and premune 
conditions, immunofluorescence showed that the particular cell subtype had been 
depleted to an extent (Table 1). However, when premune mice were subsequently 
challenged after the depletions, it was seen that the remaining, non-depleted cells were 
capable of being stimulated to levels (for example, the expression of CD4+ Τ cells 
increased to 12%) approaching that of the non-treated controls. 
Table 2 
Percentage Positive Cells 
CD4+Tcells CD8+Tcell В cells 
Treatment of Donor: 
Group AI 
CD4-depletion (in vivo ) (dl3 and 19), 3 (±1.3) 19 (±3.6) 64 (±4.5) 
Challenge with IP (d26), 
CQ-treatment (d47-52), 
PBS-treatment (d59 and 65), 
Use of ISC in transfer (d75) 
Group АП 
PBS-treatment (dl3 and 19), <1 (±0.02) 11 (±1.0) 56 (±5.5) 
Challenge with IP (d26), 
CQ-treatment (d47-52), 
CD4-depletion (in vivo ) (d59 and 65), 
Use of ISC in transfer (d75) 
Immunofluorescence (IF) analysis of immune spleen cells (ISC) of donor mice immune 
to immunogenic parasites (IP). The percentage of fluorescing CD4+ Τ cells remaining 
after treatment with an anti-CD4 monoclonal antibody (mAb) before and after challenge 
with the IP is shown. ISC from these mice were used in transfers to acceptor mice 
(n=3). IF was done on the ISC from two groups of donors on the day (d) of transfer 
(refer also to figure 1 AI and All). ISC from mice in group AI were measured 56 days 
after the last mAb treatment and ISC from mice in group All were measured 10 days 
after the last mAb treatment. (CQ=chloroquine drinking water, PBS=phosphate-buffered 
saline) 
Transfer with ISC from in vivo CD4+ Τ cell depleted, IP immune mice 
Because of the ability of CD4+ Τ cell depleted mice to control the IP (but not the 
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VP) challenge and survive (Figure 5B), their immunity was further tested by using them 
as spleen donors in our standard transfer. It was observed that ISC transferred from 
these donors resulted in 100% immunity in intact acceptors demonstrating also their 
resistance to a VP challenge. IF analysis of the ISC at transfer showed 3% positively 
fluorescing CD4+ Τ cells (Table 2); a slight contrast to other CD4+ Τ cell depletions 
involving sterile immune mice where less than 1% positively fluorescing CD4+ Τ cells 
were usually seen (Table 1). This result indicates that possibly due to the challenge after 
the initial CD4+ Τ cell depletion, that the remaining CD4+ Τ cells (less than 1%) could 
have been stimulated to the 3% level. PBS-treated, IP immune control mice were also 
included.in this experiment. These IP immune mice were depleted for CD4+ Τ cells in 
vivo and then transferred (Figure 1 All). No positive transfers (i.e., no immune mice) 
resulted after mice were given a VP challenge. IF analysis of these ISC, showed that 
less than 1% CD4+ Τ cells were present (Table 2). Thus, the increase of CD4+ Τ cells 
from < 1% immediately after depletion to 3% depended on the IP challenge. This in turn 
was essential for successful transfer. 
DISCUSSION 
The results of the transfer experiments presented in this paper show a direct role 
for both В cells and CD4+ Τ cells in the transfer of immunity against virulent P. berghei 
while indicating a more regulatory function for CD8+ Τ cells. Furthermore, in vivo 
depletion of CD4+ Τ cells in immune mice indicated the involvement of CD4+ Τ cells in 
the maintenance of immunity, particularly against the virulent form, VP, of the parasite. 
To carry out the adoptive transfer experiments, several base conditions had to be 
first determined regarding transferred cells and stimulation by the parasite. In this 
virulent P. berghei (КПЗ) mouse model, immunity is not transferred directly by cells 
from an immune donor; transferred cells must be stimulated by an immunogenic form of 
the parasite (IP), which must proliferate in the acceptor before immunity to the VP is 
obtained (Chapter 4). Previous experiments also showed that ISC and neither IP alone 
nor in combination with NSC could induce immunity in the acceptors (Figure 2). The 
results indicate that specific antiparasitic information is transferred, but immunity to VP 
must develop in the acceptor and this process takes about 1 week. Two weeks after 
transfer of ISC, or rather 2 weeks after stimulation of the ISC with IP and 1 week after 
challenge with VP, parasitemias remained low in immune mice and were high and 
progressively increased until death in non-immune mice (Figure ЗА). 
An important observation is that ISC depleted of В cells always were ineffective 
in the transfer of immunity (Figure 2). This is consistent with the role of В cells reported 
in immunity to P. chabaudi (16) and P. yoelii (4, 12). Moreover, В cell depletion of ISC 
resulted in low antibody titers in the acceptors (Figures 2 and 3). Low antibody titers 
were also generated in mice stimulated with IP alone. 
104 
These dala suggest that antibody production mediated by ISC-B cells 
(specifically activated), and not by acceptor В cells (virgin В cells), play an important 
role in a timely production of antibody and possibly the development of immunity to VP 
upon transfer. 
A direct role of CD4+ Τ cells in the development of immunity in the acceptors 
came from two observations: 1) no positive transfer when ISC depleted of CD4+ Τ cells 
were transferred to either TX or TX and CD4+ Τ cell-depleted acceptors and 2) positive 
transfer when CD4+ Τ cell-depleted ISC were given to CD8+T cell-depleted acceptors or 
in other words, immunity developed very well in acceptors possessing CD4+ Τ cells, 
among other cell types, but not CD8+ Τ cells. These results indicate that CD4+ Τ cells 
are essential, but do not necessarily have to come from an immune donor; host CD4+ Τ 
cells may be sufficient. Results even seem to show that the presumed relatively low 
number of CD4+ Τ cells present in ISC and transferred to CD4+ Τ cell-depleted 
acceptors (Figure 2C) were less effective in the development of immunity than CD4+ Τ 
cell-depleted ISC transferred to CD4+ Τ cell possessing, but CD8+ Τ cell-depleted 
acceptors (Figure 2D). In this condition, there is most likely a presence of higher 
numbers of CD4+ Τ cells in the acceptor than in the transferred ISC. A quantitative 
aspect in the development of immunity was also suggested by Meding and Langhorne 
(16). 
Our results on the role of the CD4+ Τ cells may implicate that ISC-CD4+ Τ cells 
have no memory function in this type of immunity (compare Figure 2C and D). In 
contrast to our results with P. berghei, Fahey and Spitalny (7) suggested that for 
successful transfer of P. yoelii immunity, CD4+ Τ cells had to interact with host Τ cells 
to expand the immune response and mediate protection. However, they have not 
reported testing CD4+ Τ cell depletion of ISC in combination with CD8+ Τ cell depletion 
of the acceptor. 
Without CD4+ Τ cells either from ISC or present in the acceptor, there is also 
almost no antibody production, suggesting that CD4+ Τ cell stimulation regulates ISC-B 
cell functioning in the development of immunity in the acceptors. The results also 
indicate that presence of CD8+ Τ cells suppressed (early) antibody production, and 
except when present in ISC given to intact mice, also suppressed the ability to 
transfer/develop immunity. This may indicate that except when non-depleted ISC and IP 
stimulation are given to intact acceptors, stimulation of CD8+ Τ cells leads to down-
regulation of CD4+ Τ cell function. 
Meding and Langhorne recently stated (16) that several models claiming that only 
Τ cells were involved in immunity may have underestimated the role of В cells because 
mice in these studies contained а В cell complement. In the Meding and Langhorne 
model, SCID mice (deficient in both В and Τ cells) were used and it appeared that both 
В cells and CD4+ Τ cells were necessary for immunity against P. chabaudi infection. 
The role of В cells in immunity was further supported in our experiments by the 
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correlation between the anti-parasitic antibody titer on Days 7 and 14 after transfer to 
intact and Day 14 titers after transfer to depleted acceptors and immunity. Antibody titers 
were always higher in mice that became immune. It should be noted that this correlation 
was found despite the fact that whole parasite extracts were used as antigen. 
Consequently not all antibody measured is involved in control of the parasite (Figures 
3C and 4B). 
Despite an overall higher antibody titer in mice that developed immunity, 
antibody titers on Day 7 were independent of the actual parasitemia and were not a 
reliable predictor of immunity in CD4+ or CD8+ Τ cell-depleted acceptors. In other 
words, there could be either a low (<1%) or comparatively high (up to 10%) parasitemia 
associated with approximately the same antibody titer. This correlates with the notion 
that immunity is considered to be present at about Day 14 after transfer (i.e., 14 days 
after IP and 7 days after VP challenge). Antibody increase in the second week after 
transfer, that is, in the week after VP challenge, to levels which are approximately 10 
times higher, are correlated with immunity. So far, antibody production parallels rather 
than precedes development of immunity. Antibody production seems to be slightly 
delayed in CD4+ or CD8+ Τ cell-depleted acceptors probably explaining why in such 
mice Day 7 titers are not correlated to immunity. The delay probably implicates the role 
of the acceptor cells in the kinetics of the development of immunity. 
The observation that antibody production in the second week after transfer (the 
week after challenge with VP) correlates with immunity may also indicate that VP 
contain antigens not present in or on IP and that antibody control of these antigens is 
essential. 
A direct role of CD4+ Τ cells in effector function of immunity was also seen 
when established immune mice lost immunity after the depletion of CD4+ Τ cells. These 
studies also showed that immunity to VP but not to IP was lost after CD4+ Τ cell 
depletion. This confirms a role of CD4+ Τ cells for VP immunity observed in the 
subsequent transfer experiments using CD4+ Τ cell depleted and IP challenged mice as 
donors, where there is immunity to IP but not VP directly after transfer. 
Antibody studies under these circumstances are complicated by the fact that there 
is a high antibody titer at the moment of depletion and a gradual loss of antibody related 
to their biological half life. In addition, not all antibody measured is specific for the 
control of the parasites. 
A remarkable observation was that despite a comparable depletion of CD4+ Τ 
cells in premune and sterile immune mice as determined by IF, only sterile immune mice 
lost immunity to VP. Sterile immune mice did not lose immunity to IP. Moreover, the IP 
immune mice were also capable of transferring immunity. One striking feature of the 
composition of the ISC taken from these CD4+ Τ cell- depleted and IP challenged mice 
was the increase from < 1% positively fluorescing CD4+ Τ cells at the moment of IP 
challenge to 3% at the moment that these cells were used for transfer. In other transfers 
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involving the depletion of CD4+ Τ cells in parasite-free immune donors (Figure 2), the 
remaining fluorescing CD4+ Τ cells were less than 1% too (Table 2). Transfers using 
ISC with less than 1% positively fluorescing CD4+ Τ cells resulted in very poor to 
negative transfers, particularly when acceptors were CD4+ Τ cell depicted too. In the 
transfers, however, using IP stimulated mice after the CD4+ Τ cell depletion, where the 
transfers were successful, the number of positively fluorescing CD4+ Τ cells had 
increased to 3% at the moment the cells were used for transfer (Table 2). This suggests a 
quantitative aspect of CD4+ Τ cells, that is, that in response to challenge enough CD4+ 
T cells or perhaps enough P. berghei specific CD4+ Τ cells had proliferated to act 
effectively in the immune transfer. In addition, if one compares Tables 1 and 2 in the two 
conditions where mice were first treated with anti-CD4 mAb then challenged, it is seen 
that in the mice challenged with IP, 3% positively fluorescing CD4+ Τ cells (Table 2) 
were observed while the mice challenged with VP showed 12% positively fluorescing 
CD4+ Τ cells (Table 1). The latter mice exhibited an effective CD4+ Τ cell depletion 
immediately after mAb treatment (<1%, Table 1). That there is a difference in the 
percentages may not only be due to the elapsed time between the challenge and 
measurement, but in view of the difference in increase of CD4+ Τ cells after depletion 
and challenge by either VP or IP, there is also the possibility that specifically the VP 
challenge is responsible for a further increase in the proportion of CD4+ Τ cells (e.g., 
from 3% to 12%). 
Looking at the effectively CD4+ Τ cell-depleted premune mice (Table 1), <1% of 
CD4+ Τ cells were found after anti-CD4 treatment; however, after the mice were 
rechallcnged with VP, a considerable number of CD4+ Τ cells were found (11%). A 
similar observation was made by Goldschmidt et al. (8) in their CD4+ Τ cell associated 
arthritis model. They found that injected anti-CD4 antibodies could interfere with CD4+ 
T cell-dependent reactions in vivo when mice were treated before immunization with 
type II collagen, that is, there was a reduction in arthritis development and formation of 
anti-type II collagen antibodies. The same anti-CD4 treatment, given after immunization, 
however, did not effect arthritis development nor prevent in vitro proliferation, despite 
reduction of the number of CD4+ Τ cells to the same levels in both treatments. They 
proposed that either activated Τ cells were less susceptible to depiction or that the 
presence of antigen led to a relative enrichment of antigen specific Τ cells. Since in our 
experiments a subsequent depletion shortly after or while the parasite was present 
(premune) was shown to be incomplete (i.e., there was not a 100% depletion), the 
fraction of cells surviving treatment may have contained relatively more specific CD4+ Τ 
cells sufficient to proliferate and mediate immunity. Moreover, since CD4+ Τ cell 
depleted (< 1%) immune mice resisted IP challenge, and VP challenge only after a 
foregoing IP challenge, the increase in CD4+ Τ cells after IP challenge apparently is 
important for immunity to VP challenge. 
CD8+ Τ cell depletion of ISC reduces the capacity to transfer immunity from 
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93% (seen in the non-depleted ISC controls to intact mice) to 50%, (when CDS + Τ cells 
are depleted (Figure 2A)). This positive role of CD8+ Τ cells was not found in mice with 
an established immunity since depletion of CD8+ Τ cells in such mice had no visible 
effect (Figure 5). The role of CD8+ Τ cells from immune donors also contrasts with the 
apparent negative role of CD8+ Τ cells in the acceptors. Possibly in intact ISC, the 
counteractive role of CD4+ and CD8+ Τ cells is in balance and depletion of either cell 
type disrupts this balance. At the same lime, there is a significantly higher (p< 0.03) 
anti-parasitic titer in mice that develop immunity after transfer of CD8+ Τ cell depleted 
ISC to either intact or CD8+ Τ cell-depleted acceptors, as compared to those that did not 
become immune (Figures 3 and 4). Moreover, in the absence of transferred В cells, 
antibody production remained low suggesting that transferred В cells are responsible and 
apparently are activated to parasitic antigens. These results suggest that IP and/or VP 
stimulated CD8+ Τ cells effect regulation of antibody production and also interfere with 
development of immunity. 
To further elaborate on this mechanism of immunity, Meding and Langhome (16) 
proposed that there is a switch from a T
n
l-type to a specific antibody-mediated 
immunity under T
n
2 cells during infection. It has been reported that clones of T
n
 1 and 
T
n
2 cells have also been found to be protective in transfer (22). Though T
n
l and T
n
2 
cells could not be determined in our model, the increased antibody production in immune 
versus non-immune mice could be explained in this way. The necessity to stimulate mice 
with IP after transfer with ISC might indicate that IP can and VP cannot stimulate this 
T
n
l-T
n
2 switch. Possibly IP stimulate T
n
2 overT
n
l allowing antibody production to 
VP antigens, whereas VP alone enhances T
n
l over T
n
2 favoring development of 
pathology. 
These results highlight the extremely dynamic process in malaria immunity and 
the important role of immune В cells and CD4+T cells (but not necessarily immune 
CD4+ Τ cells) for transfer of immunity, as well as an important regulatory role for CD8+ 
Τ cells in this process. Probably CD4+ Τ cells stimulate В cells in the production of 
specific antibody and CD8+ Τ cells are able to down-regulate this reaction. 
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Chapter 6 
The Role of Macrophages in the Transfer and Maintenance of 
Immunity to Plasmodium berghei in Mice 
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SUMMARY 
This study describes the importance of (splenic) macrophages on the 
development and maintenance of immunity in mice to two forms of the rodent malaria 
parasite Plasmodium berghei (strain K173): (1) the virulent parasite (VP) and (2) an 
immunogenic parasite (IP). Both parasites were used in a transfer model to examine the 
transfer of acquired immunity. Immune spleen cells (ISC) transferred to acceptor mice 
were found to require stimulation with the IP for at least a period of 7 days in order to 
control a challenge with the VP. Though IP stimulation of ISC for at least 7 days in 
acceptor mice was essential, it could be delayed for as long as 3 months and still result 
in effective development of immunity to VP. Acceptor mice were depleted of 
macrophages by giving either single or multiple doses of liposome-encapsulated 
dichloromethylenc diphosphonate (LIP-CI2MDP) which temporarily depletes 
macrophages (i.e., subpopulations of macrophages are reported to return at different 
times). By altering the time after transfer of ISC at which IP are given to 0, 14 or 28 
days, it was observed that no mice became immune when IP were given to macrophagc-
depleted mice on Day 0, 35% of mice became immune when the IP were given on Day 
14 and 100% of the mice became immune when the IP was given on Day 28. This 
demonstrated that macrophage depletion of mice receiving ISC prevented control of IP 
as well as VP infection. IP and VP immunity, however, could be obtained when 
stimulation of ISC was delayed to 4 weeks after macrophage depletion, indicating that 
from 2-4 weeks an effective complement of macrophages returned after their initial 
depletion. This suggests that macrophages play an essential role in the adoptive transfer 
of acquired immunity to P. berghei. 
To test the role of macrophages in the maintenance of immunity, premune 
(immune mice carrying subpatent numbers of parasites) and sterile immune mice 
(immune mice treated with chloroquine (CQ) to remove parasites) were depleted of 
macrophages and challenged with IP and VP at various time points ranging from 7 to 84 
days. It was seen that after a single injection of LIP-CI2MDP in premune mice that there 
was little effect on the parasitemia, while sterile immune mice challenged with VP 
developed progressively higher parasitemias as the challenge time increased. In some 
cases, mortality resulted. When IP were given, there was no significant increase in 
parasitemia compared to controls. 
The results of both types of experiments suggest that a subpopulation(s) of 
macrophages, probably marginal zone and/or marginal metallophilic macrophages, are 
involved in a dynamic process wherein the absence of macrophages, malaria immunity 
fades. In other words, macrophage processing/presentation is needed to develop and 
maintain malaria immunity. The role of the macrophage as effector as well as in antigen 
processing/presentation in malaria immunity is discussed. 
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INTRODUCTION 
A role for mononuclear phagocytes as effector cells in cell-mediated immune 
responses against malaria has been suggested from several experiments using murine 
models. Experimental evidence obtained via the administration of agents such as 
Mycobacterium bovis (BCG) or Propionibacterium acnes suggested increased host 
resistance to malaria infection due to activation of non-specific immune mechanisms 
mediated by mononuclear phagocytes (6, 7, 10, 25, 32, 33). Furthermore, it was 
demonstrated by several investigators that macrophages are activated during the course 
of malaria in both experimental animals and man by exhibiting increased phagocytosis of 
normal and infected mouse erythrocytes (31). While enhanced phagocytosis is an 
important component of malaria immunity, it does not appear to be critical for recovery 
from an infection. Products of activated macrophages were found to destroy 
intraerythrocytic parasites both in vitro and in vivo. There is a large body of evidence 
indicating that activated macrophages release factors toxic to the malaria parasite. These 
include reactive oxygen species (ROS) and lipid peroxidation products generated from 
these molecules, factors in tumor necrosis serum, and enzymes (e.g. polyamine oxidase) 
which have been reported to cause intraerythrocytic death of the parasite (3, 8, 9, 13, 
26,27, 28,41) resulting in crisis forms (degenerated parasites inside intact erythrocytes) 
(35). 
A role for macrophages as accessory cells for class I major histocompatability 
complex (MHC) restricted responses has been reported (11,18), while macrophages 
have also been found to play a pivotal role in the processing of particulate antigen to 
peptides that can be presented in combination with class II MHC (36). Moreover they 
produce immunomodulating cytokines so that an appropriate protective immune 
response is evoked (29). The protective immune response, especially to the erythrocytic 
stages of Plasmodium, is dependent on CD4+ Τ cells (1, 4, 20, 22, 34, Chapter 5). Of 
the CD4+ Τ cells at least two sub-populations, T
n
l and T
n
2, are implicated as playing a 
role in malaria immunity (21, 22). These cells, which are highly integrated and contra-
regulated by the cytokines produced, respond to stimulation by antigen-presenting cells, 
including macrophages. Specifically, T
n
l cells produce the cytokines IFN (γ), IL3, GM-
CSF and TNF (α and β), which as one of the functions, activates macrophages, while 
T
n
2 cells produce cytokines associated primarily with В cell responses, including IL4, 
IL5 and IL6 (5, 23, 24, 29). Numerous examples of T(,l-T
n
2 regulation have been 
proposed, including a model for Plasmodium chabaudi (21, 22). Our own adoptive 
transfer model (Chapters 3 and 4) showed that В cells, as well as CD4+ Τ cells, were 
essential for immune transfers, suggesting the involvement of the macrophage in the 
processing and presentation of antigen to other cells, including В and Τ cells, rather than 
only having an effector function. 
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To study the role of macrophages in our model, a useful approach was to 
examine the effects on the system after their removal. Temporary depletion of 
macrophages in the spleen and liver can be achieved by treatment of the animals with 
LIP-C12MDP (36). Within 24 hours after a single treatment with LIP-C12MDP, red pulp 
macrophages, marginal metallophilic macrophages and marginal zone macrophages 
appeared to be eliminated simultaneously. The reappearance of new macrophages 
belonging to each of these subpopulations occurs at predictable times (38), that is, red 
pulp macrophages return within 1 to 2 weeks, marginal metallophilic macrophages 
within 2 to 4 weeks and the marginal zone macrophages require 6 weeks or more for 
their complete repopulation (40). 
Adoptive transfer studies using macrophage-depleted ISC and LIP-CI2MDP-
treated acceptors, as well as kinetic studies where parasite challenges were manipulated 
in immune mice treated with LIP-CI2MDP, were carried out to determine the effect of 
macrophage depletion on (and eventually macrophage involvement in) the transfer and 
maintenance of immunity to the immunogenic and virulent forms of Plasmodium 
berghei parasites. 
MATERIALS AND METHODS 
Mice. Naive, female, C57BL/10 mice, used as acceptors at 6 to 8 weeks old were 
obtained from the Central Animal Facility at the University of Nijmegen (The 
Netherlands). Mice were housed under specific pathogen-free conditions in plastic cages 
(39 χ 22 χ 14 cm) and received food (RMH, Hope Farms, The Netherlands) and water 
ad libitum. All mice (3-6/group) in any particular experiment were age-matched. 
Experiments were repeated at least once and results summarized. 
Parasite. The virulent form (VP) of Plasmodium berghei, strain K173 was used in the 
challenge infections and an attenuated form, IP, obtained in this laboratory (see below, 
Chapter 3), was used as both stimulation in the transfer experiments as well as in 
challenge infections where indicated. Both parasites were used at 1(H parasitized RBC 
per mouse. Aliquots of parasitized blood were stored in liquid nitrogen. VP were kept 
viable by weekly passage in intact mice and IP were passaged weekly or biweekly in 
splenectomized C57B1/10 mice using 10* parasitized RBC. Blood was collected from 
mice by bleeding from the tail, the erythrocytes counted and the percent parasitemia 
determined by counting the percentage of parasitized RBC (pRBC) to uninfected RBC 
appearing in May-Griinwald/Giemsa (Merck, Germany)-stained thin bloodsmears. 
RBC/pRBC were diluted in sterile, physiological saline containing 5U heparin per ml, 
adjusted to the appropriate concentration and injected intraperitoneally (i.p.) into passage 
or experimental mice. 
IP. Immunogenic parasites were isolated on Day 28 from blood of mice being 
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immunized with 3 x 1 0 ' VP/mouse administered on Day 0 and given sulfonamides (see 
below) in the drinking water from Day 2 onward to maintain a subpatent infection (15). 
Immunization of mice against P. berghei VP. Mice were immunized against P. 
berghei КПЗ VP by (1) a chemolherapeutically-controlled VP infection (15), (2) a 
chemotherapeutically-controlled IP infection or (3) transfer of ISC to naive acceptors, 
stimulation with IP and challenge with VP (see below). 
Immunization with VP: Briefly, mice were infected with 3 χ 10 ' VP (Day 0) and 
placed on sulfonamide-drinking water (sulfathiazolc-Na 300 mgA or sulfadiazine 30 
mg/1) from Day 2 to Day 33 after which time they were returned to normal drinking 
water. At Day 35, all mice received a challenge infection (105 VP/mousc). 
Immunization with IP: Mice received 10" IP and sulfadiazine treatment from either 
Day 0 or Day 2 to Day 19 and a challenge infection with VP on Day 21 (Chapter 3). 
Mice that controlled the challenge infection or showed a temporary low grade infection 
(usually <1%) that returned to subpatcnt levels were considered immune. VP immune 
mice were always IP immune. Immunized mice were given an additional challenge with 
10* VP before use in experiments to determine their immune status. Usually parasitemia 
remained subpatent after this challenge, but peak parasitemias of 0.5% were seen 
occasionally. All immune mice were then treated with CQ (Nivaquine® 100 mg/1) 
drinking water ad libitum for 5 days to clear any parasites and used in the transfer 
experiments. After CQ treatment, mice were termed sterile immune (i.e., parasite-free). 
Adoptive transfer studies. 
A) Preparation of spleen cells. Spleens were removed from immune donors, 
dissociated by gentle pressure with a glass rod and passed through a sieve fitted in a 10 
ml syringe containing cotton wool. Cells were treated with ammonium chloride-Tris 
(ACT) (19) to lyse the RBC. For macrophage depletion, ISC were incubated for 1 hour 
at 37°C on a glasswool column. 3-5 χ 10 ' non-depleted or macrophage-deplcted ISC 
were collected and transferred by intravenous (i.v.) injection to naive, intact or 
macrophage-deplcted (i.e., LIP-C^MDP-treated) acceptors. 
B) Macrophage depletion in acceptor mice. Macrophages were depleted in 
acceptor mice by the use of LIP-CI2MDP prepared as described by Van Rooijen (32). 
The dichloromcthylene diphosphonate (Cl2MDP)was a kind gift supplied by 
Boehringer-Mannheim (Germany). 0.2 ml LIP-CI2MDP per acceptor mouse was 
injected i.v. 3 days before the transfer of ISC. Non-depleted control mice received i.v. 
injections with PBS. 
C) Kinetics of the transfer model and stimulation with IP. It was found in this 
laboratory (Chapter 4), that stimulation of the ISC with living IP was necessary for 
successful transfer of immunity. In our base experiments, IP was routinely given on the 
same day as the ISC; however, though IP stimulation of ISC was required, its 
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administration could be delayed for months after the initial injection of ISC and still be 
effective, that is, control the VP. VP was given 7 days after the IP stimulation to test the 
immune status of mice. This information was adapted to transfer studies designed to 
observe the functional kinetics of the repopulation of macrophages. This was done in the 
following manner: Acceptor mice were either depleted for macrophages (i.e., treated 
with LIP-CI2MDP) or not depleted (i.e., treated with PBS) 3 days before transfer with 
ISC. The acceptors received intact or macrophage-depleted ISC. The transfer of ISC 
was termed Day 0. In order to study the kinetics of the macrophages, these mice were 
assigned to five separate groups in which the stimulation with IP was delayed until 
different times after the injection of ISC (see Figure ΙΑ-E). In the first group (A), 
transferred ISC were stimulated with IP but received no additional VP challenge to 
determine if macrophages were necessary for the processing and control of the IP. The 
second group, our standard control group, received stimulation with ICH IP on Day 0 
and IO5 VP on Day 7 (Figure IB), the third group received IP on Day 14 and VP on 
Day 21 (Figure 1С), the fourth group received IP on Day 28 and VP on Day 35 (Figure 
ID), and the fifth group (Figure IE) received two treatments of LIP-CI2MDP, not only 
on Day -3, but also on Day 25 followed by injection of IP on Day 28 and VP on Day 
35. Immunity was assessed by examination of bloodsmears taken at weekly time 
intervals. The conditions are represented in the figures by the day when the IP was 
given (i.e., 7 days before VP). 
Depletion of macrophages in immune mice (refer to Figure 2). Immunity 
was first confirmed in mice previously immunized by VP challenge. One group of 
immune mice remained on normal drinking water (Figure 2A) and was treated with LIP-
CI2MDP to test the effects of LIP-CI2MDP on premune mice (i.e., carriers of parasites). 
Other groups of immune mice were treated with CQ-containing drinking water to clear 
any parasites to test the effect of LIP-CI2MDP on sterile immune mice. In all 
experiments in sterile immune mice, the first day of CQ treatment was designated as Day 
0. In a group of experiments depicted in Figure 2B, 0.2 ml LIP-CI2MDP per mouse 
was injected on Day 1 (i.e, under CQ-containing drinking water, and so soon after the 
start of CQ treatment that there was a possibility that parasites could be present). To 
observe the effects of macrophage depletion (and their recovery) on the ability of 
immune mice to control a VP infection, individual groups of these mice were randomly 
selected to be challenged with VP on either Day 7, 14,22, 28,42 or 84. Another group 
of mice received, in addition to LIP-CI2MDP on Day 1, a second LIP-C12MDP injection 
on Day 25, followed by a VP challenge on Day 28. (Figure 2C). CQ-treated immune 
mice injected with PBS in place of LIP-CI2MDP were used as controls (not indicated). 
In a further group of experiments depicted in Figure 2D, LIP-CI2MDP was 
given on Day 6 (i.e, after CQ treatment to remove parasites, and in this case, long 
enough after the CQ treatment that no living parasites should be present). Individual 
groups of mice were randomly selected and then challenged with VP or ΓΡ on Days 28 
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or 42. Another group of immune mice of was given, in addition to LIP-CI2MDP on Day 
6, a second injection with LIP-CI2MDP on Day 25 and challenged with VP or IP on Day 
28 (Figure 2E). CQ-treated immune mice injected with PBS in place of LIP-CI2MDP 
were used as controls (not indicated). 
RESULTS 
Adoptive Transfer Experiments 
To study the effect of macrophage depletion on transfer of immunity, 
macrophage-depleted or non-depleted ISC were transferred to macrophage-depletcd or 
non-depleted acceptors. To study the kinetics of the reappearance of macrophage 
function in the transfer of immunity, IP stimulation (essential for the transfer of 
immunity) of macrophage-depleted ISC or non-depicted ISC was delayed with respect to 
the macrophage depletion (LIP-CI2MDP treatment) in the acceptors. To determine if 
macrophages were important in processing and control of IP, macrophage-depleted 
acceptors were given IP and the infection followed. In addition to IP stimulation, some 
mice also received a challenge with VP 7 days later to determine their immune status. 
The results of these experiments (schematically depicted in Figure 1) are given in Figure 
3. Figures ЗА and В show the results of macrophage-depleted acceptor mice challenged 
with VP 7 days after the injection of depleted (Figure ЗА) or non-depleted (Figure 3B) 
ISC and IP stimulation. The time points listed in the figures are those days when the IP 
stimulation was given. The percentage immune mice observed after receiving 
macrophage-depleted ISC is shown in Figure ЗА. Mice given ISC and IP stimulation on 
Day 0 and VP challenge on Day 7 did not become immune. When the ГР stimulation was 
delayed to Days 14 (VP Day 21) and 28 (VP Day 35) in the LIP-Cl2MDP-treated mice, 
the percentage of immune mice seen was 33 and 100%, respectively. All PBS-treated 
(i.e., non-depleted) controls at all time points became immune. By contrast, when non-
depleted ISC (i.e., ISC possessing macrophages) and IP were given to LIP-CI2MDP-
treated and non-depleted acceptors (Figure 3B) on Day 0 (VP Day 7), 33% immune mice 
were seen in the LIP-C^MDP-treated condition. When the IP was delayed to Days 14 
(VP Day 21) and 28 (VP Day 35), the percentage immune mice of those treated with 
LIP-CI2MDP was 33 and 100%, respectively; comparable to the condition where 
acceptor mice received macrophage-depleted ISC. Again, all of the PBS-treated controls 
at all time points became immune. The percentage of immune mice resulting after 
transfers of macrophage-depleted ISC to acceptor mice that were treated twice with LIP-
CI2MDP is given in Figure 3C. Acceptor mice received IP stimulation on Day 28 (VP 
challenge on Day 35), which in the once LIP-C^MDP-treated mice (Figure ЗА and B) 
was the time for recovery; however, mice depleted twice (3 days before ISC transfer and 
3 days before VP challenge) failed to become immune. 
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Figure 1 : Macrophage depletion and transfer of immunity. Diagram of the transfer of 
immune spleen cells (ISC) to acceptors treated with LIP-G2MDP 3 days before transfer 
(Α-E) and a second time at Day 25 after transfer (E). Stimulation of ISC in acceptors 
with immunogenic parasites (IP) was either given on Day 0 (A -B), 14 (C) or 28 (D-E). 
Challenge with virulent parasites (VP) was always given 7 days after IP stimulation (B-
E). Controls received PBS in place of LIP-CI2MDP (not shown). 
Depletion of macrophages in immune mice 
To look at the effects of macrophage depletion on the maintenance of immunity, 
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Figure 2: Macrophage depletion in immune mice. Diagram of LIP-CI2MDP treatment in 
immune mice challenged with virulent parasites (VP) on Day -14 to confirm immune 
status before start of the experiment. (A): premune mice received LIP-CI2MDP 
treatment. Mice in groups B-Ε were chloroquine (CQ)-treated to eliminate persisting 
parasites, (B): LIP-CI2MDP treatment was given to all mice on Day 1 and individual 
groups were randomly selected and challenged with VP on Day 7, 14, 22, 28, 42 or 84, 
(C): LIP-CI2MDP treatment was given on Days 1 and 25 and mice were challenged with 
VP on Day 28, (D): LIP-CI2MDP treatment was given to all mice on Day 6 (1 day after 
CQ treatment) and individual groups were randomly selected and given VP or 
immunogenic parasites (IP) at Day 28 or 42 and (E): LIP-CI2MDP treatment was given 
on Days 6 and 25 and challenged with VP or IP at Day 28. Controls received PBS in 
place of UP-C12MDP (not shown). 
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Figure 3: The percentage immune mice resulting from transfers of macrophage-depleted 
immune spleen cells (ISC) (A) or non-depleted ISC (B) to acceptor mice treated with 
LIP-CI2MDP or PBS on Day -3. Transfer of macrophage-depleted ISC to acceptors 
treated with LIP-CI2MDP on Days -3 and 25 (C). Data on the x-axis represents the day 
when the immunogenic parasites (IP) were given. The bars show treatment of the 
acceptor mice.-
immune mice were treated with LIP-CI2MDP and challenged with ГР or VP at various 
times (refer to Figure 2) to monitor the ability of mice to continue to control the parasite. 
Figures 4A and В show the effect of LIP-CI2MDP given on Day 1(1 day under CQ; 
with the possibility of the presence of parasites) in comparison to PBS-treatment (Figure 
4C). Figure 5 A and В show the effect of LIP-CI2MDP given on Day 6 (1 day after mice 
were taken off CQ; with the absence of parasites). In addition, in both of these 
conditions, separate groups of mice were given a second treatment on Day 25 with LIP-
C12MDP (Figure 4D and 5C). Premune mice after LIP-C12MDP and VP challenge 
showed little increase in parasitemia after challenge (Figure 4A). VP challenge on Days 
7 or 14 (Figure 4A) in sterile immune and macrophage-depleted mice resulted in only a 
slight increase in parasitemia while a VP challenge on Days 22, 28 and 42 (Figure 4A 
and B) in such mice showed a relative greater increase in parasitemia when compared to 
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Figure 4: Percentage parasitemia seen after injection with LIP-CI2MDP in premune mice 
and premune mice 1 day after start of chloroquine treatment and challenge with virulent 
parasites (VP) on days indicated (A and B) as well as PBS-treated controls challenged 
with VP (С) (n=6). (D) Sterile immune mice given two LIP-CI2MDP treatments on 
Days 1 and 25 then challenged with VP on Day 28 (n=3). (t=death of mouse) 
the PBS-treated sterile immune controls (Figure 4C). When the late, Day 84, VP 
challenge was given, the LIP-CI2MDP-treated and PBS-treated controls both showed an 
increased parasitemia, characteristic of "fading" (15,17) or diminished immunity. When 
immune mice were given two LIP-CI2MDP treatments on Days 1 and 25 and challenged 
with VP on Day 28 (Figure 4D), the parasitemia approached nearly the same levels seen 
in the one-time LIP-C12MDP treatment and challenge on Day 28 (10 and 12%, 
respectively); however, with the two-time treatment, 33% of the mice died. In the 
second series of experiments (Figure 5), LIP-CI2MDP was given on Day 6 and both IP 
and VP were tested at those time points in the First set of experiments (i.e., Days 28 and 
35) where challenge with VP resulted in peak parasitemia not seen in the matched PBS-
treated controls. Figure 5A shows that immune mice treated with LIP-CI2MDP and 
challenged with IP on Day 28 were perfectly able to control the infection. The 
parasitemia remained low (<1%); however, mice challenged with VP developed a higher 
parasitemia (compare the PBS-treated controls in Figure 5B) and 66% died. Immune 
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mice treated with LIP-CI2MDP and challenged with VP on Day 42 (Figure 5A) 
developed an increased parasitemia (6%), slightly higher than that seen in PBS-treated 
controls, but lower (14%) than in those mice of the first set of experiments at this 
challenge time (Figure 4C). Unlike the Day 28 VP challenge, none of the mice died at 
this later challenge time. When mice were given two treatments with LIP-CI2MDP on 
Days 6 and 25 (Figure 5C), followed by VP challenge on Day 28, mice developed 
parasitemias and 50% died. The mice that did not die never developed high parasitemias. 
Mice receiving two treatments of LIP-CI2MDP and IP challenge developed only slight 
parasitemias (<5%) and all survived. 
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Figure 5: Percentage parasitemia seen after injection of sterile immune mice with LIP-
CI2MDP on Day 6 after start of chloroquine treatment and challenge with virulent (VP) 
or immunogenic (IP) parasites on days indicated (A) and PBS-treated controls 
challenged with VP or IP (B) (n=6). (C) Sterile immune mice given two LIP-C12MDP 
treatments on Days 6 and 25 then challenged with VP or IP on Day 28 (n=6). 
Parasitemia after VP challenge on Day 28 is depicted separately for surviving and 
succumbing mice. (t=death of mouse) 
DISCUSSION 
For successful adoptive transfer of P. berghei immunity in this model, three 
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elements appeared to be essential: (1) the stimulation of transferred ISC with IP before 
challenge with the VP (Chapter 4), (2) the presence of В cells in transferred ISC 
(Chapter 5) and (3) the presence of CD4+ Τ cells (Chapter 5). 
This study shows that depletion of macrophages from ISC and acceptors has an 
important effect on adoptive transfer of P. berghei immunity. In addition, depletion of 
macrophages in mice with established immunity that either possessed parasites or not 
(i.e., premunity versus sterile immunity), differently effected the control of a subsequent 
challenge, especially with VP. It was seen with both approaches that the time of the 
depiction of macrophages, accomplished by treatment of naive acceptors of ISC or 
sterile immune mice with LIP-CI2MDP, dramatically effected the ability of mice to either 
become immune or stay immune. By using the data derived from experiments involving 
the increasing of time between LIP-CI2MDP treatment and IP stimulation after transfer 
or LIP-CI2MDP treatment and VP challenge in immune mice and applying what is 
already known about the kinetics for the reappearance of macrophages, an estimate of 
the involvement of a particular type of macrophage in P. berghei immunity can be made. 
The spleen is required for development of immunity (16). It has been earlier 
described (36, 38) that although within 24 hours after administration of LIP-CI2MDP, 
red pulp, marginal metallophilic and marginal zone macrophages are eliminated in the 
spleen, reappearance occurs at various times. Red pulp macrophages appear within 1 to 
2 weeks, marginal metallophilics fully regain a position at the border of the marginal 
zone and the periartcriolar lymphatic sheath (PALS) within 2 to 4 weeks and the total 
reappearance of the marginal zone macrophages takes 6 weeks or more. Thus all cells, 
with the exception of the latter, return to their normal numbers approximately 2 weeks 
after depletion (38). 
Marginal zone macrophages have been reported to be required for an antigen 
processing step in the splenic immune response against the particulate antigen 
trinitrophenyl-conjugated sheep red blood cells (12, 40). Furthermore, marginal zone 
macrophages have a strategic position in the marginal zone close to the site where 
antigens are discharged from the white pulp capillaries (38). When we look to our 
experimental findings, this information becomes particularly important in understanding 
the role of macrophages in the transfer of immunity. 
Particularly, in our ISC transfer experiments (Figures ЗА and B), acceptor mice 
treated with LIP-CI2MDP then given ISC were best capable of controlling IP and VP 
only when given later on Days 28 and 35, respectively. Furthermore, LIP-CI2MDP-
treated mice given ISC and IP on Day 0 and not challenged with VP were also unable to 
develop immunity and died. By contrast, in PBS-treated controls, mice were able to 
develop immunity by IP stimulation and VP challenge within 7 days. That the LIP-
C^MDP-treated mice required a longer period before being able to control IP and VP 
challenges could be attributed to the recovery period for macrophages. The later time is 
presumably that time when a sufficient complement of macrophages has reappeared or, 
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most likely, when specific subpopulations of macrophages, particularly, marginal 
metallophilic macrophages and marginal zone macrophages, have reappeared in adequate 
numbers. Moreover, these macrophages probably play a role in the initial processing of 
the IP since the mice treated with LIP-CI2MDP and given only the ISC with IP 
stimulation (i.e., not followed by VP challenge) failed to become immune. 
Macrophages have been found to play an important role in the mechanism of 
antigen processing of particulate antigens (parasites), which can then be transferred to В 
cells or dendritic cells which are responsible for presentation to Τ cells (40). It is 
postulated that in the spleen, В cells meet antigen in the marginal zone, migrate to the 
outer part of the PALS and present their processed antigens to the appropriate Τ cells 
(39). Moreover, it has been postulated that although В cells may process small and 
soluble antigen, macrophages, especially marginal zone macrophages, arc required for 
processing of particulate antigens (39,40). Because we observed recovery of transfer at 
the time (approximately 1 month) correlating with the reappearance of marginal 
metallophilic and marginal zone macrophages, it is probable that these macrophages play 
an important role in processing of the parasite antigen in our model. 
Further evidence to expand on the above hypothesis involving the role of 
macrophages, В cells and CD4+ Τ cells in immunity comes from our previous transfer 
experiments (Chapter 5) where it was seen that both В cells and CD4+ Τ cells were 
essential for immunity. Without В cells or CD4+ Τ cells, there was no positive transfer. 
That В cells from immune ISC were absolutely required for successful transfer indicates 
that (memory) В cells could be the recipients of processed antigen that then present 
processed antigen to the appropriate Τ cells and receive Τ cell help, followed by 
differentiation into antibody-forming plasma cells. In support of this, higher anti­
parasitic antibody titers were seen in mice that developed immunity than in those that did 
not (Chapters 4 and 5). 
In addition, it appears that the type of antigen, IP or VP, as well as the type of 
CD4+ Τ cell (T
n
l or T
n
2) is important. A T
n
l-T
n
2 pathway that directs the elimination 
process has been postulated for development of immunity to P. chabaudi (21) which 
may also apply to our model. For example, earlier experiments showed that without IP 
stimulation, acceptors receiving ISC could not resist VP challenge; the challenge given 
to test immunity. In view of the importance of В cells and antibody production for 
positive transfer (Chapters 4 and 5), this suggests the IP stimulation of T
n
2 cells rather 
than T
n
l cells. VP, on the other hand, may preferentially stimulate T
n
l pathology and 
down-regulate a necessary T^2 response; a mechanism also reported for a murine 
Leishmania model (2). 
To look at the effect of macrophage depletion on the maintenance of IP and VP 
immunity, three types of experiments were carried out involving treatment with LIP-
CI2MDP in premune mice and mice given LIP-CI2MDP on Day 1 or 6 after CQ 
treatment (Figures 4 and 5). In premune mice, CI2MDP treatment had no effect on 
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immunity. There was no significant increase in parasitemia while higher parasitemias and 
even mortality were observed in mice where parasites were eliminated by CQ treatment 
before injection with LIP-CI2MDP. In the CQ-treated mice, loss of VP immunity was 
stronger when LIP-CI2MDP treatment was given 6 days compared to 1 day after the 
start of CQ. In the experiments, the suppression of malaria immunity following LIP-
CI2MDP treatment depends on the presence of the parasite, which by activating 
macrophages may interfere with the ability of macrophages to ingest the LIP-O2MDP-
containg liposomes. A study by Schwarzer et al. (30) showed that once activated 
macrophages ingest P. falciparum parasites containing malarial pigment, they lose their 
ability to subsequently phagocytize efficiently, which could explain the results we 
described above. Thus, the longer the period after the parasite-dependent activation of 
macrophages, the more effective the LIP-CI2MDP treatment. 
LIP-CI2MDP treatment of established immune mice resulted both in high 
infections and loss of immunity in VP-challenged mice but not in IP-challenged mice 
(Figure 5A). By contrast, in transfers with ISC and IP, acceptor mice treated with LIP-
CI2MDP were unable to develop immunity. It appeared that macrophages were 
necessary for the processing of IP. That there were differences seen between mice used 
in transfers of ISC and established immune mice both given IP could be attributed to the 
production of antibody. In the transfers of ISC, acceptors had not been previously 
exposed to the parasite and time was needed to develop an appropriate antibody 
response, while in the established immune mice with previous experience with the 
parasite, there may be sufficient antibody to control the parasite. 
As mentioned above, in the CQ and LIP-C^MDP-treated mice (Figures 4 and 5) 
experiments, a single LIP-CI2MDP treatment resulted in loss of immunity exhibiting 
higher parasitemia the longer the VP challenge was delayed and even death when LIP-
C12MDP was given 6 days, rather than 1 day, after the start of CQ treatment. When a 
double treatment with LIP-CI2MDP was given, the result was an even stronger 
suppression of immunity, suggesting that the reappearance of macrophages after the 
single treatment contributed to the recovery after the VP challenge. The increasing 
parasitemia in relation to an increasing period between macrophage depletion and VP 
challenge up to a period of 42 days indicates that macrophages are important in 
maintaining the immune response at an effective level rather than for the elimination of 
parasites in an effector mechanism of immunity. 
Previous experiments with this model (14, 15, 18, Chapter 7) showed that 
immunity faded with time after the elimination of the parasite. This can help to explain 
what was seen in the experiments reported in this paper for both PBS- and LIPCI2MDP-
treated mice when challenged 84 days after the start of CQ treatment. Both treatment 
groups showed increases in parasitemia, indicating a reduction in immunity. Though the 
macrophage complement in the LIP-CI2MDP group is expected to have returned to 
largely the same levels as the PBS-treated group by Day 84, it is thought that in the 
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absence of parasites in both groups during this period, that the number of specific Τ 
and/or В cells has been reduced to the same extent responsible for the observed 
reduction in immunity. Furthermore, adhering to this concept, parasites in premune mice 
function to keep immunity at a high level which is brought about by the continuous 
processing/presentation of (VP) parasite antigens by marginal zone macrophages and/or 
marginal metallophilic macrophages to comparatively short-living (less than 3 months) 
specific Τ and/or В cells. Since immune В cells appeared to be more important than 
immune CD4+ Τ cells in this model (Chapter 5), maintenance of a pool of specific В 
cells may be an essential function of premunity. 
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Chapter 7 
Fading of immunity to virulent and immunogenic 
Plasmodium berghei in adoptive transfer and established immunity 
Christina M. Celluzzi, Theo J. J. M. van de Wiel, Рек Liong Liem, 
Joep H. E. Th. Mcuwissen and Wijnand M. С. Eling 
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SUMMARY 
Fading or loss of immunity resulting from the lack of exposure of the host with 
the Plasmodium berghei virulent parasite (VP) or its immunogenic form (IP) was tested 
using adoptive transfer of spleen cells from immune donors to naive C57BL/10 acceptor 
mice. By varying the length of time between a parasite challenge in an immune spleen 
cell donor and its use in a transfer, it was found that mice most recently challenged with 
the parasite and transferred were able to confer immunity to acceptor mice, while donor 
mice without recent exposure to the parasite did not. Furthermore, it was seen that 
immunity to IP was longer lasting than immunity to VP, presumably due to a selective 
memory. When antibody titers were measured after long sterile periods (i.e., when the 
mice were parasite-free) followed by later rechallenge with the VP, IP or both IP then 
VP, boostered antibody titers were seen in all mice; however, the VP-challenged mice 
had the lowest titers and died while the IP- challenged mice survived. Antibody titers 
were higher in mice given IP, possibly explaining their survival. Variations of our 
transfer model and the role of antibody is discussed. 
INTRODUCTION 
In the mouse model used in our laboratory, immunity developed by a 
chcmotherapeulically-conlrolled infection with the virulent form of P. berghei depended 
on the development of an attenuated immunogenic form (IP) during the immunization 
period (Chapter 3). This IP played an essential role in the transfer of VP immunity from 
immune to naive mice (Chapter 4). It is generally believed that for maintenance of 
immunity, the relevant antigen must persist or repeatedly be presented (1). On studies of 
Τ cell memory, the physical properties of antigen, in vivo persistence, and dose and 
frequency of rcexposurc all can influence the length of immunity (1). Furthermore, 
decay of Τ cell memory in the absence of antigen suggests that memory cell survival can 
be driven by specific antigen which persists in vivo and provides low-level stimulation 
(1). Immunity with persistence of low numbers of the specific pathogen is called 
premunition (16). Both in human and experimental erythrocytic-stage malaria 
premunition, fading of immunity in the absence of the parasite (3, 6, 7, 13, 14) and 
maintenance of immunity in the presence of the parasite are well-established (2, 4, 5, 
11, 12).Fading is marked by increased peak parasitemias after challenge with the 
parasite or if the fading period is long enough, mortality. Because of the time course of 
the infection, that is, the gradual change from solidly immune transient patency ending 
in lethality in P. berghei infections, the question arises whether there is a gradual 
quantitative difference of loss of a specific element of the immune response. 
In this paper, fading of immunity in the absence of persisting live parasites is 
studied in relation to transfer of immunity as well as in established immune mice. 
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Persistence of immunocompetent cells in the absence of persisting parasites both in the 
donor of immune spleen cells (ISC) as well as in the acceptor before being stimulated 
with IP to develop VP immunity was studied. In addition, fading of established 
immunity after elimination of persisting parasites to challenge with either IP or VP was 
investigated. It appeared that fading was related to a decrease in CD4+ Τ cells and a 
reduction of the specific anti-parasitic antibody titer. Fading of immunity to VP challenge 
was apparent after a parasite-free period of 3 months; however, immunity to IP persisted 
for more than 6 months. 
MATERIALS AND METHODS 
Mice. Naive, C57BL/10 mice, were obtained from the Central Animal Facility at the 
University of Nijmegen (The Netherlands). Mice were housed under specific pathogen-
free conditions in plastic cages (39 χ 22 χ 14 cm) and received food (RMH, Hope 
Farms, The Netherlands) and water ad libitum. Experiments were repeated at least once 
and results summarized. 
Parasite. Plasmodium berghei (strain КПЗ), VP, and an attenuated immunogenic 
isolate, IP (see below), were kept viable by weekly and biweekly passage in intact and 
splenectomized C57B1/10 mice, respectively, using 1CP parasitized RBC obtained via the 
tail blood of infected mice. Aliquots of parasitized blood were stored in liquid nitrogen. 
Blood from infected mice was collected in heparin (5 U/ml), the erythrocytes were 
counted and the percent parasitemia was determined by counting the percentage of 
parasitized to uninfected RBC appearing in May-Griinwald/Giemsa (Merck, Germany)-
stained thin bloodsmears. The blood sample was diluted in sterile, physiological saline at 
the appropriate concentration and injected intraperitoneally (i.p.) into passage or 
experimental mice. 
Immunogenic parasites (IP). The isolation and characteristics of IP have been 
described elsewhere (Chapter 3). Briefly, IP were isolated on Day 28 from blood of 
mice being immunized with 3 χ 10' VP administered on Day 0 then given either 
sulfathiazole-Na (300 mg/1) or sulfadiazine (30 mg/1) in the drinking water on Day 2 to 
maintain a subpatent infection (2). IP were used at 10* per mouse in experiments except 
where otherwise indicated. 
Immunization of mice against P. berghei VP. Mice were immunized against P. 
berghei К173 (VP) by a chemotherapeutically-controlled 5 week VP (12) or 3 week IP 
infection (Chapter 3) or by transfer of ISC to naive acceptor mice, stimulation with IP 
and challenge with VP (Chapter 4). Briefly, in the 5 week immunization procedure, mice 
were infected with 3 χ IO7 VP (Day 0) and placed on sulfonamide-containing drinking 
water from Day 2 to Day 33, after which time they were returned to normal drinking 
water. At Day 35, all mice received a challenge infection (10^ VP/mouse). In the 3 week 
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immunization procedure, mice received 10" IP and sulfadiazine treatment from either 
Day 0 or Day 2 to Day 19, thereafter placed on normal drinking water and on Day 21, 
challenged (IO5 VP/mouse) (Chapter 3). 
Preparation of spleen cells. In the standard procedure for transfer of immunity, 
spleens were removed from immune donors (previously treated with chloroquine (CQ) 
to clear proliferating parasites), dissociated by gentle pressure with a glass rod and 
passed through a sieve fitted in a 10 ml syringe containing cotton wool. RBC were lysed 
with ammonium chloride-Tris (ACT) (10). ISC were stained with the vital stain trypan 
blue, counted on a hemocytometer (Neubauer, Germany) and injected intravenously 
(i.v.) to intact acceptor mice at 2-4 χ 10' ISC per mouse or at the various amounts 
indicated in the figures. The term immune was given to those mice whose parasitemia 
remained subpatent and/or did not exceed 1% when challenged with the VP or IP. 
Immune mice usually exhibit low numbers of parasites (e.g., 1 parasite for 10" 
erythrocytes) and are therefore called premune. 
Adoptive transfer and fading. 
Adoptive transfer. The basic procedure for adoptive transfer has been described 
in detail in Chapter 4. Briefly, immune donors are challenged with VP and treated with 
CQ, 14 and 7 days, respectively, before transfer. ISC from the donors are transferred to 
naive acceptor mice that arc stimulated with 10* IP and 7 days later challenged with 10* 
VP. P. berghei immunity persists in premune animals and fades in the absence of the 
parasite with lime (3). The effect of varying the time periods, referred to as fading 
periods (FP), in the basic model was analyzed. A schematic of the model used to 
analyze the role of different FP in the immune donor and in the acceptor of ISC is given 
in Tabic I and the results of its manipulation are given in Figures 1-3. 
Fading in the immune donor: Since immune mice can spontaneously 
eliminate all parasites, the period between the last contact with the parasite and collection 
of ISC for transfer is uncertain in a number of cases; therefore, mice were given CQ to 
clear any residual parasites. The period between the last VP challenge and the day of 
transfer including treatment with CQ 7 days before transfer was called FPL The time 
between the beginning of CQ in the donor and the transfer of ISC to an acceptor was 
called FP2. Three groups of experiments were performed (Table 1). In group 1, the data 
from groups of mice that were given a FP1 ranging from 13 to 79 days and a FP2 
ranging from 7 to 13 days obtained in independent experiments were summarized. In 
group 2, the data from groups of mice with a FP1 ranging from 14-95 days and a FP2 
ranging from 21-51 days were summarized. The results of group 2 indicated the 
importance of FP2 on successful transfer; therefore, the effect of the length of FP2 was 
tested in group 3 where the basic transfer model with a fixed FP1 of 14 days was 
applied to a large group of mice with a FP2 that varied from 7 to 126 days in randomly 
chosen subgroups. 
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Table 1 
Fading periods and the transfer of immunity 
Basic model: 
CHALLENGE 
VP 
IMMUNE 
DONOR 
CHLOROQUINE 
(CQ) TREATMENT 
Fading periods: 
Group 1 
Group 2 
Group 3 
Group 4 
FP1 
(days) 
13-79 
14-95 
14 
14 
TRANSFER 
FP2 
(days) 
7-13 
21-51 
7-126 
7 
ISC 
NAIVE 
ACCEPTOR 
STIMULATION 
IP 
FP3 
(days) 
0 
0 
0 
1-270 
CHALLENGE 
VP 
7 
7 
7 
7 
Transfer model: from treatment of immune donor to transfer of immune spleen cells 
(ISC) to naive acceptor mice. Each step has a "fading" period (FP). IP=immunogenic 
parasites, VP=virulent parasites 
Fading in the acceptor: In the basic transfer model, transferred ISC are stimulated 
with IP on the day of transfer. To study survival of transferred cells in the acceptor in the 
absence of persisting live parasites, as compared to survival in the donor (FP2), the 
period between transfer of ISC and stimulation with IP was varied from 1 to 270 days 
and called FP3 (Table 1 : group 4). In all cases (groups 1 to 4), VP challenge was given 
7 days after IP stimulation of transferred ISC as in the basic model. 
Fading of immunity to IP and VP in established immune mice. The fading 
of immunity to IP and VP was tested by giving established immune mice CQ drinking 
water to clear parasites then waiting either 126, 161, 182 or 210 days before 
rechallenging the mice with VP, IP or first IP then 7 days later VP. The parasitemias and 
percentage immune mice after the challenge were determined for all test groups. In 
addition, the anti-parasitic Ig and IgG2A titers were determined weekly after rechallenge 
in the group of mice having a sterile period of 182 days. 
Malaria-specific ELISA. Antibody titers (Ig total and/or IgG2a) to the parasite were 
measured from plasma samples removed on the days listed in Figure 3B. Briefly, 96-
well, flat-bottom plates (Costar, Massachusetts, USA) were first coated with a parasite 
extract (100 μΐ/well) obtained via lysis of IO7 VP in 1% triton-xlOO in PBS. Sodium 
azide (0.05%) was added to prevent bacterial contamination and the plates stored 
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overnight at 4°C before use. Directly before use, plates were emptied, subsequently 
coated with a 1% BSA/PBS/0.1% Twcen 20 buffer (buffer A) at 100 μΐ/well and 
allowed to stand for 1 h at room temperature. All subsequent operations were performed 
at room temperature. Two-fold dilutions in 100 μΐ/well of the test plasma or control sera, 
prepared from a pool of immune mouse sera (IMS) obtained from immune mice 14 days 
after a VP challenge, were then added to the wells and incubated for 1 h. Plates were 
washed with PBS then either: (A) for the total Ig determination, a 1 h incubation with a 
RAMPO conjugate (rabbit anti-mouse peroxidase, Dakopatts, Denmark, 1:1000 dilution 
in buffer A, 100 μΙΛνεΙΙ) and a 20 min incubation with TMB (tetramethylbenzidine in 
DMSO, 100 μΐ/well) was done with intermittent PBS washes or (B) for the IgG2a 
determination, samples were first incubated with rabbit anti-mouse IgG2a antibody 
(1:1000, diluted in buffer A at 100 μΐ/well) for 1 h, followed by SWARPO (swine anti-
rabbit peroxidase, Dakopatts, Denmark, 1:1000 diluted in buffer A at 100 μΐ/well) for 
lh, and finally TMB with intermittent PBS washes. The reactions were stopped with 4 
N H2SO4 and the antibody concentrations measured at 450 nm on a Titertek Multiskan 
MCC/340, MKII reader. Sera from malaria-negative mice were included as negative 
controls. Antibody titers are reported as a percentage of the IMS values, used as a 
reference throughout. 
Immunofluorescence (IF) Assay. В cells, CD4+ and CD8 + Τ cells were 
measured by using IF. Briefly, spleen cells (10" per ml) were suspended in monoclonal 
antibody (mAb) for the measurement of CD4+ and CD8+ Τ cells (H129.19 (MT4), anti-
CD4; rat IgG2a and 53.6.72, anti-CD8; rat lgG2a kindly provided by Dr. W. van Ewijk, 
Erasmus University, Rotterdam, The Netherlands). The mAbs were appropriately 
diluted in IF medium (PBS with 10% RPMI 1640/0.5% sodium azide) and incubated at 
4°C for 30 min. The cells were washed twice at 1000 RPM and then incubated for 30 
min at 4°C with rabbit anti-rat Ig FITC (Dakopatts, Denmark, 1:10000). For В cell 
measurement, the spleen cells were suspended in rabbit anti-mouse Ig FITC (Dakopatts, 
Denmark, 1:10000). After the FITC incubations, cells were washed and resuspended in 
50% glycerol/TF medium for examination under a fluorochrome, lOOx water immersion 
lens (Leitz, Germany). 200-500 cells were counted. 
RESULTS 
Adoptive Transfer 
Previous experiments have shown that for transfer of immunity to naive mice, it 
was essential to transfer ISC that were stimulated with live IP for a period of 7 days to 
protect against a VP challenge (Chapter 4). Mice that receive either IP (10^ or more per 
mouse), VP alone or IP in combination with VP develop increasing parasitemias and 
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die. Mice receiving ISC plus IP and a VP challenge on Day 7 may exhibit a temporary 
parasitemia, but eventually clear the infection to subpatent levels and remain subpatent 
after additional challenges. 
The effect of variation of FP1, FP2 and FP3 on transfer of immunity 
with ISC 
In pilot experiments carried out to develop the basic format for the adoptive transfer of 
immunity, both FP1 and FP2 varied. The summarized results of these experiments are 
given in Table 2. 
Table 2 
Fading periods in the donor and transfer of immunity 
Time period (days) Immune mice 
FP 1 FP2 % (number) 
Group 1 13-79 7-13 74(126) 
Group 2 14-95 21-51 5( 91) 
The data indicate that variation of FP1 had little effect on the capacity to transfer 
immunity, but variation of FP2 effected the capacity to transfer immunity. Consequently, 
the effect of a longer parasite-free period in the donors of ISC (i.e., FP2) was more 
closely studied (Table 1: group 3) in a standardized experiment and the results given in 
Figure 1A. The results of this experiment show that the capacity to transfer immunity 
resulting from varying the "fading" periods in donor mice before transfer.immunity by 
spleen cells from donors that had not been exposed to parasites for more than 1 month 
progressively decreased and was completely lost after a parasite-free or sterile period of 
126 days. Analysis of the spleens at the end of the FP2 showed a strong reduction in the 
percentage of CD4+ Τ cells and В cells already 70 days after parasite clearance whereas 
the percentage of CD8+ Τ cells showed comparatively minor variation. In the next scries 
of fading experiments, the immune donors received the standard VP challenge and CQ 
treatment 14 and 7 days, respectively, before the transfer of ISC to naive acceptors. IP 
stimulation in the acceptors was varied from 1 to 270 days after the transfer of ISC, but 
VP challenge was always given 7 days after IP stimulation. It was observed (Figure 2) 
that ISC transferred to acceptors could be effectively stimulated for a period of 
approximately 3 months with the capacity decreasing thereafter. 
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Figure 1: Fading period 2 (FP2). (A) Percentage of immune mice resulting after transfer 
of immune spleen cells (ISC) from donors that were parasite-free from 7 to 126 days. 
(B) The percentage of B, CD4+ and CD8+ Τ cells counted per spleen at Days 14, 70 
and 126. (n>6) 
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Figure 2: Fading period 3 (FP3). The percentage immune mice resulting after delays 
between the injection of immune spleen cells (ISC) and stimulation with immunogenic 
parasites (IP). (n= 3-7) 
Test of fading of immunity to IP and VP ¡η established immune mice 
In addition to fading of capacity to transfer immunity, established immune mice 
were studied to determine their ability after long sterile periods to control challenges with 
VP, IP, or IP plus a subsequent VP challenge 7 days later (Figure ЗА). Two remarkable 
observations were made. First, all mice controlled an IP challenge, even after a sterile 
period of 182 days. Second, no mice controlled a VP challenge after a sterile period of 
126 days or more. Despite the control of an IP challenge, the capacity to control a 
subsequent VP challenge 7 days later decreased with an increasing sterile period, 
reaching 50% after 200 days (result not shown). 
Anti-parasite antibody was measured after challenges following a sterile period 
of 182 days. The results are depicted in Figure 3B. After 182 days, immediately before 
challenge, the anti-parasite antibody titer was very low in comparison to premune mice. 
Anti-parasite antibodies rose to levels 2 to 8 times higher than what was normally found 
in established immune mice 14 days after challenge and gradually returned to the 
normally observed levels over the following 4 weeks. The anti-parasite antibody 
response was significantly higher in mice challenged with IP followed by VP (828±154) 
than in mice challenged with IP alone (545±23). Despite an anti-parasitic antibody 
production of more than 2 times the amount normally seen in immune mice, VP-
challenged mice succumbed to the challenge infection. Plasma samples were also 
analyzed with respect to the amount of anti-parasite antibody of the IgG2a isotype 
(results not shown). The titers on Day 14 were all approximately 5 times higher than 
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those observed in established immune mice, independent of the challenge type or 
survival. 
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Figure 3: Fading of immunogenic and virulent parasite (IP and VP) immunity. (A) The 
percentage immune mice resulting after the listed sterile (i.e., parasite-free) periods and 
rechallenge with either VP, IP or IP followed 7 days later with VP (ΙΡΛ17 VP). (В) The 
total Ig titers in mice after the 182-day sterile period. 
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DISCUSSION 
Live parasites play an essential role in the development and maintenance of 
immunity (6, 7, 8 (Chapter 2)). Established immunity fades after a parasite-free period 
of approximately 3 months. Immunity to P. berghei in mice can be transferred by ISC 
which in acceptor mice must be challenged with live IP for a period of at least 7 days to 
be able to control a subsequent challenge with the VP (Chapter 4). This confirms the role 
of live parasites in development of immunity. In the transfer model, immunity to VP 
present in established immune mice cannot be transferred by ISC as such, but must be 
developed in the acceptor of ISC by IP stimulation in the absence of VP over a period of 
1 week (Chapter 4). In other words, only IP can provide the proper signal to ISC to 
generate VP immunity, which is consistent with the observation that an attenuated IP 
appears during immunization by a chemotherapeulically-controllcd VP infection (Chapter 
3). 
Fading of immunity in the absence of the parasite raised the question whether the 
capacity to transfer immunity by ISC also faded in the absence of the parasite. The 
capacity to transfer immunity by ISC did not depend strongly on the period between the 
last VP challenge and transfer of ISC (FP1). This is not surprising since in the majority 
of immune mice, parasites persist for a considerable period of time after a VP challenge 
(5, 6 (Chapter 2)). Apparently, these persisting parasites stimulate ISC to levels needed 
for control of the parasite and for successful transfer of immunity. When immune mice 
spontaneously eliminate parasites or parasites are eliminated by radical CQ treatment, 
fading progresses with an increasing parasite-free, sterile period (FP2) and the chances 
for successful transfer decrease. Parasite-free periods between 2 and 3 months caused 
the complete loss of the capacity to transfer immunity (Figure 1). At the same time, a 
considerable reduction in the number of CD4+ Τ cells and В cells was observed 
consistent with previous findings showing the importance of these cell types in transfer 
of immunity (Chapter 5); Fading of immunity was also observed when ISC were left 
unstimulated in the acceptor (FP3). After a parasite-free period of 4 months or more, IP 
were unable to stimulate VP protection (Figure 2). Why immunity fades faster in the 
donor than in the acceptor of ISC remains to be determined. 
Fading of immunity with time and the observation that transfer of immunity 
depends on the number of ISC (Chapter 4) suggests that cells carrying critical anti­
parasitic information (e.g., CD4+ Τ cells) have a limited lifespan, perhaps 3 to 4 
months. In established immune mice, immunity to VP fades after a period of 4 months 
(Figure ЗА). By contrast, fading of immunity to IP was not observed (Figure ЗА) even 
up to periods of 270 days. Thus, immunity to IP is long-lasting (more than 7 months) 
while immunity to VP lasts for a shorter period of lime (4 months). The capacity to resist 
a VP challenge after a foregoing stimulation with IP for a period of 1 week, however, 
decreased after a parasite-free period of 3 months (FP2) in the donor of ISC, 4 months 
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(FP3) in the acceptor of ISC and 6 months or more in mice with an established 
immunity (Figure ЗА). Fading of protection, therefore, to a direct challenge with VP 
proceeds faster than after a foregoing IP stimulation. This supports the idea that IP 
stimulation of ISC generates protection to VP as observed after transfer of ISC (Chapter 
4). After increasing parasite-free periods, memory to IP protection is still enough to 
generate timely IP protection; however, the capacity to generate timely VP protection 
decreases (Figure 3). In view of the long-lasting capacity to mount strong antibody 
responses after challenge and the observed need of CD4+ Τ cells for the control of VP 
but not IP, these results may indicate that specific В cells persist for long periods of 
time, while CD4+ Τ cells only persist for periods of 3 to 4 months. The different fading 
periods in the donors and the acceptors of ISC with respect to protection against VP 
challenge may also reflect a quantitative aspect of immunity to IP and VP. 
Previous experiments showed an association between successful transfer of 
immunity and the concomitant production of anti-parasitic antibody (Chapter 4) which 
correlated with the necessity of immune В cells in ISC used for transfer (Chapter 5). 
Although antibody titers fell after long-lasting parasite-free periods, the amount of anti­
parasitic antibody produced after challenge paralleled the capacity to control the 
challenge (Figure 3B). The remarkable observation was that the amount of anti-parasitic 
antibody rose to peak values of 2.5 to 8 times the amount seen in established immune 
mice (i.e., premune or recently challenged mice). It should be noted, however, that 
despite an antibody level of 2.5 times that of established immune mice, VP-challenged 
mice were not able to control the infection after a fading period of 182 days. Anti­
parasitic antibody levels, as such, are therefore no guarantee for protection. The IgG2a 
levels were approximately the same after the three different challenges (IP, IP+VP.VP) 
in the established immune mice suggesting that a possible relationship between antibody 
level and protection to challenge did not depend on IgG2a anti-parasitic antibodies as has 
been reported for immunity to P. vinckei (9). 
The results indicate a long-lasting memory to IP immunity and a comparatively 
short memory for protection to VP. This supports the important role for live VP in the 
maintenance of an established VP immunity. This may also explain the observation that 
in contrast to VP, IP usually do not persist in immune mice. 
IP stimulation is essential for the generation of VP protection both during 
immunization by a chemotherapeutically-controlled infection (Chapter 3) and after 
transfer of ISC. In addition, fading of VP protection can be upregulated by IP 
stimulation. This may reflect phenotypic differences between IP and VP where VP have 
pathology-promoting characteristics that are absent in IP (Chapter 3). In view of the 
importance of specific subsets of Τ cells involved in immunity to Plasmodium (15), an 
hypothesis is that IP and VP trigger different subsets of Τ cells (i.e., T
n
l or T
n
2 cells) 
and that a balance between these subsets is needed for protection (Chapter 5). IP 
stimulation before VP challenge may generate this balance both after transfer of ISC as 
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well as after long parasitc-frce period in immune mice. 
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GENERAL DISCUSSION 
The aim of this study was to examine the effects of virulent Plasmodium 
berghei parasites (K173, ANKA) and an immunogenic variant on the development of 
immunity in mice. The virulent parasite (VP), when given without suppressive therapy 
was always lethal, even when given in small amounts. However, VP, when given with 
suppressive therapy, such as sulfonamide treatment, were capable of immunizing mice 
within a 5 week period. Blood removed from mice during the 5 week immunization 
procedure with VP and inoculated into new acceptor mice was found to immunize mice 
within 3 weeks against a VP challenge. It appeared then that the VP, in their interaction 
with the host under conditions where pathology was prevented by suppressive therapy, 
became attenuated, more immunogenic. These parasites were called immunogenic 
parasites (IP). 
The property of attenuation seen in IP was apparent from the observations of the 
course of untreated infection, the ability to induce immunity faster than the VP and the 
capacity to stimulate immune spleen cells (ISC) for the generation of VP immunity. 
Whereas a single VP was enough to establish infection and cause cerebral malaria in 
mice (a condition marked by early death in the second week and associated with a fast 
decrease in body temperature) (Curfs et al., 1989, Chapter 2), IP at low numbers either 
did not establish infection, produced transient infections followed by immunity or 
resulted in long-lasting, eventually lethal infections that did not lead to cerebral malaria 
(Chapter 3). When mice were preinfected with VP (i.e., given infections with VP for 
short periods followed by radical cure with chloroquine), there was protection against 
the development of cerebral malaria (Curfs et al., 1992) in a subsequent infection. IP, 
however, was not effective in prevention of cerebral malaria using the same procedures 
(Chapter 3). These results when taken together suggest that IP, compared to VP, have 
lost the capacity to induce immunopalhological reactions and have developed qualities 
that enhance the induction of immunity; pointing toward possible phenotypic differences 
between IP and VP. Furthermore, the gradual change in the course of primary untreated 
infections when increasing numbers of IP were inoculated, from no infection to transient 
to lethal infection, might even suggest quantitative rather than qualitative changes in IP 
compared to VP (Chapter 3). 
Live parasites, both VP and IP, have been found to be important in immunization 
(Jerusalem and Eling, 1969, Eling et al, 1991, Chapter 2, see Chapter 4); in the absence 
of parasites, established immunity fades after a long sterile period. Immunity to P. 
berghei in mice can be transferred by ISC in acceptor mice, as stated above, but the 
acceptors must be stimulated with living IP for a period of at least 7 days to be able to 
control a subsequent challenge with VP (Chapter 4). Immunity depends on the 
development of specific reactions that directly control parasite proliferation or stimulate 
independent (specific) effector reactions, including architectural changes in the spleen 
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(Weinbaum et al., 1976, Weiss et al., 1986). If a cascade of reactions is involved, the 
kinetics of individual reactions may differ. Experiments designed to analyze the role of 
time in the absence of live parasites in various phases of the transfer of immunity 
compared to fading of established immunity to both the VP and the ΓΡ were done (see 
Chapter 7). 
In transfer tests with ISC, it was observed that mice with an established 
immunity to VP could not transfer immunity to VP directly (Chapters 3 and 4). 
Transferred ISC, however, were able to confer protection to IP infection and stimulation 
of transferred ISC with IP could generate protection to VP within a week. In addition, 
sufficient numbers of both ISC (> 107 ISC/mouse) and IP (> 104 IP/mouse) were 
needed for optimal results. Extra challenges in the donor with IP, shortly before transfer 
of its ISC to "booster" its capacity to transfer immunity, were not protective to VP 
challenge in the acceptor. "Boostering" of the donor does not provide more efficient 
ISC. The interaction between IP and ISC must take place in the acceptor. Both 
transferred ISC and stimulation with IP in acceptors were essential for the immunization 
to VP challenge in the transfer model (Chapter 4). 
CD4+ Τ cells have been reported to contribute to malaria immunity (Süss et al., 
1988, Langhome, 1989, Langhorne et al., 1990, see Melancon-Kaplan and Weidanz, 
1990). CD4+ Τ cells play an important role both as helper cells for antibody production 
and as effector cells (see Süss et al, 1988). Various models (see Melancon-Kaplan and 
Weidanz, 1986), have reported that mice depleted of CD4+ Τ cells were unable to 
control infections against an array of normally avirulent infections. In addition, mice that 
were initially immune or resistant to challenge with a malaria parasite, when depleted for 
CD4+ Τ cells, lost the ability to resist subsequent challenges (sec Langhorne et al, 
1990). In other words, mice failed to maintain immunity when CD4+ Τ cells were 
removed. Several animal models have been proposed to explain what might occur in the 
development of immunity to erythrocytic malaria infections. It is suggested that 
protective immunity is dependent on the generation of antigen-specific CD4+ Τ cells 
involving macrophage activation or antibody production or both (Langhome, 1989, 
Groux et al., 1990). 
In our model, transfers with ISC depleted for B-, CD4+ T- and CD8+ T- cells 
were done in intact and depleted acceptor mice. Transfer experiments, showed that 
immunity could not be transferred in the absence of В cells or when CD4+ Τ cells were 
absent in both the transferred spleen cell suspensions or in the acceptor mice (see 
Chapter 5). A direct role of CD4+ Τ cells in the development of immunity in the 
acceptors came from two observations. First, there were no positive transfers when ISC 
depicted of CD4+ Τ cells were transferred to CD4+ Τ cell-depleted acceptors. Second, 
there were positive transfers when CD4+ Τ cell-depleted ISC were given to CD8+ Τ 
cell-depleted (but CD4+ Τ cell-possessing) acceptors. CD4+ Τ cells were essential, but 
did not necessarily have to come from an immune donor. Memory В cells probably are 
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present in the donor and necessary for transfer; however, CD4+ cells present in the host 
seem to be sufficient for a positive transfer. Results even indicate that the presumed 
relatively low number of CD4+ Τ cells present in non-depleted ISC given to CD4+ T-cell 
depleted acceptors were less effective in the development of immunity than CD4+ Τ ccll-
depleled ISC transferred to CD8+ Τ cell-depleted (i.e., CD4+ Τ cell-possessing) 
acceptors. In this condition, it is likely that there is a presence of higher numbers of 
CD4+ Τ cells in the acceptor than in the ISC preparation. 
In the absence of В cells in the transfer inoculum, acceptor mice did not develop 
immunity. Anti-parasite titers were measured on Days 7 and 14 from acceptor mice 
following the transfer of ISC and stimulation with IP. Low titers were found in B-cell 
depleted compared to control mice receiving non-depleted ISC that did become immune. 
Furthermore, without CD4+ Τ cells either from the transferred cells or present in the 
acceptor, there was almost no antibody production, suggesting that CD4+ Τ cells 
stimulate the immune spleen В cell functioning in the development of immunity in the 
acceptor. 
Thymectomy was performed to prevent reestablishment of the depicted Τ cell 
populations of mice treated with anti-CD4+ or -CD8+ Τ cell monoclonal antibodies. 
Therefore, acceptors referred to as CD4+ T-cell-depleted or CD8+ Τ cell-depleted were 
first thymectomized before treatment with monoclonal antibody. As mentioned above, 
CD4+ T-cell depleted ISC were unable to transfer immunity in CD4+ Τ cell-depleted 
acceptors, however, were, interestingly enough, able to transfer immunity to CD8+ Τ 
cell-depleted acceptors at levels observed in the non-depleted ISC transfers. When anti­
parasitic antibody liters were measured, significantly increased titers were seen on Day 
14 (compare to Day 7 titers) during the development of immunity. These results indicate 
that the presence of CD8 + Τ cells can suppress antibody production and the ability to 
transfer/develop immunity. Except when non-depleted ISC and IP stimulation are given 
to intact acceptors, stimulation of CD8+ Τ cells leads to down-regulation of CD4+ Τ cell 
function. 
Antibody production seems to parallel rather than precede development of 
immunity. It is slightly delayed in CD4+ or CD8+ T-cell depleted acceptors implicating 
the role of acceptor cells in the kinetics of the development of immunity. The observation 
that antibody production in the second week of transfer (i.e., the week after the 
challenge with VP) correlates with immunity suggests that VP contain antigens not 
present in or on IP and that antibody control of these antigens is essential. 
A direct role of CD4+ Τ cells in effector function of immunity was also seen 
when established sterile immune mice (mice without persisting parasites) to VP, but not 
to IP, lost immunity after the depletion of CD4+ Τ cells. Mortality in premune mice 
(mice with persisting parasites) given the monoclonal antibody was not observed despite 
comparable depletions in both groups measured by immunofluorescence. Survival of 
these mice is presumably due to the constant stimulation, by the parasites present, of the 
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CD4+ Τ cells which eventually over time, reach levels seen before their depiction with 
the monoclonal antibodies (see Chapter 5). 
Macrophages have been found to play an important role in the mechanism of 
antigen processing of particulate antigens (parasites) which can then be transferred to В 
cells or dendritic cells which are responsible for presentation to Τ cells (Van Rooijen, 
1992). It is postulated that in the spleen, В cells meet antigen in the marginal /one, 
migrate to the outer PALS and present their antigens to the appropriate Τ cells (Van 
Rooijen, 1990). Moreover, it has been postulated that although В cells may process 
small and soluble antigens, macrophages, especially marginal zone macrophages, are 
required for processing of particulate antigens. The role of the macrophage and its 
involvement with processing of the IP in our model was examined. Depletion of 
macrophages in donor ISC preparations and acceptors had deleterious effects on the 
adoptive transfer of VP immunity under certain conditions. Depletion in acceptor mice 
was done with liposome-encapsulated methylene diphosphonate (LTP-Cl^MDP) which 
temporarily depletes macrophages. Over a predictable period of time, different 
populations of macrophages (e.g., red pulp macrophages, marginal mctallophilic 
macrophages, marginal zone macrophages) return (i.e., 1 to 2 weeks, within 2 to 4 
weeks and 6 weeks or more, respectively (Van Rooijen et al., 1989)). In our transfer 
model, we observed that no positive transfers (i.e., mice were not immune to VP 
challenge) occurred when acceptor mice receiving ISC and stimulation early after 
depletion (i.e., IP on Day 0 and VP on Day 7), but did occur when the stimulation with 
IP and challenge with VP were delayed (i.e.. Days 14 and 21 Days or later, 
respectively). That immune transfers occurred later represents the original non-depleted 
situation. In other words, by delaying the time before stimulation, the macrophage 
complement has relumed to levels that allow the development of the immune proccss.At 
the later times, the reappearance of marginal mctallophilic and marginal zone 
macrophages takes place. It is probable that these macrophages play an important role in 
processing of the parasite antigen in our model. 
Premune mice depleted for macrophages and followed by challenge with VP or 
IP experienced no increased parasitemia compared to control mice. Because of the 
presence of the parasites, it is presumed that activated macrophages were unable to 
further take up the liposomes but were still able to control the infections at control (non-
treated) levels (Schwarzer et al., 1992). Parasitemias in macrophage-depleted sterile 
immune mice challenged with IP also compared to controls; however, parasitemias in 
macrophage-depleted sterile immune mice challenged with VP increased progressively at 
the different time intervals tested. These results indicate a different type of processing 
for IP than VP and/or the involvement of other cell types, for example В cells or CD4+ 
T cells, which could be more critically involved in the control and processing of VP than 
IP. Furthermore, within the CD4+T cell group, specific subsets (i.e., T
n
l , T
n
2) could 
be preferentially triggered or 'fade' over time thus affecting the optimum control of the 
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VP. These ideas with regard to VP and IP are discussed below. 
Fading (Chapter 7) was studied in both the immune donors and acceptors that 
received ISC using the transfer model. Fading periods within the model were defined as 
follows: FPl-the period in the donor between the day of challenge with VP and the first 
day of chloroquine (CQ) treatment, FP2- the period in the donor between the first day of 
CQ treatment and the removal of ISC for transfer and FP3- the period in the acceptor 
between the transfer of ISC and stimulation with IP. In transfer experiments, FP1 did 
not appear to be as critical as FP2 in the transfer of immunity. However, a reduced 
capacity to transfer immunity was seen in mice with an FP2 of 21-51 days. When ISC 
were transferred and the time of stimulation in the acceptor with IP was delayed (FP3 1-
9 months), there was a gradual loss, after 3 months, in the capacity to develop 
immunity. ISC that are transferred to acceptor mice can still be effectively stimulated 
with IP after a period of months, but their capacity to do so decreases with time. It 
appears, therefore, that fading in the absence of contact with live parasites seems to be 
faster in the immune donors than in the acceptors receiving ISC. In the development of 
the transfer model (see Chapter 4), it was observed that the cell number was important. 
Because of loss of immunity or fading over time, it seems that cells carrying critical anti­
parasitic information in ISC have a limited lifespan (perhaps 3-4 months). These cells 
probably included the В cells and CD4+ Τ cells critical to our model. Their measurement 
in the fading experiments (Chapter 7) showed that В cells and CD4+ Τ cells decreased 
from 55% to 20% and from 60% to 5% of the total cells, respectively. The relative 
proportion of these cells decreases faster in the absence of live parasites in established 
immune mice than in acceptor mice receiving ISC (for as yet unknown reasons). 
In established immune mice, immunity to VP fades after a period of 4 months 
(see Chapter 7). In contrast, fading of immunity to IP was not observed even up to 
periods of 9 months. When other mice with equally long sterile periods as the preceding 
groups were first stimulated with IP followed by VP challenge 7 days later, there was a 
capacity to mount VP immunity when stimulated first with IP, however, the capacity 
decreased after a long sterile period (5 months). Thus, immunity to IP is long-lasting 
while immunity to VP lasts for a shorter time (3-4 months). 
The amount of anti-parasitic antibody produced after challenge of established 
immune mice (with long sterile periods) paralleled the capacity to control the challenge. 
That is, titers were highest when there was full control (i.e., condition with a challenge 
with IP), less when control was incomplete (i.e., condition with IP challenge followed 
by VP challenge 7 days after) and least in the absence of control (i.e., condition with a 
challenge with VP). In these measurements, the amount of anti-parasite antibody actually 
rose to values of 2.5 to 8 times the amount seen in recently challenged established 
immune mice (i.e., mice that did not have long sterile periods). Despite these increased 
titers, the mice that were given the VP challenge were not able to control the infection 
after a fading period of 182 days. Therefore, it seems, that anti-parasitic antibody levels, 
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as such, are no guarantee for protection 
These data suggest that IP and VP trigger different reactions IP infections alone 
do not easily lead to immunity, but when controlled by either chemotherapy or ISC, then 
immunity develops Apparently, IP can stimulate both protective and adverse reactions, 
however, protective reactions can inhibit/down-regulate the adverse reactions rather 
quickly. VP have a strong capacity to stimulate adverse reactions and apparently a very 
low capacity to stimulate protective reactivity Only in fully-established immune mice can 
VP maintain immunity In other cases, adverse reactions triggered by VP 
dominate/inhibit/down-regulate protective reactions resulting m pathology (e g , cerebral 
malaria) and death Only fully-developed IP immunity can control/down-regulate a VP-
tnggered adverse reaction Substances such as cytokines, triggered by protective 
reactions, may help to down-regulate adverse reactions In order to control a challenge 
infection, protective reactions should teach a level where they are able to inhibit the 
adverse reactions For IP infection with a low signal for the adverse reactions, this 
occurs earlier than for VP That is, more protective reactivity is needed to counteract the 
strong VP signal than the weak IP signal for adverse reactivity The level of control of 
VP can be obtained, however, by IP stimulation The experiments showed that in 
established immune mice, VP can be controlled even when the system is not activated by 
parasites for several months (Chapter 7), however, in transfer experiments, all spleen 
cells from a recently challenged immune donor were unable to transfer protection to the 
VP in acceptor mice (Chapter 7) Acceptor mice receiving ISC must first be stimulated 
with IP. Though cell number and cytokine production capacity are contributing to a 
response, there is a possibility that IP stimulation must induce a newly-established 
reaction in the acceptor that is not triggered by VP. 
IP must proliferate for approximately 1 week to induce VP protection (Chapter 
4). Neither freeze-thawed IP nor IP proliferation limited by chloroquine to periods 
shorter than 1 week (Chapter 3) could induce VP immunity The reason for the 1 week 
proliferation process is unclear, however, could include several possibilities One 
possibility is that the immunizing factor is leleased by IP rather than being a surface 
molecule Another is that only live, prolifeiating IP arrive at places where cells of the 
immune system can be stimulated (e g , in the white pulp of the spleen) Still another, is 
that only proliferating IP, not VP, can induce an essential architectural change in the 
spleen like the banner system described by Weiss (Weiss et al., 1986, Weiss, 1990). This 
was tested (Chapter 4) by pretreating mice with IP to determine if IP could either 
stimulate development of the "right" architecture in the spleen or "drive" the immune 
system toward a dominant activity of a specific subset of Τ cells The IP pretreatment 
proved unsuccessful, so that an interaction of IP with immunocompetent cells in the 
transferred ISC is essential The role of the transferred cells in the induction of VP 
immunity was also tested (Chapter 4) 
Induction of immunity by IP stimulation of transferred ISC was successful when 
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ISC were transferred to same-sex acceptors or from female to male acceptors, but not 
when male ISC were transferred to female acceptors; explained by a well-established H-
Y dependent rejection of male cells in female acceptors (Eichwald and Lustgraaf, 1961). 
It was observed (Chapter 4) that female ISC could be transferred to two subsequent male 
acceptors, of which the ISC of the last male induced immunity in subsequent female 
acceptors. It appears that survival of a property in the original female cells was still 
sufficient for subsequent transfer to females; supporting a role of specifically-triggered 
cells in the ISC responsible for the development of protection. 
Another hypothesis is that IP could preferentially trigger a particular Τ cell subset 
that controls the stimulation of another subset specifically triggered by VP. Interactions 
between T^l and T^2 subsets (mentioned earlier in the model of Langhome 
(Langhome,1989, see Taylor-Robinson and Phillips, 1992)) or predominant reactions 
have been reported in other parasitic infections (Pearce et al., 1991, Peterson et al., 
1992, Sayles and Wassom, 1992, Waki et al., 1992). T
n
l reactions have been often 
associated with protection, while T^2 have been associated with pathology (Waki et al., 
1992); however, the response is dependent on the type of parasite. With respect to 
malaria, both or one T
n
 cell subset have been found to be associated with protection (see 
Melancon-Kaplan and Weidanz, 1990, Taylor-Robinson and Phillips, 1992). It becomes 
apparent then that it is important to identify antigens that mediate these protective or 
pathological outcomes for the construction of effective vaccines. 
There are apparent different qualities between the IP and VP which might be 
attributed to phenotypic differences or quantitative differences in phenotypic expression. 
Persistence of the parasite is sufficient for life-long immunity. Competition between VP 
and IP makes it less likely that persistence of immunity depends on the presence of a 
small amount of IP among the VP population. Furthermore, in contrast to VP, IP are 
cleared from the circulation in established immune mice. In our model, there is a clear 
association between development of immunity in the acceptor mice after transfer of ISC 
with IP stimulation and production of anti-parasitic antibody (Chapters 4 and 5). This 
may indicate that T^2 activity is especially important for the development of immunity in 
this model since both CD4+ Τ cells and В cells were required for transfer (Chapter 5); 
however, this remains unclear because antibody increases paralleled rather than preceded 
development of immunity. Other protective mechanisms are probably involved. 
The results presented in this dissertation and the information reported from other 
malaria models are relevant to consider for the development of a vaccine. The target for 
development of a protective vaccine may be present on IP rather than VP. It remains to 
be determined whether characteristics of the P. berghei (K173) model are relevant to 
human malaria. 
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SUMMARY 
Chapter 1 
In this dissertation, a mouse model of immunity against the malaria parasite, 
Plasmodium berghei, is presented. The Plasmodium parasite, its life cycle, different 
species (including the virulent parasite (VP) and an 'immunogenic' variant (IP) of Ρ. 
berghei developed in this laboratory) and the immunization techniques that have been 
reported in rodents, are discussed in Chapter 1. To aid in the understanding of the mouse 
model, general immunological principles as well as those specific to malaria are 
discussed. In particular, the emphasis is on the role of Τ and В lymphocytes in the 
transfer and maintenance of immunity to P. berghei. Finally, the mouse model itself is 
introduced followed by an overview of the remaining chapters in which supporting 
research is presented and discussed. 
Chapter 2 
This chapter serves as an overview of experiments designed to look at the 
differences between live, proliferating and non-proliferating virulent parasites in 
immunization and maintenance of immunity to P. berghei. Mice could be immunized 
when given live parasites and sulfonamide treatment to prevent development of patent 
infection; however, when mice were given non-proliferating, disrupted parasites 
(obtained via sonification or freeze-thawing) the majority of mice were not protected. 
Fading (the gradual loss of immunity) was observed in the absence of parasites. Once 
mice developed immunity, it was necessary to maintain it by repeated infections with the 
parasite. Mice receiving non-proliferating, disrupted parasites at regular intervals or live, 
proliferating parasites removed with chloroquine soon after injection to prevent the 
proliferation of the parasite, showed fading, while mice given regular injections with the 
live parasite did not. The results imply that the important signal may be produced in 
certain amounts by the living, proliferating parasite or that the living parasite makes 
contact with or delivers appropriate signals to an essential part of the immune system. 
The terms premunition and sterile immunity are introduced in this chapter. The 
term premunity is used to describe the condition where parasites persist while sterile 
immunity applies to that condition where parasites do not persist. 
Chapter 3 
Previously reported rodent studies have provided information about specific and 
non-specific malaria immunity by using different parasite strains. By using several 
variants of malaria parasites in animal models, the differences between infections and the 
types of immune responses they trigger within a host can be studied. A few lethal and 
self-limiting parasites, already available, have been found either in nature or induced 
under specific conditions. Chapter 3 is used to report the development of an attenuated 
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parasite from this laboratory which was isolated from mice immunized with the wildtype 
form of the P. berghei parasite. Untreated infections with the wildtype are normally 
lethal; however, if chemotherapeutically controlled with sulfonamide, mice can be 
immunized within 5 weeks. By the removal and testing of blood from mice during the 
immunization, an isolate was found that possessed properties different from those of the 
wildtype form. The isolate, when given under the same chemotherapeutic control, was 
able to immunize mice within a shorter period of time (3 weeks). Furthermore, when the 
isolate was used in transfer experiments with immune spleen cells (ISC) the 
immunization period was effectively reduced to 7 days. The parasite was called 
"immunogenic" because it was able to immunize mice within shorter periods of time and 
it seemed to lack characteristic pathological properties (e.g., cerebral malaria) associated 
with the lethal wildtype parasite. Several characteristics of these immunogenic parasites 
(IP) and details of how they were obtained are discussed in this chapter. 
Chapter 4 
Animal transfer models (e.g., the transfer of cells, serum) have been widely 
reported as a fairly easily manipulatable means to study cell populations or factors that 
can be protective against a variety of malaria parasites. To study the P. berghei 
immunogenic parasite (IP), discussed in more detail in Chapter 3, and the cells that are 
protective against it, a transfer model using immune spleen cells (ISC) was designed. 
The transfer of ISC from an immune donor to a naive acceptor mice was not protective 
against the virulent parasite, VP, infection. However, when IP was given along with 
ISC, mice were able to control a challenge with VP. Moreover, these mice were able to 
control the VP 7 days after receiving stimulation with IP. Mice given either IP alone or 
ISC alone were not able to control a VP challenge within 7 days. Both the number of 
ISC and IP were important for successful development of VP protection in acceptor 
mice. An attempt was made to optimize the protective effect of ISC by stimulating or 
'boostering' donor mice with IP or VP. The results were negative, however. ISC in 
immune donors could not be boostered to protect against VP challenge of acceptor mice. 
The presence of the live, proliferating IP was essential for the development of VP 
protection in acceptors receiving immune spleen cells. ISC could not be stimulated by 
non-proliferating freeze-thawed IP. Furthermore, it was observed that ISC persisted in 
acceptor mice in 'across-sex' transfers. ISC transferred from female to male, then from 
this male to a subsequent male and finally from the second generation male back to a 
female (a condition that was unable to produce immune mice in a first generation 
transfer), induced immunity. Stimulation of the transferred spleen cells with IP was 
essential. This formed the basis of the transfer model described in this chapter: acceptor 
mice were given ISC and IP stimulation then were challenged 7 days later with VP to 
determine if immunity had developed. Several parameters used in the standardization 
and the steps involved in the development of the transfer model are discussed. 
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Chapter 5 
Different cell populations have been reported to be protective against malaria 
parasites in a number of animal models. Our transfer model described in Chapter 4 for 
P. berghei was applied to look at specific subpopulations of cells protective against this 
parasites. The results are reported in Chapter 5. By the use of (monoclonal) antibodies to 
deplete specific cell populations in both donor immune spleen cells (ISC) and acceptor 
mice, it was observed that both В cells and CD4+ Τ cells were necessary for the 
development of immunity. Because В cells were important for the transfer of immunity, 
antibody titers on days 7 and 14 after the transfer of ISC and IP stimulation were also 
measured. Intact acceptor mice receiving either non-depleted, CD4+ Τ cell-, or CD8+ Τ 
cell-depleted ISC had higher antibody titers on Day 7 than acceptor mice depleted for 
CD4+T cell- or CD8+ Τ cells receiving these same cells. On Day 14, in all mice that 
developed immunity, antibody titers were significantly higher than in mice that did not 
develop immunity. CD4+ Τ cells were also found to play an important part in the 
maintenance of immunity to the virulent form of P. berghei (VP), but not necessarily to 
IP. When CD4+ Τ cell-depleted mice were challenged with VP, most mice died, while 
IP-challenged mice survived with little or no patent parasitemia. A mechanism for the 
role of different cell populations is given in this chapter. 
Chapter 6 
In some models, acquired immunity to Plasmodium has been demonstrated to be 
a cell-mediated mechanism. It has been hypothesized that the cell-mediated mechanism 
occurs via Τ cell activation of cells of the mononuclear phagocyte lineage 
(macrophages). We found in our model, a requirement for Τ cells (i.e., CD4+ Τ cells) 
and В cells in the transfer (and for the former, the maintenance) of immunity (see 
Chapter 5). In Chapter 6, we attempted to look at the involvement of macrophages in 
infection of immune mice with virulent and immunogenic P. berghei parasites (VP and 
IP, respectively) and their role in our transfer model (Chapter 4). Macrophages can be 
depleted temporarily in mice by administering liposome-encapsulated dichloromethylene 
diphosphonate (LIP-CI2MDP), a method useful for studying effects in vivo. Different 
subpopulations of macrophages return at different times after their depletion which can 
also be used to determine the group of macrophages involved. In the basic transfer 
model, immune spleen cells (ISC) are given along with stimulation with IP. A challenge 
with the virulent parasite (VP) is then given 7 days later. Though IP is essential for 
stimulation of ISC, it does not have to be given simultaneously with the ISC (established 
from fading experiments, see Chapter 7). IP stimulation can be delayed for as long as 3 
months and still produce immunity in acceptor mice. Using this information and the 
information about the return of macrophages after a one-time depletion, time-course 
experiments (described in Chapter 6) were designed. IP stimulation was given on the 
day of transfer of ISC (Day 0), or on Day 14 or Day 28 after the transfer of ISC. It was 
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found that macrophage-depleted acceptor mice did not become immune when given IP 
stimulation early (i.e., on day 0 after transfer of ISC, soon after depletion). Mice did, 
however, become immune at later time points (i.e., on days 14 or 28 after transfer of 
ISC; times coinciding with the return of greater proportions of macrophages, probably 
marginal zone and/or marginal metallophilic macrophages). The effect of macrophage 
depletion on the maintenance of immunity was also studied in either premune or sterile 
immune mice (i.e., immune mice with or without persisting parasites, respectively) 
depleted of macrophages and challenged with the VP or IP at different time intervals. 
Little effect on parasitemia was noted in premune mice or sterile immune mice given IP, 
while progressively higher parasitemias were seen in sterile immune mice given 
challenges with VP over time. The differences seen between the two parasites suggest 
different mechanisms of antigen presentation/processing but may also indicate the 
involvement or interaction with other cell types (e.g., CD4+ Τ cells) which have 'faded' 
over the course of the study (see Chapter 7) to effect the parasitemia. These ideas are 
further discussed in this chapter. 
Chapter 7 
Fading or loss of immunity results from the lack of exposure of the host to the 
parasite. Fading was studied using both the virulent parasites (VP) and the immunogenic 
parasites (IP) in the transfer model described in Chapter 4. The basic model was 
manipulated to study different fading periods between the donor and acceptor. It was 
found that immune spleen cells from donor mice most recently challenged with the living 
parasite before transfer were able to confer immunity on naive acceptor mice, while 
donor mice not recently challenged with the parasite before transfer did not, presumably 
due to a specific memory. Furthermore, fading of immunity to VP and IP occurred at 
different times. Immunity to IP was longer lasting than immunity to VP. When antibody 
titers were measured after long sterile periods (i.e., when parasites were not present in 
mice) followed by later rechallcnge with VP, IP or IP and VP 7 days later, "boostered" 
titers (compared to controls) were seen in all cases; however, the titers were higher after 
the IP challenge. The increased titers may contribute to the survival of the mice. Further 
manipulations of the fading periods are reported in this chapter. 
Chapter 8 
In the general discussion presented in this chapter, the main conclusions of the 
research are given. The P. berghei virulent parasites (VP) and paticularly the 
immunogenic parasites (IP) are further discussed with respect to their possible roles in 
the stimulation of specific cell populations involved in the development and maintenance 
of immunity. 
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SAMENVATTING 
Hoofstuk 1 
In deze dissertatie wordt de ontwikkeling van immuniteit tegen de malaria-
parasiet Plasmodium berghei in een muismodel besproken. De inleiding in hoofdstuk 1 
bespreekt de Plasmodium parasiet: de levenscyclus, de verschillende soorten (incl. de 
virulente en de in ons laboratorium ontwikkelde immunogene P. berghei) en de voor 
knaagdieren gerapporteerde immunisatietechnieken. Voor een beter begrip van het 
muismodel worden zowel algemene als specifieke, op malaria van toepassing zijnde 
immunologische principes besproken. Er wordt daarbij met name ingegaan op de rol van 
Τ en В lymphocyten in de overdracht en handhaving van immuniteit tegen P. berghei. 
Tenslotte wordt het muismodel zelf geïntroduceerd gevolgd door een overzicht van de 
resterende hoofdstukken, waarin eigen onderzoek, dat met behulp van dit model gedaan 
is, wordt gepresenteerd. 
Hoofdstuk 2 
Dit hoofdstuk geeft een overzicht van ons onderzoek naar de verschillen in 
effectiviteit tussen prolifererende en niet-prolifererende virulente parasieten in de 
verwerving en handhaving van immuniteit tegen P. berghei. Muizen konden worden 
geïmmuniseerd na injectie met prolifererende parasieten gecombineerd met een 
sulfonamide behandeling ter voorkoming van een patente infectie; echter, de meerderheid 
van de muizen bleek niet beschermd te zijn na injectie met niet-prolifererende parasieten. 
Verder bleek herhaalde infectie met de prolifererende parasiet noodzakelijk te zijn ter 
handhaving van eenmaal opgebouwde immuniteit. 'Fading' (het verdwijnen van 
immuniteit) trad op wanneer deze vorm van herhaalde infectie onderbroken werd en de 
parasiet vervolgens met behulp van chloroquine verwijderd werd. Fading trad verder op 
na herhaalde stimulatie met de niet-prolifererende parasiet. Deze resultaten impliceren een 
belangrijke signaalfunktie van prolifererende parasieten voor het immuun systeem. 
Hoofdstuk 2 introduceert tevens de begrippen 'premuniteit' en 'steriele immunititeit.' In 
geval van premuniteit en sterile immuniteit is er resp. wel en niet sprake van het 
voortbestaan van de parasieten in immune muizen. 
Hoofdstuk 3 у 
Voorgaande studies hebben informatie opgeleverd over de ontwikkeling van 
specifieke en niet-specifieke malaria-immuniteit ten opzichte van verschillende 
parasieten-stammen. Door verschillende parasieten in diermodellen met elkaar te 
vergelijken, kunnen verschillen in infectie en in het type immuunrespons dat zij in de 
gastheer oproepen worden bestudeerd. Zowel parasieten die een lethale als een 
voorbijgaande infectie oproepen zijn voor dit type onderzoek beschikbaar. Dergelijke 
parasieten komen in de natuur voor, maar ook na inductie onder speciale 
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omstandigheden. In hoofdstuk 3 wordt de ontwikkeling beschreven van een verzwakte 
variant van de P. berghei parasiet, geïsoleerd tijdens de immunisatie van muizen met het 
wildtype. Niet-behandelde infecties met het wildtype zijn normaliter dodelijk; echter, met 
behulp van een chemotherapeutische behandeling met sulfonamide kunnen muizen 
binnen 5 weken geïmmuniseerd worden. In een tijdens de immunisatieprocedure 
genomen bloedmonster werd een parsasiet gevonden die andere eigenschappen bezat 
dan het wildtype. Met behulp van parasieten uit een dergelijk isolaat konden muizen na 
een chemotherapeutische behandeling met sulfonamide in een kortere periode (nl., 3 
weken) geïmmuniseerd worden. De immunisatieperiode kon verder gereduceerd worden 
tot 7 dagen wanneer het isolaat gebruikt werd in een transfer met immune miltcellen 
(immune spleen cells, ISC). Deze parasiet werd als 'immunogeen' aangeduid, aangezien 
ze in staat was om in een kortere tijd te immuniseren en de karakteristieke pathologische 
eigenschappen (bijv., cerebrale malaria) van het wildtype mist. Het hoofdstuk eindigt 
met een bespreking van de verschillende eigenschappen van deze immunogene 
parasieten (IP) en van de details omtrent de manier waarop ze verkregen werden. 
Hoofdstuk 4 
Diermodellen voor de overdracht van immuniteit met serum of cellen zijn 
veelvuldig gebruikt en aangepast om de faktoren die bescherming bieden tegen een 
verscheidenheid aan malaria-parasieten te bestuderen. Om de immunogene Plasmodium 
berghei parasiet, zoals die in hoofdstuk 3 verder in detail beschreven is, te bestuderen, 
evenals de cellen die daartegen bescherming bieden, is een model ontwikkeld voor de 
overdracht van immuniteit met behulp van immune miltcellen(ISC). De overdracht van 
immune miltcellen alleen naar een naieve muis bleek geen bescherming te bieden tegen 
infectie met de virulente parasiet(VP), echter wel wanneer eerst IP werd gegeven. In dat 
geval bleken de muizen 7 dagen na de stimulatie van ISC met IP immuniteit tegen VP 
ontwikkeld te hebben. Zowel het aantal ISC als IP bleken van belang voor een 
succesvolle ontwikkeling van bescherming tegen infectie met VP in acceptormuizen. Er 
werd geprobeerd om de beschermende werking van overgedragen ISC te optimaliseren 
door immune donormuizen met IP of VP extra te stimuleren. De resultaten waren 
negatief: acceptormuizen bleken niet beter bestand tegen infectie met VP. Stimulatie van 
ISC in de acceptor met levende, prolifererende IP bleek noodzakelijk te zijn voor een 
succesvolle ontwikkeling van bescherming tegen VP in acceptormuizen. Stimulatie met 
niet-prolifererende IP of extracten van IP, verkregen door vriezen en dooien van de 
parasieten bleek ineffectief te zijn. De beschermende werking van ISC bleek voort te 
bestaan als de ISC werden overgedragen over de sex-bariere heen. Immuniteit kon 
worden overgedragen van een immuun vrouwtje naar een naief mannetje, dat op zijn 
beurt immuniteit weer kon overdragen naar een volgend naief mannetje, dat tenslotte zijn 
immuniteit weer kon overdragen naar een naief vrouwtje(deze laatste overdracht zou op 
zichzelf geen overdracht van immuniteit tot gevolg hebben. Stimulatie van ISC met IP 
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bleek daarbij telkens van essentieel belang Deze observatie vormt de basis van hel in dit 
hoofdstuk beschreven transfermodel, waarbij acceptormuizen zowel ISC als IP 
stimulatie ontvangen en 7 dagen later met VP op de aanwezigheid van immuniteit getest 
worden De experimenten die gebruikt zijn voor de standaardisatie van de faktoren die 
betrokken zijn bij de ontwikkeling van het "transfer"-modcl worden besproken. 
Hoofdstuk 5 
In verschillende diermodellen wordt aan verschillende celpopulaties een 
beschermende werking tegen de malanaparasiet toegekend In dit hoofdstuk wordt het 
transfermodel voor P. berghei (zie hoofdstuk 4) gebruikt om te onderzoeken welke 
specifieke celpopulaties bescherming bieden legen deze parasiet Depletie van specifieke 
celpopulaties in zowel donor immune milt cellen (ISC) als in de acceptormuis met behulp 
van monoclonale antilichamen liet zien dat zowel В cellen als CD4+ Τ cellen nodig 
waren voor de ontwikkeling van immuniteit. Omdat В cellen belangrijk zijn in de 
overdracht van immuniteit via ISC werden ook de anti-parasitaire antistoftiters bepaald 
Anti stof titers in de acceptoren van ISC bleken hoger te zijn als de CD4+ of CDS+ cellen 
uit de ISC gedepleteerd waren, in vergelijking met depletie van deze Τ cellen in de 
acceptoren van de ISC Antistoftiters waren significant hoger in immune in vergelijking 
met met-immune muizen. CD4+ Τ cellen bleken met alleen belangrijk te zijn voor de 
overdracht van immuniteit, maar ook voor het voortbestaan van immuniteit, met name 
het voortbestaan van VP immuniteit. Na depletie van CD4+ Τ cellen in immune dieren 
leidde een VP challenge tot een dodelijke infectie, maar een IP challenge werd goed 
gekontroleerd Hoofdstuk 5 bespreekt de mogelijke rol van verschillende celpopulaties 
in het ïmmuunmechanisme legen P. berghei. 
Hoofdstuk б 
In sommige modellen is aangetoond dat verworven immuniteit tegen 
Plasmodium het gevolg is van een cel-gemedieerd mechanisme Er is gesuggereerd dat 
dit cel-gcmedieerd mechanisme werkt via Τ cclactivatie van cellen van de mononucléaire 
fagocyten lijn (macrofagen). In ons model werd gevonden dat de aanwezigheid van Τ 
cellen (i.e., CD4+ Τ cellen) en В cellen noodzakelijk was voor de transier (en van CD4+ 
T cellen tevens voor de handhaving) van immuniteit (zie hoofdstuk 5). Het onderzoek in 
hoofdstuk 6 gaat na in hoeverre in het transfermodel macrofagen een rol spelen tijdens 
infectie van acceptormuizen met P. berghei virulente parasieten (VP) en immunogene 
parasieten (IP). Daartoe vond depletie van macrofagen in muizen plaats middels 
toediening van hposoom-ingekapseld dichloromethyleen diphosphonaat (LIP-
CL^MDP), een methode die geschikt is voor het bestuderen van effecten in vivo. Het is 
bekend dat verschillende subpopulaties van macrofagen terugkeren op verschillende 
tijdstippen na hun depletie. Deze informatie kan gebruikt worden om te bepalen welk 
type macrofagen specifiek betrokken is bij de ontwikkeling en het vasthouden van de 
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immuniteit tegen P. berghei.. In het standaard "transfer" model worden immune 
miltcellen direkt gestimuleerd met IP en wordt de challenge met VP 7 dagen later 
gegeven Ofschoon stimulatie van ISC met IP in de ontvanger noodzakelijk is, hoclt dit 
niet direkt na overdracht van ISC te gebeuren, maar kan tot 3 maanden na overdracht 
van ISC worden uitgcstcld(dil is verder beschreven in hoofdstuk 7). Op grond hiervan 
en rekening houdend met een verschillend snelle terugkeer van de diverse subpopulaties 
van macrofagen na deplelie, kunnen experimenten worden uitgevoerd, waarbij de 
periode tussen aan de ene kant depletie van de macrofagen in en overdracht van ISC naar 
acceptormuizen en aan de andere kant stimulatie van de acceptoren met IP wordt 
gevarieerd. De resultaten helen zien, dat macrofaag-gedcpleteerde ontvangers van ISC 
niet immuun werden als ze direkt na overdracht van ISC met IP gestimuleerd werden en 
7 dagen later met VP werden gechallenged De ontvangers werden wel immuun als de 
stimulatie met IP 14 of 28 dagen na depletie en overdracht van ISC werd uitgevoerd. Dit 
valt samen met de periode waarin een belangrijk deel van de marginale zone 
macrofagen/marginale mctallophiele macrofagen terugkeren. Naast het effekt van 
depletie van macrofagen op de overdracht van immuniteit, werd ook het effekt op het 
voortbestaan van een bestaande immuniteit onderzocht. Depletie werd uitgevoerd in 
zowel premune als steriel-immune muizen (i.e. immune muizen die resp al dan niet 
drager zijn van de parasiet) en dit werd na een vanabel tijdsinterval ge\olgd door een 
challenge met IP of VP. Werd na depletie gechallenged met IP, dan kwam er nauwelijks 
of geen parasitcmie op, noch in premune, noch in steriel-immune muizen. Werden 
premune muizen met LIPCL^MDP behandeld dan kwam er ook geen parasilemie op, 
terwijl de behandeling in steriel-immune muizen tot een toenemend hogere infektie 
leidde, als de penodc tussen depletie en de challenge met VP toenam, maar dit gold weer 
niet voor een challenge met IP Dit verschil in reaktie op een VP of IP challenge kan 
wijzen op een verschil in antigenpresentatieAerwerking, dan wel op een verschillende 
interaktie van macrofagen met andere cellen(e g. CD4+ Τ cellen), die bloot staan aan 
"fading"(het verdwijnen van immuniteit in de tijd;zic verder hoofdstuk 7). In hoofdstuk 
6 wordt nader ingegaan op deze interpretatie van de resultaten 
Hoofdstuk 7 
Als de gastheer geen kontakt meer heeft met de parasiet, dan verdwijnt een 
eenmaal opgebouwde immuniteit weer("fading" van immuniteit). De rol van "fading" 
werd geanalyseerd, uitgaande van het standaardmodel voor de overdracht van 
immuniteit(zoals dat beschreven wordt in hoofdstuk 4) en zowel ten aanzien van VP als 
IP immuniteit. In het standaardmodel voor de overdracht van immuniteit werden diverse 
perioden in en tussen donor-en acceptormuis gevarieerd. Immuniteit kon alleen vanuit 
donoren worden overgedragen die recentelijk gechallenged waren, maar niet vanuit 
donoren die lang geleden hun laatste kontakt met de parasiet gehad hadden Mogelijk is 
er sprake van een specifiek geheugen Verder bleek dat een bestaande immuniteit tegen 
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VP in steriel-immune dieren eerder verloren gaat dan immuniteit tegen IP. Als na een 
lange steriele periode(immuun, maar zonder voortbestaan van de parasiet in de gastheer) 
de dieren opnieuw gechallenged worden met VP of IP, of IP gevolgd door VP 7 dagen 
later, dan leidde dit tot sterk verhoogde antistoftiters, met name na een IP challenge, al 
dan niet gevolgd door VP. Mogelijk leveren de hoge antistoftiters een bijdrage aan de 
immuniteit van de muizen. In dit hoofdstuk komt ook het effekt van de wijziging van 
andere "fading"-perioden aan de orde. 
Hoofdstuk 8 
In de algemene discussie in dit hoofdstuk worden de hoofdconclusies van het 
onderzoek besproken. De virulente P. berghei parasiet (VP) en in het bijzonder de 
immunogene parasiet (IP) worden verder besproken ten aanzien van hun mogelijke rol in 
de stimulatie van specifieke celpopulaties betrokken bij de ontwikkeling en handhaving 
van immuniteit. 
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THESES 
belonging to the dissertation 
Attenuated immunogenic parasites: Essential stimulators of Plasmodium bergkei immunity 
Christina M. Celluzzi 
1. Our Western 'immunity' to malaria is unjustified given that in developing countries the 
disease causes millions of deaths annually. 
2. Attenuated immunogenic parasites are essential stimulators for P. berghei immunity 
which protect against its virulent parent in mice. This dissertation 
3. The immunogenic effect of attenuated but not the virulent P. berghei parasites makes 
further research into their molecular properties desirable. This dissertation 
4. Exposure to the living, proliferating parasite is necessary for maintenance of immunity 
against a blood induced P. berghei infection in mice. This dissertation 
5. The observation that only live, proliferating parasites and not parasite extracts can induce 
or maintain immunity against a blood induced infection poses a serious problem for the 
development of a molecular or epitope vaccin against this parasite stage. 
6. The presence of CD4+ Τ cells is critical for the demonstration of transfer and 
maintenance of immunity to a blood induced P. berghei infection in mice. This 
dissertation 
7. One has to admire the persistence of the malaria parasite almost as much as the 
persistence of those who study it. 
8. It is desirable to change prejudice against a foreign culture into 'after-judice' after one 
has gained access to the relevant data. 
9. The international character of science creates a perfect forum for bringing different 
cultures together. 
10. Upon the introduction of a foreign animal researcher to the Dutch culture, it is advisable 
to not immediately confront him/her with the expression 'beschuit met muisjes' (biscuits 
with mice). 



